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Abstract 
Oral  cancer  has  caused  great  concern  in  all  of  the  western  countries  over  the  past  two 
decades  because  of  its  progressively  increasing  incidence,  mainly  in  young  males,  and  its 
consistently  low  5-year  survival  rate.  Oral  premalignant  lesions  (dysplasias)  are  thought  to 
precede  the  development  of  cancer,  but  no  clinical  or  histological  criteria  is  at  present 
available  to  predict  their  potential  for  malignant  transformation.  Therefore,  it  would  be  of 
diagnostic  and  therapeutic  relevance  to  understand  the  molecular  events  involved  at 
different  stages  of  oral  cancer. 
Using  a  unique  series  of  primary  cultures  from  biopsies  of  normal  oral  mucosa,  dysplasias 
and  squamous  cell  carcinomas  we  have  identified  molecular  changes  characteristic  of  early 
oral  cancer  progression.  Our  group  reported  previously  that  acquisition  of  the  immortal 
phenotype  is  an  early  event  in  oral  cancer  development  (McGregor  et  al.  1997):  data 
obtained  during  the  course  of  this  thesis  project  indicate  that  about  half  of  oral  dysplasia 
cultures  are  immortal  and  this  is  associated  with  loss  of  expression  of  retinoic  acid  receptor 
(RAR)-p  and  the  cell  cycle  inhibitor,  p161NK4',  p53  mutations  and  increased  levels  of 
telomerase/hTERT  mRNA.  In  contrast,  increased  expression  of  the  EGF  receptor  (EGF-R), 
known  to  be  a  characteristic  of  oral  cancer,  does  not  occur  until  after  the  dysplasia  stage  in 
squamous  cell  carcinomas  (SCCs).  Interestingly,  one  atypical  mortal  dysplasia  with  a 
considerably  extended  lifespan  has  lost  expression  of  RAR-P  and  p16  INK4,  but  it  still 
expresses  wild-type  p53  (albeit  at  higher  level  than  normal)  and  has  not  activated 
telomerase.  Further  experiments  demonstrate  that  retroviral  transduction  of  hTERT 
immortalises  D17  and  this  is  associated  with  telomere  lengthening  but  p53  remains  wild- 
type.  In  contrast,  transduction  of  hTERT  does  not  extend  the  lifespan  of  two  other  typical 
mortal  dyplasia  cultures  (that  retain  RAR-P  and  p16'NK4'  expression),  even  though 
telomeres  are  lengthened.  Thus,  telomerase  activation/telomere  maintenance  is  not 
sufficient  per  se  to  immortalise  mortal  dysplasias  without  concomitant  loss  of  RAR-P 
and/or  p16  INK4a,  but  p53  mutation  is  not  required  if  telomerase  is  activated  exogenously. 
However,  further  work  is  required  to  clarify  whether  the  molecular  changes  associated 
with  the  acquisition  of  an  immortal  phenotype  in  culture  have  any  clinical  or  prognostic 
significance. I 
1  Oral  cancer 
1.1  Epidemiology  and  risk  factors 
Oral  cancer  is  estimated  as  the  loth  most  frequent  cancer  worldwide,  representing  2.6%  of 
all  cancers  in  1990  (Parkin  et  al.  1999).  Despite  this  low  percentage,  a  high  level  of 
concern  arose  recently  from  the  observation  that  the  incidence  of  oral  cancer,  both 
worldwide  and  particularly  in  Scotland,  was  raising  progressively  over  the  years.  The 
general  trend  was  of  a  1.5  fold  increase  in  one  decade,  with  the  trends  relating  to  Scotland 
closely  mirroring  those  of  Europe  and  of  the  whole  world,  but  being  in  excess  of  both  (fig. 
1).  Males  are  more  susceptible  to  oral  cancer  than  females,  and,  although  an  increase  in 
incidence  was  seen  for  both  genders,  it  was  particularly  dramatic  in  males  belonging  to  a 
middle  age  group  (data  from  ISD  Scotland  NHS  statistics  division).  The  reasons  for  such 
increases  are  not  clear  and  the  European  School  of  Oncology  Advisory  report  in  1995 
strongly  suggested  that  this  matter  needed  further  investigation.  In  keeping  with  this,  a 
significant  increase  in  the  incidence  of  tongue  cancer  was  observed  in  individuals  younger 
than  40  years  in  the  USA  (Schantz  and  Yu  2002). 
The  most  common  risk  factors  for  oral  cancer  have  been  assessed  since  1988  in  a  series  of 
reports,  reviewed  and  summarized  by  Boyle  (Boyle  et  al.  1992)  and  by  McFarlane 
(Macfarlane  et  al.  1995).  There  is  strong  consensus  identifying  tobacco  in  all  forms,  both 
smoked  and  chewed,  as  the  major  risk  factor  for  oral  cancer.  In  India,  the  high  incidence  of 
this  condition  is  associated  with  the  widespread  habit  of  chewing  tobacco  or  betel  nuts, 
whereas  in  other  countries  the  strongest  association  was  reported  with  length  of  time  of 
exposure  to  cigarette  smoking  or  to  different  types  of  cigarettes  smoked.  Almost  all  of 
these  studies  also  report  alcohol  consumption  as  being  an  important  risk  factor, 
independently  of  the  type  of  alcohol  consumed,  its  effects  being  synergistic  rather  than 
additive  to  those  of  tobacco.  For  other  risk  factors,  like  mouthwash  use  and  poor  oral 
hygiene,  the  evidence  accumulated  is  not  enough  to  draw  strong  conclusions. 
In  the  light  of  all  this  background  information,  it  is  particularly  interesting  to  notice  that  the 
"western  world"  trend  in  the  past  decade  has  been  a  reduction  in  the  percentage  of  tobacco 
smokers  and  alcohol  drinkers.  In  particular,  the  Scottish  Health  Survey  of  1998  reported  a 
sharp  decline  in  the  prevalence  of  male  smokers  of  all  age  groups,  although  a  slight 
increase  of  alcohol  drinkers  was  also  reported. Chapter  1 
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Fig.  1:  Incidence  of  oral  cancer  in  Scotland,  Europe  and  the  whole 
world  in  the  last  two  decades. 
Graphic  illustration  of  the  incidence  of  oral  cancer  in  the  last  two  decades. 
Data  relative  to  Scotland,  Europe  and  the  world  is  compared. 
A  progressive  increase  in  the  number  of  cases  diagnosed  per  year  is 
observed  for  all  three  groups.  In  particular,  oral  cancer  appears  to  be 
increasing  in  Europe  at  a  higher  rate  than  in  the  world.  The  trend  observed 
in  Scotland  closely  mirrors  that  of  the  european  countries,  but  the  number 
of  cases  reported  in  the  former  are  higher. 
From  the  ISD  Scotland  NHS  Statistics  Division 
(http:  //www.  show.  scot.  nhs.  uk/isd/cancer). 
2 Chapter  1 
The  reduction  of  alcohol  and  tobacco  consumption  are  known  to  be  important  preventive 
measures  for  oral  cancer,  but  the  apparent  discrepancy  between  reduction  of  risk  factors 
and  epidemiological  trend  observed  in  the  last  decade  suggests  other,  as  yet  unidentified, 
risk  factors  being  implicated  in  the  pathogenesis  of  these  condition.  Interestingly,  lung 
cancer  mortality  rates  have  shown  a  significant  decrease  in  most  European  countries  in  the 
past  decades,  reflecting  the  reduction  of  tobacco  consumption  (Brennan  and  Bray  2002). 
Although  these  data  might  suggest  that  tobacco  consumption  plays  a  greater  role  in  the 
pathogenesis  of  lung  cancer  compared  to  oral  cancer,  this  study  does  not  indicate  the 
changes  in  incidence  of  lung  cancer  in  the  same  period.  Therefore,  it  is  not  possible  to 
determine  whether  this  change  in  trend  is  due  to  a  reduction  of  the  exposure  to  risk  factors 
or  to  an  improvement  of  therapeutic  strategies. 
Another  aspect  of  oral  cancer  that  is  cause  of  concern  for  Health  Authorities  is  the  5-year 
survival  rate,  which  has  not  improved  in  the  last  two  decades.  In  Scotland,  it  was  assessed 
around  45%  in  the  period  between  1991-95,  remaining  virtually  unchanged  when 
compared  to  the  43%  figures  reported  for  1976-80  and  considerably  lower  than  the  52.3% 
figure  assessed  in  the  USA  in  the  period  between  1993-1990.  The  reasons  for  this  figures 
remaining  stationary  over  the  years  are  largely  unknown.  A  report  on  the  British  Medical 
Journal  (Zakrzewska  1999)  attributed  this  phenomenon  to  the  poor  public  awareness  about 
this  cancer,  despite  the  easy  accessibility  of  the  oral  cavity  for  medical  inspection.  This 
causes  delays  in  diagnosis  and  reduced  survival  times.  No  major  improvement  in 
therapeutic  strategies  was  reported  in  recent  decades  (Boyle  et  al.  1995),  and  the 
importance  of  examining  new  radio-therapeutic  and  chemo-therapeutic  modalities  was 
strongly  suggested. 
1.2  Clinical  and  histological  aspects 
The  most  common  histotype  of  oral  cancer  is  squamous  cell  carcinoma  (SCC),  which 
accounts  for  91%  of  all  oral  cancers  (Silverman  and  Gorsky  1990).  In  the  majority  of 
cases,  SCCs  are  not  preceded  by  premalignant  lesions,  but  it  is  quite  common  to  observe 
areas  of  hyperkeratosis,  the  so  called  "white  patches",  or  red  velvety  lesions,  named 
erythroplakias,  in  the  oral  mucosa  surrounding  the  established  carcinoma.  In  addition  to 
this,  premalignant  lesions  might  precede  the  development  of  oral  cancer  by  several  months 
or  years.  Therefore,  there  is  a  strong  need  for  a  proper  clinical/histologic  classification  of 
premalignant  lesions  and  a  long-term  assessment  of  their  risks  of  malignant  transformation. Chapter  1 
The  characterisation  of  oral  premalignant  lesions  as  leukoplakias  and  erythroplakias  is 
purely  clinical.  Leukoplakias  are  white  plaques  of  the  oral  mucosa  with  histologic  features 
of  hyperkeratosis,  which  is  an  increased  thickness  of  the  epithelial  layer  producing  keratin; 
erythroplakias  are  bright  red,  velvety  plaques  often  showing  marked  epithelial  atrophy. 
Both  are  defined  as  idiopathic,  as  they  cannot  be  characterised  clinically  or  histologically 
as  any  other  disease.  Erythroplakias  may  be  associated  with  leukoplakias,  in  which  case 
they  are  referred  to  as  erythroleukoplakias. 
Leukoplakias  are  by  far  the  most  common  premalignant  lesions  of  the  oral  cavity.  A  large 
number  of  studies  assessing  their  rates  of  malignant  transformation  have  reported  huge 
variability  (0.13%-6%)  (Silverman  et  al.  1984).  Interestingly,  Silverman  and  collaborators 
have  observed  a  17.5%  of  malignant  transformation  rate  over  a  group  of  257  patients,  but 
when  this  data  was  limited  to  homogeneous  leukoplakias  the  percentage  reduced  to  6.5%, 
quite  similar  to  the  previously  reported  figures.  On  the  other  hand,  the  transformation  rate 
for  erythroplakias  was  4  fold  higher  than  that  reported  for  leukoplakias.  In  keeping  with 
this,  three  other  studies  have  reported  a  5-7  fold  higher  percentage  of  malignant 
transformation  in  erythroleukoplakias  compared  to  leukoplakias  (Kramer  1969)  (Banoczy 
1977)  (Roed-Petersen  1971). 
Histologically,  oral  premalignant  lesions  designated  with  the  general  term  of  dysplasia  may 
present  with  a  number  of  alterations  in  the  epithelial  architecture  and  in  cellular 
morphology.  The  classification  of  oral  dysplasias  as  mild,  moderate,  severe  or  carcinoma 
in  situ  is  complex,  and  is  based  on  several  internationally  adopted  criteria:  1)  loss  of 
polarity  of  the  basal  cells,  2)  increased  nuclear/cytoplasmic  ratio,  3)  altered  nuclear 
polarization,  4)  irregular  epithelial  stratification,  5)  increased  number  of  mitotic  figures,  6) 
presence  of  mitotic  figures  in  the  superficial  half  of  the  epithelium,  7)  cellular 
pleiomorphism  8)  nuclear  hyperchromatism,  9)  enlarged  nucleoli,  10)  abnormal 
keratinisation,  11)  reduced  cellular  cohesion  and  12)  invasion  of  the  lamina  propria 
(Kramer  et  al.  1978).  Not  all  of  these  alterations  are  seen  in  any  one  case,  and  indeed  not 
all  of  the  premalignant  lesions  show  features  of  epithelial  dysplasia  at  all. 
Erythroleukoplakias  are  more  likely  to  present  a  wider  spectrum  of  dysplastic  features,  and 
are  associated  with  a  higher  risk  of  cancer  development  (36.4%)  (Silverman  et  al.  1984). 
Therefore,  a  more  cautious  clinical  approach  is  advised  for  those  patients  presenting  with 
dysplasias  of  moderate  to  high  grade,  particularly  if  located  in  the  floor  of  mouth  and 
ventral  tongue,  since  these  two  sites  have  been  shown  to  be  more  prone  to  malignant 
transformation,  even  if  the  supporting  histological  evidence  is  often  unclear  (Silverman  et 
al.  1984). Chapter  I 
1.3  Treatment  of  oral  clysplasias 
5 
The  standard  treatment  for  oral  dysplasias  entails  a  needle  biopsy  of  the  lesion  for 
histological  classification  and  a  periodical  follow  up  of  the  patient.  Local  treatments,  like 
laser  ablation  or  surgical  resection,  are  not  always  appropriate,  because  a  large  number  of 
patients  present  with  multiple  lesions.  This  phenomenon  was  initially  named  field 
cancerization,  and  was  considered  a  result  of  widespread  damage  to  the  oral  epithelium  by 
carcinogens  (Slaughter  et  al.  1953).  However,  it  remains  unclear  whether  these  lesions 
arise  from  multiple  altered  clones  or  to  the  migration  of  an  altered  cell  throughout  the  oral 
mucosa.  In  addition,  local  therapies  do  not  act  on  the  remaining  oral  mucosa,  which, 
according  to  the  field  cancerization  concept,  has  been  exposed  to  the  same  risk  factors  as 
the  site  of  the  dysplasia  and  is  therefore  prone  to  develop  multiple  lesions  synchronously. 
It  is  therefore  necessary  to  develop  chernopreventive  strategies  designed  to  reverse  oral 
premalignant  lesions  or  to  prevent  their  malignant  transformation. 
Retinoids  are  the  most  prominent  chernopreventive  drugs  analysed  in  clinical  trials  (Hong 
et  al.  1986),  (Stich  et  al.  1988),  (Han  et  al.  1990),  (Lippman  et  al.  1993),  (Chiesa  et  al. 
1992).  Their  efficacy  in  reversing  oral  premalignant  lesions  varied  between  27%  and  87% 
depending  on  the  compounds  and  doses  used  in  each  study.  The  main  drawback  of 
treatment  with  retinoids  is  their  toxicity.  Serious  side  effects  have  been  reported  with  high- 
dose  treatments,  often  resulting  in  patient  drop-out.  In  addition,  high  rates  of  relapse  have 
been  observed  within  a  few  months  from  suspension  of  treatment  (Hong  et  al.  1986). 
1.4  Conclusions 
Oral  premalignant  lesions  are  easily  diagnosed  at  clinical  examination  and  readily 
accessible  for  biopsy:  these  two  characteristics  render  them  an  ideal  model  to  study  the 
multistep  process  of  oral  carcinogenesis.  Nevertheless,  it  is  as  yet  impossible  to  assess 
precisely  the  risk  of  cancerization  of  these  lesions,  based  only  on  histological, 
epidemiological  or  environmental  parameters.  The  pharmacological  treatments  presently 
available,  although  of  proven  efficacy,  do  not  invariably  revert  all  of  the  premalignant 
lesions,  they  cause  heavy  side  effects  and  they  fail  to  sustain  clinical  response  after 
suspension.  Therefore,  it  would  be  clinically  desirable  to  identify  additional  molecular 
markers  to  be  used  for  cancer  risk  assessment  in  these  patients. 6 
2  Retinoids  and  their  receptors  in  Oral  Cancer 
2.1  Structure  and  biochemical  functions  of  epithelia 
Epithelial  tissues  like  that  of  the  skin,  oral  cavity,  trachea  and  lung  are  known  as  stratified 
squamous  epithelia.  They  are  organised  in  a  multistratified  architectural  structure,  with  the 
stem  cells  residing  in  the  basal  layer.  In  response  to  as  yet  unidentified  signals,  basal  cells 
undergo  a  series  of  morphological  and  biochemical  changes  and  migrate  to  more 
superficial  compartments  of  the  epithelium,  forming  the  spinous  and  granular  layers.  This 
differentiation  process  ultimately  leads  to  the  production  of  dead,  flattened,  impermeable 
squarnes  organised  in*  a  layer  called  stratum  corneum.  This  layer  is  absent  in  non- 
keratinising  epithelia,  like  that  of  the  oral  cavity  mucosa. 
The  pattern  of  keratinocyte  protein  expression  varies  in  different  epithelia  and  in  different 
layers  of  the  same  epithelium.  Basal  keratinocytes  invariably  express  keratins  5  and  14;  in 
addition,  they  express  keratin  19  in  oral  mucosa.  Suprabasal  spinous  keratinocytes  express 
keratin  1  and  10  in  skin,  keratin  4  and  13  in  oral  mucosa  and  all  four  of  them  in 
keratinising  epithelia  of  the  oral  cavity  like  hard  palate  and  gengiva.  In  addition,  skin 
keratinocytes  express  transglutarninase  type  I  activity  and  produce  glutamine  and  lysine 
rich  envelope  proteins,  like  involucrin.  Spinous  cells  stop  producing  keratins  and  envelope 
proteins  and  specialize  in  generating  proteins  involved  in  macrofibrillar  aggregation. 
An  abnormal  pattern  of  expression  of  squamous  differentiation  markers  has  been  described 
in  head  and  neck  squamous  cell  carcinoma  (HNSCC)  in  vitro.  In  particular,  two  squamous 
cell  carcinoma  (SCQ  cell  lines  from  non-keratinising  epithelia  of  the  buccal  mucosa  and 
the  retromolar  trigone  expressed  keratin  1,  transglutarninase  type  I  and  involucrin,  whereas 
the  normal  keratinocytes  from  the  same  areas  do  not  express  any  of  those  markers  (Poddar 
et  al.  1991).  In  addition,  6/7  SCC  cell  lines  from  non  keratinising  epithelium  were  reported 
to  express'lower  levels  of  keratin  19  than  their  respective  normal  keratinocyte  counterparts 
(Hu  et  al.  1991). 
2.2  Biological  effects  of  Retinoids 
Vitamin  A  and  its  analogues  (retinoids)  are  known  to  have  several  biological  effects  in 
different  organs.  In  stratified  squamous  epithelia  they  are  mainly  involved  in  the 
maintainance  of  appropriate  cellular  growth  and  differentiation,  as  originally  suggested  by Chapter  2 
the  aberrant  squamous  metaplasia  observed  in  humans  after  prolonged  vitamin  A 
deprivation. 
In  vitro,  retinoids  inhibit  squamous  cell  differentiation  in  both  normal  skin  keratinocytes 
(Rubin  and  Rice  1986),  (Choi  and  Fuchs  1990)  and  HNSCC  keratinocytes,  as 
demonstrated  by  their  effect  on  reducing  the  expression  of  squamous  differentiation 
markers  like  keratin  1,  transglutaminase  I  and  involucrin  (Zou  et  al.  1994)  (Poddar  et  al. 
1991).  As  stated  above,  expression  of  these  specific  markers  in  HNSCC  is  aberrant  and 
indicative  of  an  abnormal  pattern  of  differentiation.  Therefore,  the  inhibitory  effect  of 
retinoids  in  this  cellular  context  could  suggest  their  involvement  in  restoring  the  normal 
pattern  of  differentiation.  Considering  that  the  onset  of  squamous  differentiation  normally 
requires  cessation  of  cellular  proliferation  (Fuchs  1990),  it  was  considered  potentially 
interesting  to  also  investigate  the  effects  retinoids  have  on  cellular  growth.  This  showed 
that  retinoids  exert  opposite  effects  on  keratinocytes  from  normal  oral  mucosa  and 
HNSCC,  the  former  being  stimulated  (Sundqvist  et  al.  1991)  and  the  latter  being  inhibited 
(Zou  et  al.  1994).  A  possible  explanation  for  this  is  that  in  malignant  cells  the  link  between 
cellular  growth  and  differentiation  is  not  as  tight  as  in  normal  cells. 
The  biological  effects  of  retinoids  are  mediated  by  a  complex  group  of  receptors.  Two 
families  of  cytoplasmic  receptors,  Cellular  Retinoid  Acid  Binding  Proteins  I  and  11 
(CRABP  I-10  and  Cellular  Retinol  Binding  Protein  I  and  II  (CRBP  I-10  are  responsible  for 
binding  these  molecules  on  the  cellular  surface,  metabolising  and  transporting  them  to  the 
nuclear  surface.  CRBP  II  is  expressed  exclusively  in  the  small  intestine,  and  is  therefore 
thought  to  participate  in  the  absorption  of  vitamin  A  (Crow  and  Ong  1985).  On  the  nuclear 
surface,  vitamin  A  and  retinoids  interact  with  nuclear  receptors,  comprising  dimers  of  the 
RAR  and/or  RY.  R  families,  which  belong  to  the  steroid  thyroid  hormone  receptor 
superfamily.  Both  RARs  and  RXRs  are  composed  by  three  isotypes,  a-p-y.  Alternative 
splicing  and  usage  of  different  promoters  gives  rise  to  further  isoforms  of  each  isotype. 
The  ligand  binding  pattern  of  these  two  families  of  receptors  is  also  different:  RARs  bind 
both  retinoic  acid  (RA)  and  9-cis-RA,  whereas  RXRs  bind  only  the  latter  and  other 
synthetic  analogues.  Retinoid  nuclear  receptors  are  formed  by  either  RXRs  homodimers  or 
RXR-RAR  heterodimers.  The  so  formed  receptors  then  act  as  ligand-dependent  DNA 
binding  transcription  factors,  whose  target  genes  are  largely  unknown  (summarised  in 
(I-eid  et  al.  1992)). Chapter  2 
2.3  Differential  expression  of  Nuclear  Retinold  Receptors  in  oral 
cancer  progression 
Nuclear  retinoid  receptors  seem  to  be  the  direct  mediators  of  the  action  of  retinoids  on 
gene  expression.  Tberefore,  a  great  interest  has  been  shown  over  the  past  decade  in  trying 
to  identify  patterns  of  differential  expression  in  normal  oral  mucosa,  premalignant  tissues 
and  SCCs.  Such  knowledge  would  be  crucial  not  only  in  understanding  the  physiological 
activities  of  retinoids,  but  also  in  targeting  treatment  or  prevention  of  oral  malignancies 
with  receptor  specific  drugs. 
Prominent  studies  on  retinoid  receptors  in  oral  cancer  have  been  carried  out  by  Reuben 
Lotan's  group.  Their  first  work  on  this  topic  was  carried  out  in  1991  (Crowe  et  al.  1991; 
Hu  et  al.  1991).  Normal  keratinocytes  were  cultured  from  the  non-keratinising  epithelium 
of  the  oral  mucosa  and  from  the  keratinising  epithelium  of  the  epidermis.  Expression  of 
RARa-y  mRNA  could  be  detected  in  all  the  cultures,  and  no  significant  changes  were 
observed  in  both  receptors  expression  in  relation  to  levels  of  retinoic  acid  present  in  the 
medium.  The  expression  of  RARP  was  more  variable:  it  was  detected  at  very  low  levels  in 
epidermal  keratinocytes  and  at  very  high  levels  in  oral  keratinocytes.  In  the  latter,  RARP 
levels  dramatically  dropped  when  cells  were  cultured  in  medium  containing  delipidized 
serum,  but  were  restored  upon  external  addition  of  RA  to  the  medium.  This  data  might 
suggest  that  while  RARa-y  are  likely  to  regulate  functions  common  to  all  keratinocytes, 
RARP  might  be  involved  in  regulating  different  patterns  of  suprabasal  differentiation  in 
stratified  non-keratinising  squarnous  epithelia. 
in  parallel  with  this  work,  the  expression  of  RAR  subunits  a-P-y  was  investigated  in  vitro 
in  oral  leukoplakias  and  SCCs  (flu  et  al.  1991).  This  study  demonstrated  loss  of  RARP 
expression  in  5/7  SCC  cultures  derived  from  non  keratinising  epithelium  of  the  oral  cavity, 
while  cultures  from  normal  mucosa  from  the  same  sites  expressed  RARP.  Cultures  of  two 
oral  leukoplakias  from  similar  sites  regularly  expressed  RARP,  but  the  number  of  samples 
was  insufficient  to  be  sure  that  this  was  a  trend.  On  the  other  hand,  no  significant  changes 
were  reported  in  RARa-y  expression  in  SCC  and  leukoplakia  cultures  compared  to  their 
normal  counterparts,  other  than  a  slight  reduction  in  levels  of  RARy.  Therefore,  this  study 
established  loss  of  RARP  as  a  frequent  event  in  oral  cancer. 
These  studies  were  then  extended  to  the  in  vivo  scenario  (Xu  et  al.  1994).  RAR  a-p-y  and 
RXR  a-P  expression  was  assessed  in  situ  in  a  large  number  of  biopsy  specimens  from Chapter  29 
normal  oral  mucosa,  normal  tissue  adjacent  to  SCC  lesions,  hyperplasias,  dysplasias,  and 
SCCs.  All  5  receptors  were  detected  in  all  of  the  biopsies  taken  from  healthy  volunteers 
with  no  significant  changes  found  in  the  expression  of  RARy  and  RXRa-P  across  the  panel 
of  samples  analysed  except  for  a  slight  decrease  in  the  percentage  of  premalignant  and 
malignant  samples  expressing  RARot.  The  major  variations  were  found  in  RARP 
expression:  in  keeping  with  the  in  vitro  findings,  expression  of  this  receptor  was  lost  in 
65%  of  carcinoma  samples  analysed,  and  interestingly  also  in  44%  of  oral  dysplasias  and 
in  27%  of  hyperplasias.  This  study  was  of  crucial  importance  not  only  because  it  extended 
the  in  vitro  findings  to  an  in  vivo  situation,  but  also  because  it  suggested  a  potential 
involvement  of  RARP  loss  at  early  stages  of  oral  cancer  progression. 
In  the  light  of  all  this  background  knowledge,  previous  work  from  our  group  (McGregor  et 
al.  1997)  has  analysed  RAR/RXR  ot-p-y  expression  in  a  series  of  primary  cultures  derived 
from  normal  oral  mucosa,  normal  tissue  adjacent  to  SCC  lesions,  dysplasias  and  SCCs 
(derived  by  Paul  Harrison's  and  Ken  Parkinson's  groups  at  the  Beatson  Institute  for  Cancer 
Research).  The  novel  information  available  in  our  study  was  the  proliferative  fate  of  all  the 
samples  analysed.  All  of  our  cultures  were  serially  passaged  until  they  reached  growth 
arrest  after  5-30  population  doublings  (and  defined  mortal)  or  until  they  proliferated 
beyond  the  100  population  doublings  threshold  (and  defined  immortal).  RXRct-y 
expression  was  not  detectable  in  any  of  the  cultures.  The  levels  of  RARa-y  and  RXRP  did 
not  show  any  consistent  changes  during  cancer  progression.  RARP  showed  a  much  more 
complex  pattern  of  expression.  In  cultures  from  normal  oral  mucosa,  RARP  was  barely 
detectable  in  vitro  unless  the  cells  were  treated  with  retinoic  acid,  but  it  was  readily 
detectable  in  the  corresponding  biopsies  in  vivo.  A  2-10  fold  induction  of  RARP 
expression  upon  retinoic  acid  treatment  has  been  reported  also  for  human  normal 
mammary  epithelial  cells  (Swisshelm  et  al.  1994).  In  mortal  dysplasias,  both  erythroplakias 
and  leukoplakias,  and  in  SCC,  RARP  expression  was  associated  with  the  proliferative  fate 
of  the  cultures.  Mortal  cultures  expressed  RARP  constitutively,  i.  e.  independently  of 
retinoic  acid  treatment,  whereas  all  of  the  immortal  cultures  had  lost  RARP  expression. 
The  only  tumour  expressing  RARP  was  also  the  only  one  that  senesced  in  culture. 
Recently  (McGregor  et  al.  2002),  our  group  has  extended  these  findings  to  a  wider  panel  of 
premalignant  and  malignant  lesions,  confirming  that  RARP  loss  of  expression  occurs  at  the 
dysplasia  stage  of  oral  cancer  progression  and  is  associated  with  the  acquisition  of  the 
immortal  phenotype.  The  only  exception  to  this  general  trend  is  our  culture  D17,  that 
proliferates  for  a  considerably  extended  life-span  (45  population  doublings)  but  is  still 
mortal.  The  features  of  D17  will  be  discussed  in  detail  in  the  Results  chapter  of  this  thesis. Chapter  2  10 
More  recently,  a  very  interesting  interventional  study  carried  out  by  Reuben  Lotan's  group 
(Wan  et  al.  1999)  further  refined  the  general  knowledge  on  the  role  of  RARP  in  mediating 
the  biological  effects  of  retinoids.  A  human  HNSCC  cell  line  that  naturally  expresses 
RXRa-p-y  and  RARa-y  but  lacks  RARP  expression  was  stably  transfected  with  a 
retroviral  vector  transducing  RARP2.  In  most  of  the  infected  clones  the  expression  of 
squamous  differentiation  markers  could  be  suppressed  with  doses  of  retinoids  that  were 
1/10.000  of  those  required  to  exert  the  same  effect  on  the  parental  line.  No  significant 
difference  could  be  observed  in  the  sensitivity  to  the  growth  inhibitory  effects  of  retinoids 
after  restoration  of  RARP  expression. 
To  corroborate  the  importance  of  RARP  in  carcinogenesis,  it  has  been  reported  that 
transgenic  mice  overexpressing  an  antisense  RARP2  transgene  are  prone  to  developing 
lung  turnours,  (Berard  et  al.  1996).  In  keeping  with  this,  expression  of  RARP  in  epidermoid 
lung  cancer-derived  cells  reduced  their  turnourigenicity  in  nude  mice  (Houle  et  al.  1993). 
2.4  RARP  and  senescence 
The  role  of  RARP  in  maintaining  the  mortal  phenotype  and  the  consequent  need  for  RARP 
silencing  to  allow  the  acquisition  of  the  immortal  phenotype  is  suggested  by  another 
finding  reported  by  our  group  (McGregor  et  al.  2002).  Keratinocytes  from  normal  oral 
mucosa  cultured  from  early  stages  to  senescence  showed  a  progressive  increase  of 
expression  of  RARP,  consistent  with  a  role  in  the  cellular  senescence  programme. 
Similarly,  an  up-regulation  of  RARP  expression  has  been  reported  in  senescing  normal 
human  mammary  epithelial  cells  (Swisshelm  et  al.  1994). 
2.5  Conclusions 
The  evidence  summarised  suggests  that  RARP  is  involved  in  several  biological  processes 
in  human  cells:  squamous  differentiation,  cellular  senescence  and  turnourigenicity.  In  oral 
cancer,  loss  of  RARP  expression  is  a  frequent  event  in  premalignant  lesions  and  SCCs  in 
vivo,  and  is  associated  with  the  acquisition  of  an  immortal  phenotype  in  vitro. 11 
3  The  role  of  Epidermal  Growth  Factor  Receptor  in 
oral  carcinogenesis 
3.1  Receptor  structure  and  signalling 
The  epidermal  growth  factor  receptor  (EGFR)  family  is  composed  of  four  members, 
EGFR,  c-erbB2,3  and  4.  They  are  located  on  the  cellular  surface  and  their  cytoplasmic 
domains  have  an  intrinsic  protein  tyrosine  kinase  activity.  Amongst  these  four  receptors, 
EGFR  is  the  only  one  able  to  bind  epidermal  growth  factor  (EGF)  and  transforming  growth 
factor  a  (TGF(x)  and  to  mediate  their  biological  activities.  In  response  to  ligand  binding, 
EGFR  forms  homodimers  or  heterodimers  with  its  preferential  binding  partner  c-erbB2  and 
becomes  activated  through  auto-phosphorylation  at  multiple  tyrosine  residues  (summarised 
in  (Mapper  et  al.  2000)).  The  precise  mechanisms  through  which  the  ligand  induced 
surface  signals  are  transmitted  to  the  nucleus  and  exert  their  effects  are  not  fully 
understood,  although  the  Stat  (signal  transducers  and  activators  of  transcription)  signalling 
pathway  seems  to  be  involved.  The  Stat  family  is  composed  by  seven  members:  Stat  1,2, 
3,4,5a,  5b  and  6)  (reviewed  in  (Aaronson  and  Horvath  2002)).  They  are  activated  in 
response  to  receptor-ligand  coupling  by  phosphorylation,  mainly  through  the  Janus  kinase 
(JAK)  receptor  associated  cytoplasmic  proteins.  Upon  activation,  Stat  proteins  dimerize 
and  translocate  to  the  nucleus,  where  they  bind  to  DNA  response  elements  and  therefore 
regulates  gene  expression.  The  EGFR  has  an  intrinsic  tyrosine  kinase  activity  and  it  has 
been  shown  to  directly  activate  Stat  1,3  and  5  (David  et  al.  1996).  Increased  activation  of 
Stat  3  has  been  reported  in  a  variety  of  turnours,  including  breast  cancer,  lung  cancer  and 
haernatologic  neoplasias  (summarised  in  (Bowman  et  al.  2000)).  Evidence  for  interactions 
between  EGFR/TGFa  and  Stat3  in  squamous  cell  carcinogenesis  has  been  brought  by 
interventional  studies  (Grandis  et  al.  1998)(a):  blocking  the  EGFR/TGFct  signalling 
pathway  by  either  TGFa  neutralizing  antibodies  or  EGFR-specific  tyrosine  kinase 
inhibitor  resulted  in  a  decrease  in  levels  of  activation  of  Stat3,  suggesting  that  Stat3 
activation  is indeed  linked  to  EGFR  signalling. 
3.2  Biological  effects  in  keratinocytes 
EGFR  and  its  ligands  are  involved  in  positively  regulating  keratinocyte  growth.  This  is 
primarily  suggested  by  the  absolute  requirement  for  EGF  when  keratinocytes  are 
maintained  in  culture.  Further  evidence  comes  from  the  fact  that  modulation  of  EGFR Chapter  3  12 
using  several  strategies,  such  as  the  use  of  inhibitors  of  EGFR  kinase  activity  (Bos  et  al. 
1997),  monoclonal  antibodies  or  antisense  oligonucleotides,  results  in  inhibition  of  cellular 
proliferation  in  HNSCC  cells  but  not  in  normal  mucosal  epithelial  cells,  as  assessed  by 
incorporation  of  H)  thymidine  (Grandis  et  al.  1997).  The  same  effect  were  observed 
using  antisense  oligonucleotides  against  TGFa  (Grandis  et  al.  1998)(b).  A  possible 
explanation  to  this  comes  from  the  observation  that  EGFR  is  overexpressed  in  SCC  cells, 
so  their  growth  might  be  more  dependent  on  the  EGFR  pathway  than  it  is  in  normal  cells. 
In  keeping  with  its  role  as  a  downstream  effector  in  the  EGFR  signalling  pathway,  Stat  3 
also  seems  to  play  a  role  in  stimulating  keratinocyte  growth,  since  transfection  of  HNSCC 
cells  with  a  dominant  negative  construct  of  Stat3  results  in  growth  arrest  (Grandis  et  al. 
2000). 
3.3  EGFR/TGFa  differential  expression  in  squamous  cell 
carcinoma  and  premalignant  lesions 
Considering  the  importance  of  EGFR  and  its  ligands  in  stimulating  keratinocyte  growth,  it 
was  a  plausible  hypothesis  that  a  quantitatively  or  qualitatively  abnormal  expression  of  this 
receptor  or  production  of  its  ligands  might  be  a  mechanism  utilised  by  squamous  cancer 
cells  to  acquire  a  proliferative  advantage  over  their  normal  counterparts.  Therefore,  a 
number  of  studies  have  been  carried  out  over  the  years  to  investigate  EGFR  and 
TGFa  expression  in  HNSCCs. 
EGFR  gene  amplification  and  protein  overexpression  was  initially  described  in  HNSCC 
samples  by  Ozanne  and  co-workers  (Ozanne  et  al.  1986).  Amplification  of  the  EGFR  was 
also  reported  in  10/12  HNSCC  cell  lines  by  Yamamoto  and  co-workers  (Yamamoto  et  al. 
1986),  but  only  in  4/21  HNSCC  cell  lines  in  a  later  study  (Ishitoya  et  al.  1989).  In  the  same 
experiments,  EGFR  protein  overexpression  was  found  in  approximately  half  of  the 
biopsies  from  well  differentiated  carcinomas  but  in  none  of  the  moderately  or  poorly 
differentiated  HNSCCs.  Following  these  early  studies,  an  increasing  amount  of  evidence 
has  since  accumulated  confirming  the  differential  regulation  and  expression  of  both  EGFR 
and  TGFa  in  head  and  neck  squamous  cell  carcinogenesis  suggested  earlier. 
Grandis  and  co-workers  (Grandis  and  Tweardy  1993)  analysed  EGFR  and  TGFct  mRNA 
expression  in  cultures  of  normal  oral  mucosa  and  HNSCC.  They  found  that  both  markers 
were  barely  detectable  in  normal  mucosa,  but  they  appeared  upregulated  in  HNSCC.  In Chapter  3  13 
keeping  with  this,  Stanton  and  collaborators  in  our  Institute  described  EGFR  upregulation 
in  8/10  cultures  from  oral  SCCs,  but  normal  levels  of  expression  in  2/2  erythroplakia 
cultures  (Stanton  et  al.  1994). 
Changes  in  EGFR  and  TGFct  expression  were  further  clarified  by  a  few  in  situ  studies  on 
fresh  biopsy  material.  Using  IHC  analysis,  Shin  and  co-workers  (Shin  et  al.  1994)  reported 
a  2-fold  increase  in  EGFR  expression  in  normal  epithelium  adjacent  to  turnours  compared 
to  normal  epithelium  from  healthy  individuals.  In  samples  from  normal  individuals,  the 
EGFR  expressing  cells  were  confined  to  the  basal  layer  of  the  epithelium,  while  in 
apparently  normal  samples  adjacent  to  SCCs  EGFR  expressing  cells  were  also  found  in  the 
suprabasal  layers.  The  upregulation  of  EGFR  in  macroscopically  normal  mucosa  adjacent 
to  turnours  could  be  an  effect  of  the  field  cancerization,  since  all  of  these  patients  had  a 
history  of  heavy  tobacco  use,  while  the  healthy  donors  had  never  smoked.  Similarly,  EGFR 
was  localised  in  basal  and  suprabasal  epithelial  layers  in  hyperplastic  and  dysplastic  lesion. 
At  the  carcinoma  stage,  a  further  increase  in  EGFR  expression  (3-fold)  was  observed,  and 
the  distribution  of  EGFR  positive  cells  was  extended  to  all  epithelial  layers,  including  the 
most  superficial  ones.  Similar  data  were  reported  by  Grandis  and  collaborators  for  the 
expression  of  the  ligand  for  EGFR,  TGFa  (Grandis  et  al.  1996)  (Grandis  et  al.  1998)(c).  In 
normal  oral  mucosa  from  non-smoking  donors,  EGFR  was  barely  detectable  and  TGFa 
staining  was  confined  to  the  suprabasal  layers  of  the  epithelium.  In  premalignant  lesions, 
EGFR  was  slightly  upregulated  in  mild  dysplasias  (1.5  fold)  and  moderate/severe 
dysplasias  (2.5  fold);  TGRE  was  slightly  upregulated  in  mild  dysplasias  (1.5  fold)  with  no 
further  upregulation  in  more  severe  dysplasia.  In  HNSCC  biopsies,  strong  staining  could 
be  observed  for  both  markers  throughout  all  epithelial  layers,  particularly  at  the  advancing 
margins  of  the  turnours,  although  the  absolute  increase  in  both  markers  was  only  2-fold 
compared  to  normal  mucosa  from  healthy  donors.  The  increased  production  of  both  EGFR 
and  its  ligand  TGFa  in  all  the  mucosal  layers  in  HNSCC  is  the  most  relevant  finding  of 
these  works,  suggesting  a  switch  from  a  paracrine  to  an  autocrine  growth  pathway.  This 
would  confer  cancer  cells  a  greater  proliferative  capacity  compared  to  normal 
keratinocytes,  and  a  relative  independency  from  the  levels  of  circulating  growth  factors. 
Higher  levels  of  EGFR  and  TGFa  protein  expression  were  also  found  to  be  negative 
predictors  of  patients  survival  (Grandis  et  al.  1998)(d). Chapter  3 
3.4  c-erbB-2  receptor  subunit  in  oral  cancer 
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Following  the  observation  that  EGFR/c-erbB2  heterodimers  are  more  stable  and  therefore 
dissociate  from  the  ligand  more  slowly  than  any  other  combination  of  subunits,  a  few 
studies  have  assessed  the  involvement  of  c-erbB2  expression  in  SCC.  Xia  and  co-workers 
(Xia  et  al.  1997)  reported  a  strong  association  between  c-erbB-2  expression  and  poor 
survival  in  patients  with  oral  SCC.  In  a  more  recent  study  by  the  same  group,  protein 
expression  of  all  the  EGFR  family  members  was  assessed  in  situ  in  a  large  number  of 
specimens  from  primary  oral  SCC  (Xia  et  al.  1999).  The  authors  reported  that  c-erbB2 
expression  was  correlated  with  lymph  node  metastasis  and  poor  disease  outcome. 
Similarly,  0-charoenrat  and  co-workers  describe  a  strong  association  between 
overexpression  of  three  members  of  the  EGFR  family  (EGFR,  c-erbB2  and  c-erbB3)  and 
advanced  stages  of  HNSCC,  particularly  with  nodal  metastases  (0-charoenrat  et  al.  2002). 
High  levels  of  c-erbB2  have  also  been  reported  in  three  cell  lines  derived  from  oral  SCC 
(Xia  et  al.  1999). 
3.5  Conclusions 
EGFR  gene  amplification  and  protein  overexpression  are  frequent  events  in  HNSCC  in 
vitro.  In  vivo,  EGFR  is  barely  detectable  in  normal  samples  and  confined  to  the  basal 
layers,  and  its  ligand  TGFcc  is  expressed  at  low  levels  only  in  the  suprabasal  epithelial 
layers.  Slight  increases  of  EGFR  and  TGFa  expression  are  observed  in  dysplasias.  In 
contrast,  SCC  express  high  levels  of  both  EGFR  and  its  ligand  TGFa  in  all  layers  of  the 
epithelium,  consistent  with  the  development  of  an  autocrine  pathway.  Both  markers  are 
indicators  of  poor  prognosis  in  HNSCC. 15 
4  Cell  cycle  regulators 
Mammalian  cells  are  simultaneously  exposed  to  a  large  number  of  stimuli  from  the 
extracellular  microenvironment:  growth  factors,  anti-mitogens  and  differentiation  inducers. 
Cells  are  sensitive  to  such  stimuli  until  a  stage  in  late  G1  phase  of  cell  cycle,  named 
restriction  point,  when  they  irreversibly  commit  to  either  entering  the  S  phase  and 
completing  cell  division,  or  to  arrest  in  a  quiescent  state  (GO).  The  cell  cycle  machinery 
governing  cellular  proliferation  is  activated  and  regulated  by  a  complex  interaction 
between  cyclins,  cyclin-dependent-kinases  (cdks)  and  negative  regulators,  like  cdk 
inhibitors,  p53  and  other  players.  These  molecules  exercise  their  functions  at  specific 
stages  of  the  cell  cycle:  GUS  transition,  S  phase,  G2/M  transition,  mitosis.  The  following 
sections  summarise  in  a  simplified  way  how  the  most  relevant  of  these  molecules  interact 
and  result  in  cells  completing  the  mitotic  division  or  pausing  in  a  growth  arrest  status  (fig. 
2). 
4.1  Gl  cyclins  and  cdks 
D-type  cyclins  (D1,  D2  and  D3)  are  key  regulators  of  the  G1-S  phase  of  the  cell  cycle 
(reviewed  in  (Sherr  1994)).  They  are  expressed  in  a  lineage-specific  manner,  and  the 
different  subtypes  show  a  greater  intra  subtype  conservation  in  evolution  than  inter- 
subtype  variation  within  a  species,  suggesting  that  they  are  not  functionally  redundant. 
Their  synthesis  is  strictly  dependent  upon  cellular  exposure  to  mitogenic  stimuli:  it  begins 
during  the  GO/G1  transition,  reaches  a  peak  level  when  cells  approach  the  S  phase  and  then 
remains  constant  during  later  phases  of  the  cell  cycle  (Matsushime  et  al.  1994).  Upon 
mitogen  withdrawal,  their  levels  drop  dramatically.  They  assemble  into  functional 
complexes  with  two  different  cyclin-dependent-kinases:  cdk4  and  cdk6.  Again,  assembly 
of  the  two  subunits  into  an  active  kinase  complex  requires  the  presence  of  mitogens.  The 
association  of  D-type  cyclins  and  their  cdk  partners  appears  to  be  transient,  allowing  cdks 
to  associate  with  other  partners  during  different  phases  of  the  cell  cycle  (Sherr  1993). 
D-type  cyclins  are  able  to  bind  directly  to  retinoblastoma  (Rb)  protein  and  phosphorylate  it 
through  their  catalytic  component  cdk4/6  (Kato  et  al.  1993).  The  phosphorylated  form  of 
Rb,  pRb,  is  no  longer  able  to  bind  to,  and  inhibit  the  functions  of,  transcription  factors,  like 
E2F,  involved  in  G1/S  transition  (Matsushime  et  al.  1994). Chapter  4 
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Fig.  2:  Cell  cycle  regulators. 
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Graphic  illustraton  of  the  cell  cycle  and  its  regulators.  The  major  cyclins, 
cyclin  dependent  kinases  and  cdk  inhibitors  are  indicated  (see  text  for 
discussion).  GI:  "Gap"  phase  1,  S:  DNA  synthesis  phase;  G2:  "Gap" 
phase  2;  M:  mitosis. 
16 Chapter  4  17 
As  cells  approach  the  Gl/S  boundary,  the  kinase  activity  of  cyclinD/cdk4-6  complex 
gradually  increases,  Rb  is  phosphorylated,  E2F  is  released  from  the  inhibitory  complex 
with  Rb,  target  genes  involved  in  S  phase  initiation  are  transcribed  and  cells  proceed  to  the 
S  phase. 
Cyclin  E  is  involved  in  the  G1  phase  of  cell  cycle,  as  well  as  the  various  cyclin  Ds.  Its 
expression  is  periodical,  reaching  a  peak  just  before  the  onset  of  S  phase  and  being 
degraded  immediately  after  (Koff  et  al.  1992).  It  forms  an  active  complex  exclusively  with 
cdk2,  but  the  precise  functions  of  this  complex  are  not  clear  (Koff  et  al.  1992).  Cyclin  E  is 
not  able  to  bind  Rb  directly,  but  inhibition  of  cdk2  prevents  mammalian  cells  from  entering 
the  S  phase,  suggesting  that  this  complex  has  indeed  a  crucial  function  in  allowing  cell 
cycle  to  progress  (Pagano  et  al.  1993). 
4.2  S  and  M  cyclins  and  cdks 
As  cyclin  E  undergoes  degradation  during  the  S  phase,  its  binding  partner  cdk2  assembles 
with  cyclin  A.  CyclinA/cdk2  complexes  are  initially  detected  as  cells  start  approaching  the 
Gl/S  boundary,  accumulate  during  the  S  and  G2  phases  and  are  degraded  at  late  stages  of 
cell  cycle  (Pines  and  Hunter  1991).  Although  their  role  is  not  precisely  known,  inhibition 
of  cyclin  A  function  inhibits  DNA  replication  and  disrupts  the  critical  temporal  gap 
between  S  and  G2  phases,  suggesting  their  involvement  in  this  stage  rather  than  the  G1 
phase  of  cell  cycle  (Girard  et  al.  1991). 
On  the  other  hand,  cyclin  B  is  known  to  be  involved  both  in  entry  to  and  in  exit  from 
mitosis.  It  is  synthesized  during  S  phase  of  cell  cycle,  forms  active  complexes  with  cdk1 
(also  named  cdc2)  and  exerts  its  kinase  activity  during  M  phase  (Pines  and  Hunter  1991). 
At  anaphase,  cyclin  B  is  rapidly  degraded  and  cdk1  released  in  its  inactive  form.  This 
process  is  thought  to  regulate  cellular  exit  from  mitosis  (Murray  1989). 
4.3  Inhibitors  of  cyclins  and  cdks 
An  additional  level  of  regulation  on  cell  cycle  progression  is  obtained  through  two  families 
INK4a  INK4b  INK4c 
of  cell  cycle  inhibitors,  the  INK4  family  with  its  members  p16  ,  p15  ip  p18  I 
p14A"  (reviewed  in  (Roussel  1999))  and  the  CIP/KIP  family  with  its  members 
p2jCIP1/WA,  F1,  p27  KIP'  and  p57  KW2  (reviewed  in  (Sherr  and  Roberts  1995)).  The  INK4  family 
inhibits  specifically  the  cyclin  D  binding  partners  cdk4  and  cdk6,  whereas  the  CIP/KIP 
family  is  able  to  inhibit  all  cdks. Chapter  4  18 
p2l  is  considered  a  universal  cdk  inhibitor,  since  it  is  capable  of  binding  both  cyclin  D 
type  dependent  kinases  cdk4/cdk6  and  cyclin  E  and  A  dependent  kinase  cdk2  (Harper  et  al. 
1995).  In  addition,  p2l.  is  able  to  inhibit  DNA  synthesis  directly  by  binding  PCNA  (Xiong 
et  al.  1992)  which  is  a  subunit  of  DNA  polymerase  8  and  functions  both  in  DNA 
replication  and  repair.  p2l  expression  is  positively  regulated  by  p53  and  its  levels  increase 
in  response  to  p53  mediated  DNA  damage  signals  (el-Deiry  et  al.  1993).  Considering  its 
dual  ability  to  inhibit  DNA  synthesis  both  directly  (through  PCNA)  and  indirectly  (through 
cdks/Rb/E2F  pathway)  and  its  regulation  by  p53,  p2l  is  considered  as  a  mediator  of  p53 
dependent  cell  cycle  arrest  in  G1. 
p27  is  thought  to  be  involved  the  cellular  decision-making  process  between  quiescing  in 
GO  or  entering  G1,  rather  than  in  the  regulation  of  cell  division  itself.  The  levels  of  p27  are 
known  to  increase  in  response  to  a  variety  of  anti-mitogenic  signals  and  to  remain  elevated 
during  GO  (Firpo  et  al.  1994).  When  cells  commit  to  cell  cycle  progression  and  enter  G1/S 
phase,  p27  is  dramatically  downregulated  as  a  result  of  titration  by  cyclinD/cdk4-6 
complexes.  This  drop  in  levels  of  p27  also  causes  activation  of  cyclinE/cdk2  complexes, 
allowing  the  cells  to  proceed  into  the  following  phases  of  cell  cycle  (Polyak  et  al.  1994). 
The  INK4a  locus  is  unusually  complex  in  its  genomic  organization,  since  it  encodes  two 
different  proteins  regulated  by  different  promoters  and  translated  with  different  reading 
frames:  p16  INK4a  and  p14ARF(p19A"  being  its  mouse  homologue)  (Quelle  et  al.  1995).  p16 
results  from  the  transcription  of  exons  la-2-3,  whereas  pl4ARFtranscription  starts  at  exon 
IP  (located  upstream  of  exon  RE),  and  proceeds  with  the  same  exons  2-3  as  p16  (fig.  3). 
Both  p16  and  p14ARF  are  considered  tumour  suppressor  proteins,  but  their  roles  in  cell 
cycle  regulation  are  completely  different.  p16  specifically  binds  and  inhibits  cdk4  and 
cdk6.  As  previously  discussed,  these  kinases  are  the  major  catalytic  partners  for  D-type 
cyclins,  and  collaborate  with  cyclin  E/cdk2  in  controlling  the  G1/S  transition  in 
mammalian  cells.  p16  mainly  binds  cdk4,  destabilizing  cyclinD/cdk4  complexes  and 
therefore  preventing  Rb  phosphorylation  and  leading  cells  to  G1  arrest  (Serrano  et  al. 
1993).  A  negative  feedback  loop  seems  to  exist  between  Rb  and  p16:  human  cells  lacking 
functional  Rb  through  mutations  or  expression  of  viral  oncoproteins  have  high  levels  of 
p16,  sufficient  for  sequestering  all  the  available  cdk4/cdk6  and  preventing  them  from 
binding  with  D-type  cyclins  (Li  et  al.  1994)  (Parry  et  al.  1995).  p16  is  also  implicated  (and 
probably  better  known)  for  its  role  in  the  process  of  cellular  senescence,  which  will  be 
discussed  in  a  later  chapter. Chapter  4 
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Fig.  3:  The  INK4a  locus  in  the  mouse. 
Graphic  illustration  of  the  INK4a  genomic  organization.  p16  is  encoded 
by  exons  la,  2  and  3  (red  boxes),  plV'"  (the  mouse  homologue  of 
human  p  14"')  is  encoded  by  exons  I  P,  2  and  3  (green  boxes).  The  white 
boxes  correspond  to  non-coding  5'  and  3'  regions.  Splicing  between  the 
exons  is  indicated  by  the  connecting  lines.  In  the  mouse,  exons  I  (x  and  I 
are  separated  by  an  intronic  sequence  of  approximately  13  Kb  length. 
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p14ARFdoes  not  bind  to  cdks,  but  rather  interacts  with  mdm2  and  stabilizes  p53  (discussed 
in  more  detail  below),  thus  participating  in  the  p53  pathway  leading  cells  to  G1  or  G2 
arrest  or  to  apoptosis.  p14  ARF  expression  is  activated  by  cellular  oncogenes  like  Myc 
(Zindy  et  al.  1998),  ElA  (de  Stanchina  et  al.  1998)  and  E2F-1  (Bates  et  al.  1998),  and 
mediates  p53-dependent  cell  cycle  arrest  or  apoptosis  in  response  to  these  stimuli.  This 
could  provide  an  additional  control  on  abnormal  cell  proliferation  in  response  to  oncogenic 
stimuli  like,  for  example,  loss  of  Rb  expression.  According  to  recent  evidence,  p14  ARF 
overexpression,  whether  induced  directly  or  through  E2F-1,  causes  cellular  senescence  in 
normal  human  fibroblasts,  and  this  effect  is  dependent  on  the  integrity  of  the  p53-p2l 
pathway  (Dimri  et  al.  2000)  (Wei  et  al.  2001).  Therefore,  a  novel  role  of  p14  A"  is  that  of 
participating  in  the  mechanisms  regulating  cellular  senescence. 
4.4  p53 
As  outlined  above,  several  structurally  related  proteins  (p16  and  p14,  p2l  and  p27)  exert 
their  roles  on  completely  different  signalling  pathways  that  may  function  either  as  positive 
or  as  negative  regulators  of  cell  division.  These  pathways,  although  somehow  distinct  and 
different,  are  inter-related  by  a  high  degree  of  "cross  talk"  as  they  converge  to  provide  a 
complex  mechanism  that  governs  cellular  proliferation. 
p53  is  a  transcription  factor  that  acts  as  a  central  relay  in  this  intricated  net  of  upstream  and 
dowstream  signals,  leading  to  cell  cycle  arrest  or  apoptosis  in  response  to  a  variety  of 
stimuli.  p53  also  has  a  role  in  cellular  senescence,  as  do  some  of  the  other  molecular 
markers  previously  described,  and  this  will  be  discussed  in  a  subsequent  chapter. 
4.4.1  Structure  and  regulation 
The  full  length  p53  protein  consists  of  393  amino  acids  and  can  be  divided  into  four 
functional  domains  (reviewed  in  (Levine  1997)  and  (Ryan  et  al.  2001))  (fig.  4).  The  43 
amino  terminal  residues  are  involved  in  transcriptional  activation  of  several  downstream 
target  genes,  and  they  also  represent  the  binding  site  for  negative  regulators  of  p53 
function,  like  MDM2.  The  DNA  binding  domain  of  p53  is  located  between  amino  acid 
residues  102  and  292,  and  their  importance  for  the  function  of  this  protein  is  testified  by 
the  fact  that  over  90%  of  mutations  described  are  located  in  this  domain.  p53  is  a  tetramer 
in  solution,  and  aminoacid  residues  324-355  are  responsible  for  its  tertiary  structure. Chapter  4 
N 
Tetra-  Regulatio 
merization 
H 
1-43  63,92  102-292  324-365  363-393 
N-terminus  Core-domain  C-terminus 
248  273 
175 
9  282 
L 
., 
I  JL 
63 
m 
N 
s 
0 
140  16216  184  18 
34.29/o  609/0 
4  0.29/o  CP/O 
2.29/o  1  6.79/o 
23.49/o  33.3/o 
Adapted  from  Olivier  and  Hainaut,  International  Agency  of  Research  on  Cancer 
)  p53  mutation  database,  2002 
Fig.  4:  p53  protein  and  localization  of  mutations. 
Graphic  illustraton  of  the  p53  protein  and  the  mutations  reported  in  human 
cancer  (IACR  database,  updated  to  year  2002). 
p53  protein  and  the  aminoacids  codifying  for  the  different  functional 
domains  are  illustrated  in  the  top  section  of  the  figure. 
In  the  bottom  section,  the  total  number  of  mutations  identified  in  each 
domain  is  reported  (T),  divided  into  the  respective  percentage  of  missense 
mutations  (M),  nonsense  mutations  (N),  silent  mutations  (S)  and  other 
mutations  (0).  A  comparative  illustration  of  the  specific  codons  mutated 
in  the  DNA  binding  domains  is  also  presented. 
Most  of  the  p53  mutations  are  missense  mutations,  localized  in  the  DNA- 
binding  domain. 
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The  carboxy  terminal  26  aminoacid  residues  are  involved  in  regulating  the  ability  of  p53 
core  domain  to  bind  to  specific  DNA  sequences:  in  a  functionally  inactive  protein,  it  folds 
back  and  "covers"  the  central  domain,  preventing  it  from  binding  to  DNA  consensus 
sequences  of  target  genes. 
Since  p53  is  an  important  mediator  of  cell  cycle  arrest  and  apoptosis,  its  regulation  needs 
to  be  strict  to  allow  cells  to  normally  proliferate.  Regulation  of  p53  function  is  exerted  at 
different  levels  and  entails  degradation  of  the  protein  by  nuclear  export  and  ubiquitination 
or  stabilization  mainly  through  phosphorylation  and  acetylation. 
The  levels  of  p53  in  ce 
' 
Ils  are  normally  low  due  to  its  short  half-life,  and  its  rapid  turnover 
is  mainly  due  to  interactions  between  the  N-terminus  of  p53  and  MDM2  protein  (Kubbutat 
et  al.  1997).  MDM2  is  responsible  for  ubiquitin  ligation  of  p53,  nuclear  export  and 
subsequent  degradation  by  the  cytoplasmic  proteolytic  machinery  (Roth  et  al.  1998).  A 
feedback  loop  exists  between  MDM2  and  p53,  the  latter  being  a  positive  regulator  of 
MDM2  transcription  (Wu  et  al.  1993). 
Another  level  of  p53  regulation  is  represented  by  its  post-translational  modifications.  As 
mentioned  in  the  structural  description  of  p53,  the  amino  terminus  has  a  binding  site  for 
MDM2.  Phosphorylation  of  this  domain  at  serine  15  and  37  or  at  serine  20  does  not  affect 
the  DNA  binding  properties  of  p53,  but  it  decreases  its  affinity  to  MDM2,  therefore 
preventing  its  degradation  and  increasing  the  protein  levels  (Shieh  et  al.  1997).  The 
carboxy  terminus  of  p53  is  regulated  by  phosphorylation  at  serine  392  (Kapoor  and  Lozano 
1998)  and  acetylation  at  lysine  residues  320  and  382  (Sakaguchi  et  al.  1998).  These 
modifications  lead  to  activation  of  the  DNA  binding  domain,  possibly  by  interfering  with 
its  folded  structure.  Nevertheless,  phosphorylation  of  p53  does  not  appear  to  be  essential 
for  its  transcriptional  activity:  several  C-terminal  and/or  N-terminal  phosphorylation  site 
p53  mutants  lost  the  ability  to  be  phosphorylated  at  the  corresponding  mutant  site  but 
retained  the  transcriptional  activation  function  (Ashcroft  et  al.  1999). 
4.4.2  Upstream  regulators 
p53  is  activated  by  a  variety  of  cellular  stresses,  including  DNA  damage,  viral  and  cellular 
oncogenes  (fig.  5).  In  response  to  these  stimuli,  p53  mediates  cell  cycle  arrest  to  allow  for 
DNA  repair  mechanisms  to  take  place  or,  when  the  extent  of  the  damage  exceeds  the 
possibility  of  repair,  leads  the  cell  to  apoptosis. Chapter  4 
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Fig.  5:  Upstream  regulators  of  p53 
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Graphic  illustration  of  the  main  upstream  activators  of  p53  (see  text  for 
discussion).  Signals  creating  a  DNA  damage  effect  or  an  uncontrolled 
proliferation  are  known  to  activate  p53  and  mediate  cell  cycle  arrest  or 
apoptosis. 
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These  functions  of  p53  provide  an  efficient  mechanism  to  inhibit  the  proliferation  of  those 
cells  that  show  genetic  abnormalities  (for  a  recent  review,  see  (Woods  and  Vousden 
2001)). 
Several  different  types  of  DNA  damage  signals  are  able  to  activate  p53,  including 
ultraviolet  irradiation,  ionising  radiation  and  chemical  damage  induced  by  topoisomerase 
inhibitors  (like  etoposide  or  camphotecin)  or  chemotherapeutic  agents  (like  adriamycin). 
Although  they  all  cause  an  increase  in  levels  of  p53  and  an  activation  of  its  transcriptional 
activity,  they  exert  this  common  function  through  different  pathways.  Ionising  Radiation 
activates  p53  through  a  double-strand  break  signal  requiring  the  integrity  of  ataxia 
teleangectasia  mutated  (ATM)  protein,  as  suggested  by  the  delayed  and  attenuated 
response  observed  in  cells  from  ataxia-teleangectasia  patients  who  harbour  mutations  in 
the  ATM  gene  (Kastan  et  al.  1992).  The  downstream  effector  of  ATM  gene  is  the  protein 
kinase  Chk2:  its  activity  is  required  to  stabilise  p53  in  response  to  y-irradiation  (Hirao  et  al. 
2000).  In  contrast,  ultraviolet  irradiation  does  not  cause  p53  stabilization  through  ATM  or 
Chk2  (Canman  et  al.  1998)  (Hirao  et  al.  2000).  Recent  evidence  has  shown  that  ataxia 
teleangectasia  related  (ATR)  protein  binds  to  and  is  activated  by  ultraviolet-damaged  DNA 
(Unsal-Kacmaz  et  al.  2002),  and  in  turn  activates  phosphorylation  of  its  downstream 
effector  Chk1  (Liu  et  al.  2000).  It  has  also  been  demonstrated  that  casein  kinase  II  (CKII) 
phosphorylates  p53  in  response  to  UN.  but  not  ionising  radiation  (Kapoor  and  Lozano 
1998).  These  data  indicate  that  the  pathway  linking  ultraviolet-induced  DNA  damage  is 
distinct  from  that  elicited  by  y-iffadiation  and  possibly  involves  ATR,  Chk1  and  CKII. 
In  addition  to  its  role  in  safe-guarding  the  integrity  of  the  genome  from  double  strand 
breaks,  p53  also  provides  an  oncogene  checkpoint  that  mediates  cellular  apoptosis  in 
response  to  hyperproliferative  stimuli.  Viral  oncogenes  like  the  adenovirus  protein  E1A 
and  cellular  oncogenes  like  Myc,  Ras  and  E217  are  able  to  activate  p53  through  a  p14  ARF 
mediated  signalling  pathway,  as  reported  by  several  studies  in  humans  and  mice  (Bates  et 
al.  1998)  (de  Stanchina  et  al.  1998)  (Zindy  et  al.  1998).  Once  activated  by  oncogenes,  ARF 
is  able  to  stabilize  p53  through  direct  interaction  with  the  carboxy  terminus  of  MDM2, 
which  in  turn  binds  p53  with  its  own  amino  terminal  domain.  This  complex  interaction 
closes  the  circuit  between  cell  cycle  promotion  through  pRb  and  apoptotic  or  growth-arrest 
responses  to  hyperproliferative  stimuli  occurring  during  oncogene  expression. Chapter  4 
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Once  p53  is  activated,  a  series  of  downstream  events  take  place,  most  of  which  lead  to  cell 
cycle  arrest  in  G1  or  G2,  DNA  repair  or  apoptosis  (fig.  6).  The  main  downstream  target  of 
p53  in  the  induction  of  G1  cell  cycle  arrest  is  p2l.  Its  role  in  inhibiting  cyclinD/cdk4-6  and 
cyclinE/cdk2  complexes  has  been  discussed  above.  p53-induced  G2  arrest  in  response  to 
DNA  damage  is  mediated  by  both  p2l  and  14-3-3(j.  The  latter  exerts  its  effect  by  binding 
to  cycIinB/cdc2  complexes  and  sequestering  them  to  the  cytoplasm,  thus  inhibiting  cell 
cycle  progression  (Chan  et  al.  1999).  Recently  it  has  also  been  shown  that  the  roles  of  p2l 
and  14-3-3(:  y  in  mediating  the  G2-M  block  triggered  by  p53  are  complementary:  14-3-30-1- 
p21-1-  cells  died  significantly  sooner  than  cells  lacking  only  one  of  the  two  genes  in 
response  to  DNA  damage  (Chan  et  al.  2000). 
Another  function  of  activated  p53  is  that  of  leading  to  programmed  cell  death.  The  ability 
of  p53  to  directly  activate  BAX  protein,  which  is  a  member  of  the  Bcl-2  family,  has  been 
known  for  years  (Miyashita  and  Reed  1995).  Another  member  of  the  Bcl-2  family,  NOXA 
(Oda  et  al.  2000)(a)  and  two  novel  genes,  PUMA  (Nakano  and  Vousden  2001)  and 
p53AIP1  (Oda  et  al.  2000)(b)  have  recently  been  described  to  mediate  the  p53-related 
apoptotic  response.  These  proteins  localise  to  the  mitochondria,  trigger  cytochrome  C 
release,  activation  of  the  caspases  and  subsequent  cell  death. 
Once  the  DNA  damaged  cells  have  stopped  in  G1  or  G2  phase  of  cell  cycle,  DNA  repair 
mechanisms  need  to  be  triggered  before  the  cells  can  be  allowed  to  proceed  to  further 
stages  of  cell  division.  Although  the  pathways  involved  are  not  completely  clear,  it  has 
been  speculated  that  p53  may  be  also  directly  involved  in  these  regulatory  mechanisms. Chapter  4 
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Fig.  6:  Mediators  of  p53  dependent  cell  cycle  arrest  and  apoptosis 
Graphic  illustration  of  the  main  mediators  of  the  effects  of  p53  in  cell 
cycle  regulation  and  apoptosis  (see  text  for  discussion).  p53  exerts  its 
control  on  cell  cycle  progression  mainly  through  p2l  and  its  inhibitory 
effect  on  cyclinE/cdk2.  Regulation  of  apoptosis  implicates  several  p53 
activated  molecules,  BAX  being  the  best  known.  p53  also  participates  in 
regulation  of  its  own  stability  through  a  regulatory  feed-back  loop 
ARF  involving  MDM2  and  p  14 
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5  Changes  in  cell  cycle  regulators  in  oral  cancer 
Out  of  the  many  cell  cycle  regulators  described  in  the  previous  chapter,  dysregulation  of  a 
number  seem  to  be  involved  in  head  and  neck  carcinogenesis. 
5.1  Cyclin  D1 
Amplification  of  the  11q13  region  of  chromosome  11  was  reported  in  8/23  (35%)  fresh 
samples  and  2/6  (33%)  cell  lines  from  HNSCC  by  Berenson  and  collaborators  (Berenson  et 
al.  1989)  and  in  5/66  (7%)  frozen  biopsies  from  HNSCC  by  Leonard  and  collaborators 
(Leonard  et  al.  1991).  Despite  the  frequent  amplification  of  this  locus,  none  of  the  three 
genes  known  at  the  time  to  be  located  on  11q13  (bcl-1,  int-2  and  hst-1)  was  overexpressed 
in  tumours,  suggesting  that  none  of  them  were  significant  targets  of  the  amplification 
(Berenson  et  al.  1989)  (Faust  and  Meeker  1992).  A  novel  oncogene,  PRAD-1,  was  later 
identified  in  this  locus,  encoding  for  cyclin  D1  (Motokura  et  al.  1991). 
Since  then,  amplification  of  PRAD-1  and  overexpression  of  cyclin  D1  gene  have  been 
reported  by  several  studies  of  HNSCC  in  vivo.  Callender  (Callender  et  al.  1994)  has 
described  a  2-10  fold  amplification  in  34%  of  fresh  samples  from  HNSCC  using  southern 
blotting  and  Okami  (Okami  et  al.  1999)  reported  a  2-6  fold  amplification  in  4/11  turnours 
using  Fluorescence  In  situ  Hybridization  (FISH).  A  2-12  fold  amplification  of  PRAD-1 
was  also  reported  in  17/46  (37%)  laryngeal  tumours,  by  Jares  (Jares  et  al.  1994),  and  a 
significant  association  was  found  between  gene  amplification  and  mRNA  over-expression. 
This  report  adds  a  functional  significance  to  the  occurrence  of  PRAD-1  locus 
amplification.  In  fact,  similar  percentages  of  HNSCCs  have  been  reported  as 
overexpressing  cyclin  D1  protein  in  vivo:  48%  by  Bartkova  (Bartkova  et  al.  1995),  40%  by 
Koontongkaew  (Koontongkaew  et  al.  2000)  and  26%  by  Schoelch  (Schoelch  et  al.  1999). 
Recently,  PRAD-1  amplification  and  cyclin  D1  overexpression  have  been  described  in  oral 
premalignant  lesions  and  carcinomas  in  vivo  (24-45%),  but  no  correlation  was  found 
between  percentage  of  samples  with  amplified  cyclin  D1  gene  and  increasing  degrees  of 
dysplasia  or malignant  transformation  (Rousseau  et  al.  2001). 
The  evidence  for  cyclin  D1  expression  in  oral  cancer  cell  lines  in  vitro  is  not  as  definitive. 
Both  Bartkova  (Bartkova  et  al.  1995)  and  Okami  (Okami  et  al.  1999),  in  two  separate 
studies  have  reported  cyclin  D1  gene  amplification  in  HNSCC  cell  lines,  but  the  number  of Chapter  5  28 
samples  analysed  in  each  study  is  very  small  (3  and  4  respectively)  and  requires  a  cautious 
interpretation. 
The  study  by  Okami  and  collaborators  also  analysed  cyclin  D1  in  the  context  of  the  p16/Rb 
pathway,  of  which  cyclin  D1  and  its  binding  partner  cdk4  are  crucial  components  (Okami 
et  al.  1999).  These  authors  reported  that  amplification  of  cyclin  D1  and  inactivation  of  p16 
are  not  mutually  exclusive,  being  found  in  concordance  in  2/4  cell  lines  and  4/4  tumour 
samples.  On  the  contrary,  loss  of  Rb  and  loss  of  p16  were  never  found  together.  Overall, 
21/23  turnours  contained  at  least  one  alteration  in  the  p16/cyclin  Dl/Rb  pathway. 
In  view  of  its  frequent  amplification/overexpression  in  HNSCC,  several  authors  have 
analysed  cyclin  D1  expression  in  vivo  in  relation  to  prognosis.  In  a  large  cohort  of  patients 
with  SCC  of  the  anterior  tongue,  cyclin  D1  was  found  overexpressed  in  68%  of  cases,  and 
this  correlated  with  high  tumour  grade  and  reduced  survival,  particularly  when  associated 
with  loss  of  p16  expression  (Bova  et  al.  1999).  A  retrospective  study  carried  out  by 
Michalides  in  1995  (Michalides  et  al.  1995)  involving  47  patients  with  HNSCC 
demonstrated  a  clear  correlation  of  overexpression  of  cyclin  D1  with  disease  recurrence 
and  shortened  survival.  Finally,  an  association  between  cyclin  D1  overexpression  and 
advanced  tumour  stage  and  regional  lymph-node  metastasis  has  recently  been  reported 
(Carlos  de  Vicente  et  al.  2002).  Overall,  these  data  indicate  that  overexpression  of  cyclin 
D1  is  an  indicator  of  poor  prognosis  in  HNSCC. 
5.2  Polo-Like-Kinase 
Polo-like  kinase  (PLK)  is  a  member  of  a  family  of  serine/threonine  kinases.  It  represents 
the  mammalian  homologue  of  Polo  kinase  in  Drosophila  Melanogaster  and  of  CDC5  in 
Saccharomyces  cerevisiae.  Its  role  in  regulating  G2-M  transition  in  mammals  is  suggested 
by  its  increased  total  levels  and  phosphorylation  status  when  cells  approach  the  M  phase  of 
cell  cycle.  It  is  also  involved  in  bipolar  spindle  formation,  as  suggested  by  its  transient 
association  with  the  spindle  apparatus  and  the  centromere  region  of  mitotic  chromosomes. 
It  has  also  been  reported  that  levels  of  PLK  expression  are  correlated  with  the  proliferative 
activity  of  the  cells,  and  a  dramatic  downregulation  is  seen  under  conditions  of  terminal 
differentiation  (Yuan  et  al.  1997). 
Following  a  report  suggesting  a  prognostic  significance  of  PLK  mRNA  expression  in  lung 
cancer  (Wolf  et  al.  1997),  this  molecular  marker  was  analysed  in  HNSCC  (Knecht  et  al. 
1999).  In  this  study,  PLK1  mRNA  was  found  to  be  overexpressed  in  the  majority  of  SCC Chapter  5  29 
of  the  oropharynx  and  larynx,  and  to  be  strictly  correlated  with  the  metastasising  potential 
of  the  tumour. 
5.3  pl  6 
As  a  tumour  suppressor  gene,  p16  is  often  inactivated  in  carcinogenesis,  through  gene  loss 
or  mutation.  The  presence  of  a  tumour  suppressor  gene  on  chromosome  9p  had  been 
suggested  by  the  fact  that  deletions  can  frequently  be  found  in  several  types  of  human 
turnours.  By  screening  a  large  number  of  HNSCC  with  several  markers  localised  on  both 
arms  chromosome  9,  Van  der  Riet  and  co-workers  were  able  to  further  refine  the  minimal 
area  of  loss  to  9p21-22  (van  der  Riet  et  al.  1994).  A  few  years  later,  the  same  group 
reported  LOH  involvin  g  this  locus  not  only  in  the  vast  majority  of  the  invasive  carcinoma 
samples  analysed  (73%),  but  also  in  20%  of  hyperplastic  lesions,  57%  of  dysplasias  and 
80%  of  CIS  (Califano  et  al.  1996).  A  candidate  tumour  suppressor  gene  for  the  INK4A 
locus  on  chromosome  9p21-22  was  p16,  although  this  locus  encodes  for  both  p16  and 
plOu  which  have  distinct  functions. 
A  smaller  proportion  of  carcinomas  from  the  HN  also  showed  homozygous  deletion  of  the 
INK4a  locus  (33%)  suggesting  that  this  is  a  frequent  mechanism  of  p16  inactivation,  even 
though  this  percentage  is  not  as  high  as  that  found  in  other  types  of  turnours  (Cairns  et  al. 
1995).  Point  mutations  in  one  allele  of  the  p16  gene  have  been  described  as  a  frequent 
event  in  oesophageal  SCC  (50%  of  cases)  (Mori  et  al.  1994),  but  they  seem  to  occur  with 
lower  frequency  in  HNSCC:  Zhang  and  co-workers  (Zhang  et  al.  1994)  report  point 
mutations  harboured  in  the  p16  gene  in  only  11/68  (16%)  HNSCC  turnour  samples. 
Another  mechanism  of  p16  inactivation  is  transcriptional  silencing  through  promoter 
methylation.  DNA  methylation  at  the  S'  CpG  island  has  been  described  in  lung  cancer  and 
HNSCC  biopsy  samples  and  cell  lines  (Merlo  et  al.  1995).  In  vitro,  methylation  was 
associated  with  complete  transcriptional  silencing,  and  this  was  reversed  by  treatment  with 
the  demethylating  agent  5-deoxyazacytidine. 
A  very  comprehensive  study  investigating  all  of  the  genetic  and  epigenetic  modifications 
of  p16  gene  and  their  effect  on  gene  expression  in  HNSCC  in  vivo  has  been  published  by 
Reed  (Reed  et  al.  1996).  They  describe  loss  of  protein  expression  as  assessed  by  IHC  in 
24/29  turnours  sections.  Of  these,  16  showed  homozygous  deletion  of  p16  locus,  2  had 
LOH  at  the  same  locus  and  5  showed  promoter  methylation,  suggesting  the  first  as  the 
most  important  mechanism  of  p16  inactivation  in  this  type  of  tumour.  In  contrast,  a  later Chapter  5  30 
study  by  Miracca  (Miracca  et  al.  1999)  reported  p16  inactivation  in  20/32  HNSCC 
samples.  Homozygous  deletion  occurred  in  only  one  case,  whereas  promoter 
hypermethylation  and  LOH  were  found  in  most  of  the  remaining  cases  (13/20),  followed 
by  hypermethylation  and  mutation  (4/20)  and  mutation  and  LOH  (2/20). 
p16  gene  inactivation  has  also  been  described  in  oral  premalignant  lesions  in  vivo.  Using 
IHC  methods,  Papadimitrakopoulou  and  co-workers  (Papadimitrakopoulou  et  al.  1997) 
described  loss  of  protein  expression  in  38%  of  oral  leukoplakias,  and  a  good  correlation 
was  found  with  LOH  at  9p2l  (80%  of  cases).  This  is  consistent  with  Califano's  data, 
reporting  LOH  at  9p2l  as  a  frequent  event  in  oral  dysplasias,  followed  by  a  sharp  increase 
in  the  invasive  tumour  stages.  Analysing  all  these  data,  loss  of  p16  appears  to  be  an  early 
event  in  oral  cancer  progression. 
Work  carried  out  in  our  Institute  has  clarified  the  dysfunctional  events  involving  p16  in 
HNSCC  in  vitro  (Loughran  et  al.  1996)  (McGregor  et  al.  1997)  (McGregor  et  al.  2002). 
Loss  of  p16  expression  was  found  in  19/19  immortal  carcinomas  and  6/7  immortal 
dysplasias,  but  only  in  1/6  mortal  carcinomas  and  1/8  mortal  dysplasias.  In  carcinomas,  the 
mechanism  responsible  for  inactivation  of  p16  was  homozygous  deletion  in  8/18  cultures, 
whereas  in  the  remaining  10  the  absence  of  mRNA  suggested  a  transcriptional  silencing 
mechanism.  In  two  of  these  cell  lines,  p16  transcripts  were  readily  detectable  after 
treatment  with  demethylating  agents  (Loughran  et  al.  1996).  In  addition  to  this,  our  group 
has  demonstrated  that  p16  was  re-expressed  after  demethylation  treatment  in  2/5  immortal 
dysplasia  cultures  but  in  none  of  the  immortal  carcinomas  (McGregor  et  al.  2002).  The 
combined  results  of  these  studies  suggest  a  correlation  between  loss  of  p16  and  acquisition 
of  immortality  rather  than  malignant  phenotype,  and  confirm  the  importance  of 
homozygous  deletion  and  DNA  methylation  as  mechanisms  of  p16  inactivation,  in  keeping 
with  what  described  in  literature. 
However,  the  INK4a  locus  encodes  for  both  p16  and  p14  ARF 
,  so  further  work  was  required 
to  clarify  which  of  the  two  proteins  was  the  crucial  target  for  inactivation  in  human  cancer. 
In  the  10  HNSCC  cell  lines  described  by  Loughran  (Loughran  et  al.  1996)  as  lacking  large 
homozygous  deletions  of  the  INK4a  locus,  4  had  specifically  inactivated  p16  and  another  4 
had  mutations  or  deletions  in  exons  2  and/or  3  that  are  shared  by  both  proteins  (Munro  et 
al.  1999).  Mutations  in  these  exons  are  anticipated  to  alter  the  function  of  p16  but  not 
p14ARF(Quelle  et  al.  1997).  The  remaining  2  cell  lines  had  lost  expression  of  p14  AU 
,  but 
no  mutations  of  exon  1P  (which  is  specific  for  p14A")  could  be  found.  In  keeping  with 
this,  a  recent  study  by  Shahnavaz  (Shahnavaz  et  al.  2001)  describes  deletion  of  exon  1oE Chapter  5  31 
and/or  exon  2  in  7/9  (72%)  in  oral  carcinomas  in  vivo,  but  specific  deletion  of  exon  1P  was 
not  found  in  any  of  the  samples.  These  studies  indicate  that  specific  inactivation  of  p16 
rather  than  p14  ARF  plays  a  role  in  human  cancer.  Nevertheless,  the  role  of  pl4ARF 
inactivation  in  cancer  development  can  not  be  excluded  in  mice:  ARF-null  mice  that 
normally  expressed  p16  were  prone  to  developing  turnours  at  an  early  age  (Kamijo  et  al. 
1997),  similarly  to  the  phenotype  described  by  Serrano  and  collaborators  (Serrano  et  al. 
1996)  in  INK4a-null  mice. 
A  very  interesting  interventional  study  has  further  clarified  that  the  loss  of  p16  expression 
in  cancer  development  plays  a  direct  role  in  allowing  cellular  proliferation.  Several  human 
carcinoma  cell  lines  were  transfected  with  a  vector  containing  p16  INK4  cDNA.  As  a  result, 
the  colony  forming  efficiency  was  reduced,  and  the  p16  expressing  transfectants  were 
selected  against  with  continuous  passage  in  culture  (Okamoto  et  al.  1994). 
The  clinical  significance  of  this  molecular  event  in  HNSCC  has  been  assessed  by  a  few 
studies,  but  it  remains  controversial.  According  to  Bova  (Bova  et  al.  1999),  loss  of 
expression  of  p16  is  a  marker  of  poor  prognosis  in  carcinoma  of  the  anterior  tongue, 
particularly  when  associated  with  overexpression  of  Cyclin  D1.  In  contrast  with  this,  Yuen 
and  collaborators  (Yuen  et  al.  2002)  found  no  clinical  significance  for  loss  of  p16 
expression  in  a  group  HNSCC  lesions  from  different  sites.  This  marker  also  seems 
unsuitable  as  a  predictor  of  malignant  transformation  in  premalignant  laryngeal  lesions, 
unless  its  loss  occurs  in  concomitance  with  p53  overexpression  (Gallo  et  al.  1997). 
5.4  p53 
The  molecular  mechanism  most  frequently  involved  in  p53  inactivation  is,  similarly  to 
other  tumour  suppressor  genes,  mutation  of  one  allele  followed  by  deletion  of  the  other 
allele,  leading  to  production  of  a  non-functional  protein.  Not  surprisingly,  loss  of 
heterozygosity  at  p53  locus  (17p13)  has  been  reported  in  50-55%  of  HNSCC  in  two  studies 
from  the  same  group  (Nawroz  et  al.  1994)  (Califano  et  al.  1996),  the  latter  also  reporting 
an  increasing  percentage  of  LOH  in  premalignant  lesions  of  increasing  grade. 
The  occurrence  of  p53  mutations  in  human  cancer  is  an  extremely  common  event,  and  a 
large  body  of  literature  is  available  describing  their  nature,  localization,  frequency  and 
worldwide  distribution  in  all  different  types  of  cancer.  A  comprehensive  and  updated 
database  of  all  the  published  literature  on  this  topic  is  available  through  the  Marie  Curie 
Cancer  Research  Institute  Paris  website.  In  addition,  a  recent  summary  on  mutations  in  p53 Chapter  5  32 
gene  has  been  presented  by  Hainaut  and  Hollstein  (Hainaut  and  Hollstein  2000).  By  and 
large,  the  most  common  type  of  human  cancer  mutation  is  a  single  base  substitution  (87%) 
but  more  complex  mutations  like  small  insertions  or  deletions  are  also  found  in  13%  of 
cases.  Point  mutations  are  most  frequently  found  at  guanine  nucleotides,  consistent  with 
the  known  action  of  benzopyrenes  and  nitrosamines  present  in  cigarette  smoke  and  with 
the  importance  of  the  smoking  habit  in  the  aetiology  of  HNSCC  (Burns  et  al.  1993)  (Boyle 
et  al.  1993).  In  keeping  with  this,  p53  mutations  occur  with  a  higher  frequency  in  tobacco 
users  than  in  patients  that  have  never  smoked  (Lazarus  et  al.  1996)  (Brennan  et  al.  1995), 
with  a  further  increase  when  cigarette  smoke  is  accompanied  by  alcohol  intake  (Brennan  et 
al.  1995).  The  DNA  binding  domain,  encoded  by  exons  5-8,  is  a  mutational  hotspot, 
harbouring  93%  of  the  described  mutations.  This  suggests  that  transcriptional  activation  of 
p53  is  essential  for  its  tumour  suppressor  activity.  Although  in  most  cases  loss  or  mutation 
of  both  alleles  is  required  to  determine  loss-of-function  of  p53,  increasing  evidence  points 
out  that  some  mutations  might  be  sufficient  in  the  heterozygous  state,  exerting  a  dominant 
negative  effect  on  the  wild  type  allele  (Zambetti  and  Levine  1993)  (Forrester  et  al.  1995). 
Wild  type  p53  has  a  very  short  half  life  and  as  a  consequence  of  this  is  almost  undetectable 
with  conventional  Western  blotting  or  immunohystochernical  assays.  Missense  mutations 
often  increase  the  half  life  and  stability  of  p53  (Finlay  et  al.  1988),  causing  protein 
overexpression  in  tissues  or  protein  samples.  Therefore,  p53  protein  overexpression  might 
be  considered  synonymous  with  gene  mutation,  and  this  assumption  has  been  commonly 
made  in  literature.  Nevertheless,  it  has  to  be  taken  into  account  that  mutations  which  result 
in  deletion  or  truncation  of  the  protein  do  not  cause  its  accumulation,  leading  to  false 
negative  results  if  the  assessment  of  p53  mutations  is  based  only  on  measurement  of 
protein  levels. 
p53  mutations  have  often  been  described  in  HNSCC,  but  the  reported  frequencies  might  be 
underestimated  considering  that  most  studies  limited  their  analysis  to  exons  5-8,  the  known 
mutational  hotspots.  A  very  early  study  (Sakai  and  Tsuchida  1992)  analysed  15  oral  SCC 
cultures  and  5  of  the  biopsies  from  which  the  cultures  were  derived,  finding  homozygous 
mutations  in  almost  all  cases  (14/15  cultures  and  515  of  the  biopsies). 
In  our  Institute,  the  p53  status  of  a  large  number  of  biopsies  from  HNSCC  and  their 
corresponding  cultures  has  been  analysed  by  K  Parkinson's  group  (Burns  et  al.  1993). 
Protein  overexpression  was  reported  in  8/24  (33%)  of  the  samples  analysed  in  vivo  and  in 
9/18  (50%)  of  the  corresponding  cultures.  Mutations  in  the  p53  gene  could  be  detected  not 
only  in  all  of  the  cultures  overexpressing  p53  but  also  in  five  cultures  that  did  not  express Chapter  5  33 
high  levels  of  p53.  Upon  sequencing,  the  mutations  found  in  these  five  cultures  either 
created  premature  stop  codons  or  altered  the  reading  frame,  creating  a  truncated  protein. 
The  absence  of  the  carboxy  terminal  region,  which  is  responsible  for  protein 
oligomerization,  might  account  for  the  absence  of  protein  stabilization  and  consequent 
overexpression.  The  cultures  overexpressing  p53  had  point  mutations  leading  to  a  single 
base  substitution.  In  most  cases  (11/13)  no  expression  of  the  normal  allele  could  be 
detected  and  the  mutation  was  assumed  to  be  homozygous.  The  same  group  has  later 
reported  that  p53  overexpression  is  associated  with  the  immortal  but  not  the  senescent 
phenotype  in  the  same  group  of  HNSCC  cultures  (Edington  et  al.  1995). 
In  a  very  interesting  study  carried  out  in  Sidransky's  laboratory,  p53  gene  has  been 
sequenced  in  a  large  number  of  fresh  biopsies  and  archival  samples  from  all  stages  of  head 
and  neck  cancer  progression  (Boyle  et  al.  1993).  The  authors  report  an  increasing 
percentage  of  p53  mutations  in  the  transition  from  dysplasias  (15%)  to  carcinoma  in  situ 
(21%)  to  invasive  SCC  (43%),  suggesting  that  the  occurrence  of  p53  mutations  starts  in 
premalignant  lesions  and  increases  in  frequency  during  the  evolution  to  fully  developed 
carcinoma.  Another  study  reports  the  occurrence  of  p53  mutations  in  none  of  six 
hyperplasias  analysed,  but  in  5/14  (36%)  dysplasias  and  26/33  (79%)  SCCs  (Kashiwazaki 
et  al.  1997). 
In  another  study,  the  percentage  of  samples  staining  positive  for  p53  progressively 
increased  with  increasing  degrees  of  dysplasia  (28-54%),  but  showed  no  further  increase  in 
carcinoma  in  situ  and  invasive  SCCs  (Sauter  et  al.  1994).  A  similar  increase  in  the 
percentage  of  samples  overexpressing  p53  was  reported  in  normal  epithelium,  hyperplasias 
and  dysplasias  all  adjacent  to  SCC  lesions  (21-45%),  with  no  further  increase  in  the  SCC 
samples  (Shin  et  al.  1994).  When  assessed  in  oral  dysplasias,  p53  expression  was  detected 
in  5114  (36%)  samples  by  Kashiwazaki  (Kashiwazaki  et  al.  1997),  9/20  (45%)  samples  by 
Shin  (Shin  et  al.  1994)  and  581145  (40%)  samples  by  Sauter  (Sauter  et  al.  1994).  In  this  last 
study,  a  clear  increase  in  frequency  of  p53  overexpression  was  noted  in  the  transition  from 
mild  (28%)  to  moderate  (47%)  to  severe  dysplasias  (54%). 
The  prognostic  significance  of  p53  overexpression  in  HNSCC  seems  controversial.  In 
four  different  studies  (Kaur  et  al.  1998)  (Gluckman  et  al.  1994)  (Sauter  et  al.  1995)  (Field 
et  al.  1993),  p53  overexpression  was  correlated  with  a  reduction  of  survival  time  after 
diagnosis  with  end  stage  disease,  but  p53  mutation  was  not  correlated  with  clinical 
outcome  (Sauter  et  al.  1995).  In  contrast,  another  study  reported  p53  mutations  but  not  p53 
overexpression  to  be  correlated  with  patients  survival  in  HNSCC  (Mineta  et  al.  1998). Chapter  5  34 
Three  studies  are  focused  on  the  association  between  p53  mutations  and  invasive  potential 
in  HNSCC.  Burns  et  al.  (Burns  et  al.  1994)  have  analysed  three  patients  with  SCC  of  the 
tongue,  finding  correspondence  between  the  mutation  in  the  primary  tumour  and  in  the 
lymph  node  metastasis.  The  high  degree  of  congruence  between  mutations  in  primary  and 
metastatic  oropharingeal  turnours  has  been  confirmed  by  Zariwala  et  al.  (Zariwala  et  al. 
1994),  indicating  that  p53  mutations  precede  metastatic  spread.  In  contrast,  Kropveld  et  al. 
(Kropveld  et  al.  1996)  found  no  correspondence  between  p53  mutations  in  a  group  of  15 
primary  tumours  and  lymph  node  metastasis  of  HNSCC.  Since  these  studies  analysed  quite 
small  cohorts  of  patients,  it  is  difficult  to  assess  the  actual  significance  of  the  data  reported. 
5.5  Conclusions 
Several  genetic  events  are  involved  in  head  and  neck  cancer  development.  Overexpression 
of  cyclin  D1  and  PLK  are  frequently  described  at  the  carcinoma  stage  in  vivo,  both 
associated  with  poor  prognosis,  but  no  definitive  data  is  available  for  either  marker  in  vitro. 
p16  is  often  inactivated  through  deletion  or  promoter  methylation  both  in  premalignant  and 
malignant  lesions  in  vivo,  and  this  event  is  associated  with  cellular  immortality  in  vitro. 
ARF 
Nevertheless,  the  clinical  significance  of  p16  inactivation  remains  controversial  .  p14 
which  is  encoded  by  the  same  genetic  locus  as  p16,  does  not  seem  to  be  specifically 
targeted  for  inactivation  in  oral  cancer  development,  both  in  vivo  and  in  vitro.  The 
frequency  of  p53  mutation  and  overexpression  progressively  increases  in  dysplasias  of 
higher  histological  grade  and  carcinomas  in  vivo.  In  culture,  mutation  of  p53  is  often 
associated  with  the  immortal  phenotype.  The  prognostic  significance  of  p53  in  HNSCC 
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6  Telorneres  and  telornerase:  an  overview 
The  first  indication  that  normal  human  somatic  cells  have  a  limited  proliferative  lifespan  in 
culture  goes  as  far  back  as  four  decades  ago  (Hayflick  1965)  and  is  known  as  the  Hayflick 
limit.  The  authors  observed  that  embryonic  cells  explanted  from  various  tissues 
proliferated  for  a  finite  number  of  population  doublings  before  entering  a  non-dividing  but 
viable  state  called  replicative  senescence.  Proliferative  potential  in  vitro  was  subsequently 
demonstrated  to  depend  on  species,  tissue  of  origin  and  donor  age  (Martin  et  al.  1970)  and 
was  therefore  thought  to  be  genetically  defined.  Over  the  last  decade,  an  impressive  body 
of  data  has  been  obtained  providing  further  insights  into  the  molecular  mechanisms 
governing  the  initial  observation  by  Hayflick.  It  is  now  well  accepted  that  the  regulation  of 
cellular  lifespan  involves  specialized  DNA  structures  at  the  end  of  chromosomes  known  as 
telomeres.  The  purpose  of  this  chapter  is  to  give  an  overview  of  the  structure,  functions 
and  components  of  both  telomeres  and  telomerase,  the  enzyme  responsible  for  telomere 
maintainance  (for  a  recent  review  on  the  general  aspects  of  this  topic,  see  (Kim  et  al. 
2002)).  The  role  of  telomerase  activity  in  cellular  immortalisation  will  be  discussed  in 
more  depth  in  chapter  7,  in  the  context  of  all  the  other  molecular  markers  known  to 
participate  in  this  process. 
6.1  Structure  and  function  of  telorneres 
6.1.1  Telomeric  DNA 
Telomeres  are  sequences  of  non  coding  DNA  located  at  the  end  of  chromosomes.  They 
consist  of  repetitive  5'-TTAGGG-3'  sequences,  their  length  being  extremely  variable 
amongst  species  and,  to  a  lesser  extent,  amongst  different  cells  within  a  species.  In  human 
germ  cells,  telomeres  measure  10-15  Kb,  whereas  in  laboratory  mice  they  exceed  30  Kb  in 
length.  Most  of  the  telomere  is  composed  of  double  stranded  DNA,  but  a  short  tract  of 
single  stranded  DNA  overhangs  at  its  3'  end.  This  phenomenon  is  explained  by  the  well 
known  "end  replication  problem"  (fig.  7).  DNA  polymerases  are  able  to  replicate  DNA 
only  in  the  5'  to  3'  direction  and  they  initiate  this  process  through  a  8-12  base  sequence  of 
RNA  hybridised  to  each  DNA  strand.  While  the  replication  of  the  leading  strand  is 
continuous  and  follows  the  replication  fork,  replication  of  the  lagging  strand  is  obtained 
through  short  fragments  (Okazaki  fragments)  synthesised  while  the  replication  fork  opens. Chapter  6 
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Fig.  7:  The  end  replication  problem 
A)  As  the  replication  fork  opens,  lagging  strand  synthesis  proceeds  from 
3'  to  5'  as  the  overall  result  of  removal  of  RNA  primers  and  ligation  of 
the  individual  5'  to  3'  synthesised  Okazaki  fragments.  Leading  strand 
synthesis  is  continuous,  starting  from  a  single  RNA  primer.  B)  After 
removal  of  terminal  RNA  primers,  gaps  remain  at  the  5'  end  of  both  the 
lagging  and  the  leading  strand. 
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The  RNA  primers  utilised  to  start  DNA  polymerisation  are  later  removed  and  the  Okazaki 
fragments  ligated  together.  The  primer  that  is  annealed  to  the  extreme  3'  end  of  the  lagging 
strand  cannot  be  replaced,  leaving  a  short  3'  overhang  in  the  leading  strand. 
This  phenomenon  is  the  base  of  the  progressive  telomere  shortening  observed  in  most 
human  somatic  cells  with  successive  cell  divisions.  According  to  the  "telomeric  clock" 
model,  when  telomeres  reach  a  critically  short  length  they  generate  an  as  yet  unclarified 
signal  that  results  in  arrest  of  cell  division  and  senescence.  Cellular  senescence  could 
therefore  be  regarded  as  a  mechanism  engineered  to  prevent  the  extreme  chromosomal 
instability  that  accompanies  extreme  telomere  shortening  and  that  would  result  in  a  genetic 
catastrophe,  with  chromosomal  breakage,  translocations,  fusions  and  anaphase  bridges. 
6.1.2  Telomere  structure 
In  order  to  prevent  the  3'  overhang  to  be  recognized  as  a  DNA  damage  signal,  telomeres 
are  organised  in  a  three-dimensional  structure  called  Woop.  The  entire  chromosome  end 
folds  into  a  circular  complex  and  the  3'  overhang  invades  a  tract  of  double  stranded  DNA 
hybridising  to  a  complementary  sequence  and  forming  a  displacement  loop  (fig.  8) 
(Griffith  et  al.  1999).  The  size  of  t-loops  varies  with  telomere  length  and  is  therefore 
different  amongst  species.  Although  this  structure  is  able  to  form  on  relatively  short 
telomeres  (-1  Kb),  probably  a  minimum  size  exists  below  which  Woops  are  no  longer  able 
to  form  and  telomeres  trigger  a  double  strand  break  response  by  the  cellular  machinery. 
6.1.3  Telomere  associated  proteins 
Mammalian  telomeres  are  associated  with  several  proteins,  regulating  one  or  more  of  their 
functions  (fig.  9)  (reviewed  in  (Kim  et  A  2002)).  TRF2  binds  directly  to  telomeric  double 
stranded  DNA  and  its  function  is  thought  to  be  crucial  for  the  formation  of  the  t-loop. 
RAP1  also  localizes  to  the  telomeres,  but  it  does  so  by  binding  to  TRF2.  TRF1  is  another 
protein  known  to  bind  directly  to  telomeric  double  stranded  DNA.  TIN2  forms  complexes 
with  TRF1  and  thus  indirectly  associates  to  the  telomeric  structure.  Finally,  POT1  is 
known  to  bind  directly  and  specifically  to  the  single  stranded  3'  overhang.  TRF1,  TIN2, 
RAP1  and  POTI  are  thought  to  co-operate  with  TRF2  is  stabilizing  the  t-loop,  and  their 
functions  are  still  under  investigation. Chapter  6 
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In  order  to  protect  the  3'  single  stranded  DNA  from  being  recognised  as  a 
DNA  damage  signal,  a  2-25  Kb  of  double  stranded  DNA  folds  back  in  a 
circular  complex  (t-loop).  This  allows  the  single  stranded  tail  to  displace  a 
tract  of  double  stranded  DNA  hybridizing  to  its  complementary  sequence 
(D-loop). 
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Fig.  9:  Telomere  associated  proteins 
Mammalian  telomeres  end  in  a  t-loop  structure  which  is  stabilised  by 
several  proteins.  TRFI  and  TRF2  bind  directly  to  the  double  stranded 
DNA,  whereas  TIN  I  and  RAP  I  do  so  by  forming  complexes  with  TRFI 
and  TRF2  respectively.  POTI  binds  specifically  to  the  3'  overhang  of  the 
t-loop. 
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6.2  Telomerase:  its  structure,  functions  and  relevance  to  cancer 
In  order  to  prevent  continuous  loss  of  telomeric  DNA  that  would  cause  chromosomal 
instability  and  cellular  senescence,  cells  require  the  activity  of  an  enzyme  capable  of 
synthesizing  telomere  ends,  telomerase.  This  enzyme  was  initially  identified  in  cell  free 
extracts  of  tetrahymena  thermophila  (Greider  and  Blackburn  1985)  and  later  in  human  cell 
extracts  (Morin  1989).  Telomerase  is  a  reverse  transcriptase  specialized  in  adding 
TTAGGGn  repeats  at  the  3'  ends  of  chromosomes.  It  consists  of  an  RNA  component 
(human  Telomerase  RNA  Component  or  hTERC)  and  an  enzymatic  component  (human 
Telomerase  Reverse  Transcriptase  or  hTERT).  The  RNA  component  functions  as  an 
internal  template,  with  an  11  nucleotide  sequence  (5'-CUAACCCUAAC)  complementary 
to  the  human  telomere  sequence.  The  enzyme  component  acts  as  the  catalytic  unit, 
responsible  for  the  reverse  transcriptase  activity  of  the  hholoenzyme. 
The  ability  of  telomerase  to  add  TTAGGG,,  repeats  at  the  3'  ends  of  telomeres  has  been 
exploited  to  develop  a  PCR  based  assay  to  measure  its  activity  using  protein  extracts,  the 
Telomeric  Repeat  Amplification  Protocol  (TRAP)  (Kim  et  al.  1994).  Since  the 
development  of  this  assay,  telomerase  activity  has  been  tested  in  a  vast  number  of  normal 
human  tissues,  tumour  biopsies  and  cell  cultures  (summarized  in  (Bacchetti  and  Counter 
1995)  and  in  (Shay  and  Bacchetti  1997)).  This  was  a  crucial  step  in  clarifying  the  pathways 
connecting  telomerase  activity,  cellular  proliferation,  immortality  and  turnourigenesis.  The 
aim  of  the  following  paragraphs  is  to  summarize  the  scientific  observations  related  to  the 
role  of  telomerase  activity  in  these  biological  processes.  All  the  interventional  studies 
aimed  at  immortalising  human  cells  using  hTERT  and  other  genetic  elements  will  be 
discussed  in  the  following  chapter. 
6.  Z  1  Telomerase  is  activated  in  germline  tissues  and  in  the  majority  of 
cancers 
Telomerase  activity  was  tested  in  a  broad  range  of  tissues  and  cell  lines  as  soon  as  a 
specific  method  for  its  measurement  became  available.  Kim  and  collaborators  (Kim  et  al. 
1994)  analysed  22  normal  cultures  derived  from  a  variety  of  tissues,  consistently  failing  to 
detect  telomerase  activity.  In  contrast,  94  naturally  occurring  immortal  cell  lines  derived Chapter  6  41 
from  turnours  of  corresponding  tissues,  telomerase  activity  was  invariably  positive. 
Similarly,  Yi  and  co-workers  were  able  to  detect  telomerase  activity  in  16/16  immortal  cell 
lines  from  different  turnours  (Yi  et  al.  2001).  Telomerase  activity  was  also  detected  in 
ovarian  carcinoma  cell  lines  (Counter  et  al.  1994)  and  in  cells  from  myelomas  and 
lymphomas  (Nilsson  et  al.  1994).  Data  collected  in  our  Institute  from  K  Parkinson's  group 
and  our  group  is  in  agreement  with  these  findings.  We  have  previously  reported  that  our 
cultures  from  normal  oral  mucosa  are  invariably  telomerase  negative  (McGregor  et  al. 
2002).  In  our  series  of  cultures  from  premalignant  and  malignant  lesions  of  the  HN, 
telomerase  activity  was  positive  in  all  of  the  immortal  cultures  and  negative  in  all  of  the 
mortal  ones,  regardless  of  their  premalignant/malignant  phenotype. 
When  assayed  in  vivo,  telomerase  activity  was  not  detected  in  most  normal  tissues, 
comprising  normal  skin,  but  high  levels  of  enzyme  activity  were  detected  in  testis,  ovaries 
and  haernatopoietic  stem  cells  (Kim  et  al.  1994).  In  contrast  with  this  initial  finding,  Harle- 
Bachor  and  Boukamp  (Harle-Bachor  and  Boukamp  1996)  reported  that  when  skin  layers 
were  dissected,  relatively  high  levels  of  telomerase  activity  were  found  in  the  proliferative 
basal  layer,  whereas  the  quiescent  dermis  and  the  differentiated  suprabasal  layers  lacked 
telomerase  activity.  These  findings  suggested  that  telomerase  activity  is  present  in  those 
normal  tissues  or  tissue  compartments  that  are  continuously  proliferating,  either  to 
maintain  tissue  integrity  or  to  produce  gametes  or  blood  cells. 
Since  those  initial  reports,  telomerase  activity  has  been  analysed  in  a  wide  variety  of 
turnours  by  several  authors  (summarized  in  (Bacchetti  and  Counter  1995)  (Shay  and 
Wright  1996)  (Shay  and  Bacchetti  1997)).  They  report  that  telomerase  activity  is  found  in 
the  vast  majority  (85-90%)  of  tumour  tissues  analysed.  In  oral  cancer,  there  is  overall 
agreement  on  the  fact  that  most  of  the  malignant  lesions  show  detectable  holoenzyme 
activity,  with  percentages  of  95%  (Miyoshi  et  al.  1999),  85%  (Mutirangura  et  al.  1996)  and 
100%  (Sumida  et  al.  1999).  Only  a  few  studies  are  available  on  telomerase  activity  in  oral 
premalignant  lesions.  Telomerase  activity  was  detected  in  4/11  samples  by  Miyoshi 
(Miyoshi  et  al.  1999),  10/26  by  Mutirangura  (Mutirangura  et  al.  1996)  and  5/7  by  Sumida 
(Sumida  et  al.  1999). 
These  data  clearly  indicate  that  telomerase  activity  is  a  feature  of  the  majority  of  cancer 
cells  as  well  as  highly  proliferating  tissue  compartments.  It  could  be  speculated  that  stem 
cells  might  be  the  precursors  of  immortal  or  tumour  cells  in  vivo,  being  per  se  endowed  of Chapter  6  42 
the  ability  to  express  telomerase  and  maintain  their  telomere  length.  On  the  other  hand, 
telomerase  positive  malignancies  might  develop  through  reactivation  of  telomerase  in  cells 
that  are  normally  telomerase  negative.  At  the  current  stage  of  scientific  knowledge,  both 
hypotheses  could  hold  true  and  are  an  interesting  field  for  future  investigation. 
6.  Z2  Telomerase  activity  is  correlated  with  hTERT  levels 
The  next  question  to  be  addressed  was  the  relationship  between  telomerase  activity  and 
expression  of  its  two  components,  hTERC  and  hTERT.  hTERC  was  analysed  through 
northern  blotting  in  a  variety  of  different  tumour  samples  and  normal  tissues  (Feng  et  al. 
1995)  (Avilion  et  al.  1996).  Its  expression,  although  slightly  upregulated  in  tumours,  was 
fairly  ubiquitous  and  unrelated  to  the  presence  of  telomerase  activity.  Work  carried  out  in 
our  Institute  has  demonstrated  amplification  of  the  hTERC  locus  in  only  4/73  tumour 
samples  analysed,  of  which  30  were  HNSCCs  (Soder  et  al.  1997).  In  these  experiments, 
high  levels  of  hTERC  expression  were  demonstrated  by  in  situ  hybridisation  in  a  lung 
tumour  and  its  metastasis  with  hTERC  gene  amplification.  The  same  group  also  analysed 
hTERC  expression  in  a  wider  panel  of  tumour  samples  of  epithelial  origin,  and  reported 
that  its  patterns  of  expression  were  tumour  specific  (Soder  et  al.  1998).  In  lung  cancer, 
hTERC  overexpression  was  frequent  in  non-small  cell  lung  cancers  (41%)  but  not  in 
adenocarcinomas  (8%),  consistent  with  the  low  hTERC  expression  reported  for 
adenocarcinomas  of  the  breast  (13%)  and  ovary  (18%).  On  the  contrary,  no  significant 
difference  was  observed  between  SCCs  (44%)  and  adenocarcinomas  (32%)  in  cervical 
cancer.  When  hTERC  was  analysed  by  RT-PCR  in  a  series  of  samples  from  normal  oral 
mucosa,  premalignant  and  malignant  lesions,  its  expression  was  detected  in  all  of  the 
samples  analysed,  regardless  of  the  presence  or  absence  of  telomerase  activity  (Sumida  et 
al.  1999). 
The  catalytic  subunit  of  telomerase  was  analysed  in  normal  tissues  and  turnours  from 
different  sites  through  northern  blotting,  using  polyA  mRNA  (Meyerson  et  al.  1997). 
hTERT  mRNA  was  detectable  only  in  those  normal  tissues  that  had  previously  been 
reported  as  having  telomerase  activity  (Kim  et  al.  1994).  It  was  also  detected  at  high  levels 
in  a  6/6  breast  and  ovarian  turnours  analysed.  Similarly,  a  good  correlation  between 
telomerase  activity  and  hTERT  mRNA  expression,  detected  through  RT-PCR,  was 
reported  by  Sumida  and  co-workers  (Sumida  et  al.  1999)  in  carcinomas,  dysplasias  and 
normal  tissues  from  the  oral  cavity.  Kolquist  and  co-workers  (Kolquist  et  al.  1998) 
analysed  the  expression  of  hTERT  through  in  situ  hybridisation  in  a  variety  of  normal 
tissues.  hTERT  expression  was  found  to  be  high  in  haernatopoietic  stem  cells  but Chapter  6  43 
undetectable  in  the  majority  of  other  adult  tissues.  In  the  skin,  hTERT  mRNA  levels  were 
high  in  the  proliferative  basal  layer,  but  no  expression  was  seen  in  the  more  superficial 
layers.  These  data  is  consistent  with  the  previously  described  data  for  telomerase  activity 
(Kim  et  al.  1994)  (Harle-Bachor  and  Boukamp  1996). 
Summarizing,  hTERC  expression  is  found  ubiquitously  in  vivo,  whereas  hTERT 
expression  widely  varies  amongst  different  tissues  and  different  compartments  of  the  same 
tissue.  hTERT  expression  levels  also  correlate  with  levels  of  telomerase  activity.  Taken 
together,  these  observations  suggest  that  although  expression  of  both  components  is 
required  for  holoenzyme  activity,  the  catalytic  subunit  is  the  actual  limiting  factor. 
6.2.3  Lessons  from  knock-out  mice 
Recent  efforts  have  lead  to  the  generation  of  mTR  (the  mouse  analogue  of  hTERQ  knock- 
out  mice.  The  phenotype  of  these  mice  initially  appeared  to  challenge  the  involvement  of 
telomerase  in  cellular  immortalisation,  oncogenesis  and  stem  cell  proliferation.  Telomerase 
null  transgenic  mice  were  viable,  able  to  develop  normally,  fertile  and  their  cells  Could  be 
efficiently  immortalised  and  transformed  in  vitro  (Blasco  et  al.  1997).  These  findings, 
however,  were  inherently  misleading,  since  mouse  telomeres  are  very  much  larger  than 
human  telomeres,  thus  potentially  delaying  the  onset  of  any  phenotype  related  to  telomere 
erosion.  Indeed,  by  the  sixth  generation  these  mice  showed  defective  spermatogenesis  and 
haernatopoiesis  (Lee  et  al.  1998)  and  a  relative  resistance  to  multi-stage  skin 
carcinogenesis  (Gonzalez-Suarez  et  al.  2000).  Telomere  length  in  fifth  generation  mTR-1- 
mice  was  only  41%  of  that  observed  in  normal  skin:  it  would  therefore  be  reasonable  to 
deduce  that  the  phenotypic  effects  described  develop  once  telomeres  become  sufficiently 
short.  These  findings  underline  the  essential  role  of  telomerase  in  long  term  viability  of 
high-renewal  tissues  and  carcinogenesis. 
Late  generation  mTR4-  mice  exhibit  a  high  degree  of  chromosomal  instability  due  to 
further  telomere  shortening,  resulting  in  a  slightly  higher  susceptibility  to  turnours  in 
highly  proliferating  cell  types  (lymphomas,  teratocarcinomas)  than  their  normal 
counterparts  (Rudolph  et  al.  1999).  Human  dyskeratosis  congenita  is  consistent  with  this 
mouse  model.  This  disease  is  characterized  by  low  levels  of  hTERC,  compromised 
telomerase  function,  telomere  shortening  and  chromosomal  instability.  The  affected 
patients  show  defects  in  highly  regenerative  tissues  such  as  skin  and  bone  marrow,  and 
predisposition  to  turnours.  These  observations  are  in  concordance  with  the  role  played  by Chapter  6  44 
telomerase  activity  in  protecting  the  chromosomes  from  degradation  and  end  to  end  fusion 
(Griffith  et  al.  1999). 
6.2.4  Regulators  of  hTERTIrelomerase  activity 
As  previously  discussed,  a  wealth  of  literature  is  now  available  indicating  a  strong 
correlation  between  telomerase  activity  and  expression  of  its  catalytic  subunit,  suggesting 
that  hTERT  represents  the  limiting  factor  for  holoenzyme  activity.  It  is  also  accepted  that 
telomerase  activation  occurs  in  cellular  immortalisation  and  carcinogenesis.  These  two 
postulates  have  generated  a  considerable  scientific  interest  in  investigating  the  regulatory 
mechanisms  of  hTERT  expression,  both  at  a  transcriptional  and  at  a  post-transcriptional 
level.  Therefore,  it  appears  appropriate  to  examine  the  current  knowledge  on  the  regulation 
of  hTERT  at  a  transcriptional  level  through  activators  (E6,  c-Myc)  and  inhibitors  (Mad, 
WT1,  unidentified  chromosomal  repressors)  and  also  at  the  post-transcriptional  level  by 
alternative  splicing. 
The  expression  of  HPV-16  E6  protein  has  also  been  shown  to  stimulate  telomerase  activity 
in  human  mammary  epithelial  cells  and  keratinocytes,  but  not  in  fibroblasts  (Klingelhutz  et 
al.  1996).  The  authors  also  examined  the  effects  of  several  E6  mutants,  and  were  able  to 
show  that  E6  is  able  to  activate  telomerase  independently  of  its  effect  on  p53  degradation. 
A  correlation  between  c-Myc  oncogene  expression  and  telomerase  activity  has  been 
initially  suggested  by  Wang  and  collaborators  (Wang  et  al.  1998).  The  authors  provided 
evidence  that  telomerase  negative  human  mammary  epithelial  cells  infected  with  a 
retroviral  vector  transducing  c-Myc  showed  a  50-fold  upregulation  of  hTERT 
transcription.  This  resulted  in  activation  of  telomerase  activity  to  the  levels  measured  in 
breast  carcinoma  cell  lines.  Subsequently,  several  c-Myc  binding  sites  were  identified  in 
the  hTERT  promoter  region  (Wu  et  al.  1999),  of  which  an  evolutionary  conserved 
proximal  E-box  (5'-CACGTG-3')  seems  required  for  c-Myc  induced  promoter  activation 
(Greenberg  et  al.  1999). 
Madl  is  another  component  of  the  Myc/Max/Mad  protein  network.  Both  c-Myc  and  Madl 
form  stable  heterodimers  with  Max  protein,  and  the  effects  of  Madl/Max  complexes  are 
antagonistic  to  those  of  c-Myc/Max,  ultimately  resulting  in  suppression  of  gene 
transcription.  Therefore,  the  identification'  of  Madl  as  a  potential  repressor  of  hTERT 
transcription  was  not  surprising.  In  telomerase  negative  cells  W138,  activation  of  a 
conditional  c-Myc/Estrogen  receptor  fusion  protein  increased  the  expression  of  hTERT Chapter  6  45 
mRNA,  but  a  sharp  downregulation  of  hTERT  was  observed  after  infection  of  the  same 
cells  with  a  retrovirus  transducing  Mad.  This  was  consistent  with  the  fact  that  the  immortal 
cell  lines  analysed  by  the  same  group  endogenously  expressed  high  levels  of  c-Myc  and 
low  levels  of  Mad,  whereas  the  mortal  cell  lines  had  low  levels  of  c-Myc  and  high  levels  of 
Madl  (Oh  et  al.  2000). 
Another  potential  repressor  of  hTERT  is  Wilms'  Tumour  1  tumour  suppressor  protein 
(WTI).  Ectopic  expression  of  WTI  caused  a  negative  regulation  of  hTERT  transcription 
and  telomerase  activity,  but  this  effect  was  not  observed  in  HeLa  cells  that  do  not  normally 
express  WTI  protein  (Oh  et  al.  1999).  Therefore,  WTI  might  act  as  a  transcriptional 
repressor  of  hTERT  in  a  cell-specific  manner. 
RA  treatment  suppresses  expression  of  hTERT  and  telomerase  activity  in  human 
myeloblastic  leukaernia  (Mano  et  al.  2000)  and  acute  promyelocytic  leukaernia  cell  lines 
(Pendino  et  al.  2001).  This  effect  is  independent  from  tumour  cell  maturation,  as  it  was 
also  observed  in  a  cell  line  that  does  not  undergo  terminal  maturation  in  response  to  RA 
treatment;  but  it  is  dependent  on  RAR  signalling  pathway,  because  it  cannot  be  evoked  by 
RXR  selective  agonists  (Pendino  et  al.  2001). 
The  idea  that  hTERT  transcription  might  be  under  the  control  of  an  unidentified 
chromosomal  repressor,  lost  in  cancer  cells,  came  from  an  early  observation  by  Bryan  and 
co-workers  (Bryan  et  al.  1995).  The  authors  reported  that  in  telomerase  positive  tumour 
lines  hTERT  transcription  could  be  extinguished  by  creating  fusion  hybrids  with 
telomerase  negative  cells.  Since  then,  chromosome  transfer  approaches  have  been  used  in  a 
number  of  studies  to  try  and  identify  putative  telomerase  repressors.  The  results  are  often 
contradictory  and  difficult  to  interpret  because  different  studies  testing  the  same 
chromosome  have  not  always  used  the  same  donor  cells  (for  a  summary,  see  (Ducrest  et  al. 
2002));  moreover,  microscopic  rearrangements  of  the  chromosome  used  for  transfer  into 
the  donor  cell  cannot  be  excluded.  Chromosome  3  was  reported  to  repress  telomerase 
activity  and  induce  permanent  growth  arrest  in  breast,  renal  and  cervical  carcinoma  cell 
lines.  Using  allelotype  analysis  of  microsatellite  markers  in  rare  immortal  revertants 
allowed  the  identification  of  two  candidate  regions  where  the  putative  telomerase  repressor 
might  be  located:  3p2l.  3-22  and  3pl.  2-21.1  (Cuthbert  et  al.  1999).  Both  regions  are 
reported  as  sites  of  LOH  in  human  cancers,  but  the  distal  one  is  the  most  likely  candidate, 
since  3p14  is  known  to  be  a  fragile  site.  Chromosome  6  has  recently  been  reported  to 
suppress  both  telomerase  activity  and  hTERT  expression  in  an  HPV16  immortalised 
keratinocyte  cell  line  and  in  a  cervical  cancer  cell  line  (Steenbergen  et  al.  2001).  No  other Chapter  6  46 
reports  are  available  on  the  effects  of  chromosome  6  transfer  in  other  cancer  cell  lines  or 
further  refining  the  locus  for  the  putative  telomerase  repressor. 
hTERT  expression  is  also  regulated  post-transcriptionally.  Several  variants  of  hTERT 
mRNA  have  been  identified,  arising  from  alternative  splicing  of  the  transcriptional  product 
(Kilian  et  al.  1997)  (fig.  10).  The  a  splice  site  generates  a  36bp  deletion  from  the  RT 
domain  A  of  the  hTERT  gene  and  has  been  described  as  a  dominant  negative  inhibitor  of 
telomerase  activity  (Colgin  et  al.  2000).  The  P  splice  site  generates  a  182bp  deletion 
resulting  in  a  premature  stop  codon.  Four  insertion  variants  have  also  been  described,  also 
generating  a  premature  stop  codon  (Kilian  et  al.  1997).  All  four  insertion  variants,  the  P 
and  the  a-P  deletion  variants  encode  for  an  inactive  reverse  transcriptase.  Recently,  it  has 
been  shown  that  telomerase  activity  corresponded  with  expression  of  full  length  hTERT 
transcript  during  the  development  of  human  heart,  kidney  and  liver,  but  splicing  variants  of 
hTERT  were  still  produced  in  the  absence  of  telomerase  activity  in  developing  kidney 
(Ulaner  et  al.  1998).  This  observation  suggests  that  different  tissues  express  different 
profiles  of  hTERT  transcripts,  and  that  these  splicing  variants  could  play  a  role  in  tissue 
development.  The  role  of  hTERT  splice  variants  in  regulating  telomerase  activation  during 
carcinogenesis  remains  an  interesting  field  for  future  investigation. Chapter  6 
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Fig.  10:  Organization  of  the  hTERT  gene  and  post-transcriptional 
variants. 
The  hTERT  gene  comprises  16  exons  and  8  domains.  Domain  T  is 
telomerase  specific,  whereas  domains  1,2  and  A  through  E  are  similar  to 
those  found  in  other  reverse  transcriptases.  The  assignment  of  these  motifs 
to  the  exons  encoding  them  is  shown.  The  deletion  variant  (x  has  been 
reported  as  having  a  dominant  negative  effect,  whereas  the  P  deletion 
variant  generates  a  premature  stop  codon  on  domain  C.  All  four  insertion 
variants  generate  premature  stop  codons,  as  indicated  in  the  figure. 
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7  The  genetic  basis  of  cellular  immortalisation 
It  is  generally  accepted  that  senescence  control  is  an  important  tumour  suppressor 
mechanism  and  that  acquisition  of  an  immortal  phenotype  is  a  crucial  step  in  the  process  of 
carcinogenesis.  However,  several  issues  regarding  the  process  of  cellular  immortalisation 
remain  as  yet  unclear:  which  molecular  events  are  required,  what  is  their  respective 
temporal  sequence  and  how  these  molecular  markers  interact  with  each  other. 
In  addition,  it  is  important  to  be  clear  that  immortalising  human  cells  does  not  mean 
rendering  them  tumourigenic.  Additional  molecular  events  need  to  take  place,  either 
endogenously  or  induced  ectopically.  The  evidence  available  on  this  topic  will  also  be 
discussed. 
This  chapter  is  an  attempt  to  summarize  the  current  state  of  knowledge  on  the  field,  which 
is  indeed  very  prolific  and  sometimes  complicated.  Most  of  the  molecular  players  involved 
in  this  mechanism  have  already  been  introduced  in  previous  chapters  of  this  work,  but  here 
their  relevance  in  the  context  of  cellular  immortalisation  is  discussed. 
7.1  Proliferative  lifespan  barriers  cause  cellular  senescence 
Almost  4  decades  ago  Hayflick  provided  evidence  that  cultured  human  diploid  cells 
proliferate  for  a  finite  number  of  population  doublings  and  then  enter  a  proliferative 
lifespan  barrier  called  senescence  (Hayflick  1965).  Since  then,  the  molecular  events 
regulating  cellular  replicative  fate  have  been  extensively  analysed  to  understand  how 
cellular  senescence  is  triggered  and  therefore  what  molecular  events  are  required  to  bypass 
it  and  reach  immortality.  Different  cell  types  exhibit  different  regulatory  mechanisms  for 
cellular  senescence  (reviewed  in  (Wynford-Thomas  1999)).  Therefore,  the  evidence 
accumulated  in  the  past  years  is  presented  separately  for  different  cellular  settings. 
7.1.1  Human  primary  fibroblasts 
Human  primary  fibroblasts  (HFs)  are  the  most  extensively  used  cell  type  in  studies 
designed  to  clarify  senescence/immortalisation  mechanisms  because  of  their  easy 
propagation  in  cell  culture.  These  cells  are  able  to  proliferate  for  50-60  population 
doublings,  (PD)  in  culture  and  then  enter  senescence,  remaining  in  a  viable  but  non- 
dividing  state  for  several  months  (Hayflick  1965). Chapter  7  49 
The  idea  that  multiple  proliferative  life  span  barriers  existed  in  normal  human  fibroblasts 
has  been  suggested  by  Shay  and  collaborators  (Shay  et  al.  1991).  They  demonstrated  that 
HFs  infected  with  SV40  tumour  virus  T-antigen  were  able  to  escape  senescence  (or 
mortality  checkpoint  1-Ml)  and  keep  proliferating  for  an  additional  30-40  PD,  but  they 
were  invariably  arrested  by  the  onset  of  another  mortality  checkpoint,  named  crisis  (or 
mortality  checkpoint  2-M2).  Very  rare  immortal  clones  spontaneously  appeared  amongst 
the  growth  arrested  cells  and  could  be  cultured  indefinitely.  Amongst  the  known  functions 
of  SV40  T-antigen  are  its  ability  to  bind  both  Rb  and  p53  and  interfere  with  their  functions. 
In  the  same  experiments,  cellular  life  span  could  not  be  extended  by  interfering  with  either 
of  these  two  pathways  individually  (fig.  11).  Transfection  with  plasmids  expressing 
individual  viral  proteins  binding  Rb,  like  human  papilloma  virus  E7  or  adenovirus  ElA,  or 
binding  p53,  like  human  papilloma  virus  E6  or  adenovirus  ElB,  still  gave  rise  to  clones 
arresting  in  M1.  In  contrast,  co-transfections  with  E6/E7  or  with  E1A/E1B  both  allowed 
the  cells  to  proliferate  beyond  the  M1  checkpoint  and  arrest  in  M2.  Similarly,  SV40  T- 
antigen  mutants  having  lost  their  ability  to  bind  either  Rb  or  p53  were  able  to  overcome 
M1  when  co-transfected  into  fibroblasts,  but  not  when  transfected  individually.  These 
experiments,  although  informative,  have  to  be  interpreted  cautiously  as  viral  proteins  are 
notoriously  multifunctional  and  the  effects  attributed  to  disruption  of  Rb  or  p53  pathways 
could  actually  be  due  to  other  unknown  mechanisms. 
The  hypothesis  that  both  p16/Rb  and  p53  pathways  had  to  be  disrupted  in  order  to  bypass 
M1  was  somewhat  challenged  by  later  reports.  Bond  and  collaborators  infected  human  pre- 
senescent  fibroblasts  with  a  dominant  negative  p53  mutant  viral  construct  (Bond  et  al. 
1994)  or  HPV  E6  protein  (Bond  et  al.  1999)  in  two  separate  experiments  (fig.  11).  Such 
cells  were  able  to  escape  senescence,  but  ceased  proliferating  after  a  significant  lower 
number  of  PD  than  reported  for  cells  in  crisis  (17  versus  30-40).  In  addition,  their 
morphologic  features  upon  reaching  growth  arrest  resembled  those  of  cells  in  senescence 
rather  than  in  crisis,  suggesting  the  existence  of  an  intermediate  arrest  state  termed  MintE6 
by  the  same  authors.  In  these  cells  p16  levels  increased  beyond  the  levels  observed  in  their 
pre-infection  counterparts,  giving  a  plausible  explanation  for  the  restored  growth  arrest 
status  after  an  incomplete  M1  bypass  and  despite  loss  of  p2l  expression.  In  the  same 
experiments,  an  incomplete  rescue  from  senescence  was  also  observed  upon  infection  with 
HPV  ET  These  cells  showed  a  limited  extension  in  lifespan  and  eventually  arrested  in  a 
crisis-like  state  named  MnE7.  MnE7  occurred  much  sooner  than  M2  and  was 
accompanied  by  increased  levels  of  p16,  p53  and  p2l. Chapter  7 
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Fig.  11:  Attempts  to  immortalise  human  fibroblasts 
Graphic  representation  of  the  effect  of  different  transduction  experiments 
on  cellular  lifespan  in  fibroblasts.  The  red  arrows  indicate  the  proliferative 
fate  of  human  fibroblasts  in  culture.  The  yellow,  green  and  blue  arrows 
show  the  effects  of  different  interventional  procedures  (indicated  next  to 
the  arrows)  on  fibroblast  life  span. 
The  corresponding  reference  is  also  indicated. 
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A  less  complex  scenario  was  found  when  human  fibroblasts  were  infected  with 
retroviruses  transducing  the  enzyme  component  of  telomerase  hTERT  (Vaziri  and 
Benchimol  1998)  (Bodnar  et  al.  1998).  hTERT  expression  resulted  in  activation  of 
telomerase,  elongation  of  telomeres  and  cellular  immortalisation,  bypassing  both  M1  and 
M2  checkpoints  (fig.  12). 
Taken  together,  these  data  suggest  that  telomere  erosion  is  the  only  barrier  to  HF 
immortalisation.  DNA  tumour  virus  proteins  do  not  activate  telomerase  directly,  but  they 
are  capable  of  extending  HF  lifespan  by  inactivating  the  control  mechanisms  regulating 
growth  arrest  in  response  to  short  telomeres. 
7.1.2  Human  mammaty  epithelial  cells 
In  human  mammary  epithelial  cells  (HMECs)  senescence  is  regulated  by  somewhat 
different  molecular  mechanisms  and  the  effects  of  viral  oncoproteins  are  also  different 
compared  to  those  observed  in  fibroblasts.  HMECs  are  known  to  encounter  a  first  growth 
plateau  after  having  completed  approximately  10-15  PD.  This  early  growth  arrest  state  is 
very  similar  to  cellular  senescence  and  has  been  termed  selection  or  mortality  stage  0  (MO) 
(Foster  and  Galloway  1996).  However,  pre-selection  cells  emerge  from  MO  with  a  high 
frequency,  estimated  between  W04  and  jX10-5 
,  and  they  are  able  to  do  so  through 
spontaneous  loss  of  expression  of  p16  (Romanov  et  al.  2001)  (fig.  13).  The  same  effect 
occurs  after  infection  with  HPV  E7  which,  as  already  discussed,  disrupts  the  p16/Rb 
pathway  (Foster  and  Galloway  1996).  In  contrast  to  HFs,  activation  of  telomerase  through 
hTERT  transduction  at  this  stage  of  HMECs  proliferative  fate  failed  to  extend  their  life 
span  (Kiyono  98).  In  the  same  experiments,  infection  with  E6  alone  had  no  effect,  but 
combined  infection  with  E6/E7  generated  immortal  clones. 
Post-selection  HMECs  show  a  progressive  increase  in  levels  of  total  p53  throughout  the 
second  phase  of  exponential  proliferation,  after  which  they  reach  a  second  growth  arrest 
state  with  features  of  cellular  crisis  (Romanov  et  al.  2001).  This  mortality  checkpoint  is 
known  as  senescence  or  M1,  but  the  same  authors  proposed  to  rename  it  agonescence  after 
its  similarities  to  crisis  were  appreciated.  Infection  of  post  MO  HMECS  with  HPV  E6  or 
with  a  retroviral  construct  transducing  hTERT  causes  immortalisation  without  any  feature 
of  crisis,  hTERT  with  a  higher  efficiency  than  HPVE6  (Kiyono  et  al.  1998)  (fig.  13). 
Kingelhultz  and  co-workers  have  demonstrated  that  HPV  E6  is  able  to  activate  the 
transcription  of  hTERT  in  several  epithelial  cell  types,  but  not  in  fibroblasts,  and  this 
occurs  independently  of  its  effect  on  p53  (Klingelhutz  et  al.  1996). Chapter  7 
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Fig.  12:  Immortalisation  of  human  fibroblasts 
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Human  fibroblasts  are  efficiently  immortalised  by  infection  with  an 
hTERT-transducing  retroviral  vector,  as  independently  reported  by  the 
two  indicated  authors. Chapter  7 
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Fig.  13:  Immortalisation  of  human  mammary  epithelial  cells 
Graphic  representation  of  the  effect  of  different  transduction  experiments 
on  cellular  lifespan  in  human  mammary  epithelial  cells.  MO  is  by-passed 
by  spontaneous  or  HPV  E6-induced  loss  of  p16.  Iminortalisation  occurs 
when  post  MO  HMECs  are  transduced  to  express  hTERT. 
The  corresponding  references  are  cited. 
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Using  several  E6  mutants,  it  was  possible  to  demonstrate  that  the  ability  of  HPV  E6  to 
immortalise  HMECs  is  related  to  its  effect  on  telomerase  activation  rather  than  p53 
degradation  (Kiyono  et  al.  1998). 
In  the  light  of  all  these  findings,  the  mechanisms  governing  HMECs  mortality  checkpoints 
are  clearer.  The  first  growth  arrest  phase  encountered  by  these  cells  (MO)  is  p16-dependent 
and  is  by-passed  by  abrogation  of  the  p16/Rb  pathway,  either  spontaneously  (as  frequently 
occurs)  or  by  infection  with  HPV  E7.  In  post  MO  HMECs,  telomeric  dysfunction  appears 
to  be  the  factor  driving  this  cell  type  into  crisis.  In  fact,  immortalisation  is  acquired  by 
reactivation  of  telomerase,  either  through  hTERT  transduction  or  through  HPV  E6 
infection  (Kiyono  et  al.  1998).  Telomerase  activation  is  not  sufficient  per  se  to  confer 
HMECs  an  unlimited  proliferative  potential  in  the  presence  of  an  intact  p16/Rb  pathway 
(Kiyono  et  al.  1998). 
7.1.3  Human  keratinocytes 
A  similar  scenario  is  observed  with  other  types  of  epithelial  cells.  According  to  Dickson 
and  collaborators,  expression  of  hTERT  in  normal  epidermal  keratinocytes  and'in  oral 
keratinocytes  causes  incomplete  rescue  from  senescence:  cells  enter  a  long  phase  of  slow 
growth  from  which  rare  immortal  cells  emerged  (fig.  14)  (Dickson  et  al.  2000).  These  cells 
show  normal  levels  of  Cyclin  D1,  cdk4/6  and  pRb  but  have  lost  expression  of  p16. 
Exogenous  expression  of  hTERT  has  been  shown  to  be  sufficient  to  immortalise  normal 
epidermal  keratinocytes  previously  transduced  to  express  HPV  E7  protein  (Kiyono  et  al. 
1998)  (fig.  14)  and  also  a  premalignant  cell  line  that  had  lost  expression  of  p16  through 
homozygous  deletion  (Dickson  et  al.  2000).  In  keeping  with  this,  Rheinwald  and 
collaborators  have  shown  that  abrogation  of  both  p16  and  p53  pathways  extends 
keratinocyte  life  span,  but  immortalisation  occurs  only  after  hTERT  transduction 
(Rheinwald  et  al.  2002). 
Recent  evidence  by  K  Parkinson's  group  (in  press)  better  defines  the  features  of  crisis  in 
HNSCC.  In  vitro,  loss  of  p16  and  mutation  of  p53  is  associated  with  growth  arrest  in  M2 
crisis,  with  high  grade  of  telomere  dysfunction  as  assessed  by  the  Anaphase  Bridge  Index 
(ABI).  Restoration  of  telomerase  activity  at  this  stage  causes  cellular  immortality, 
accompanied  by  lowering  of  the  ABI  index.  These  observations  suggest  that  epidermal  and 
oral  keratinocytes  need  both  reactivation  of  telomerase  and  loss  of  expression  of  p16/Rb 
pathway  in  order  to  acquire  immortal  phenotype. Chapter  7 
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Fig.  14:  Immortalisation  of  human  keratinocytes 
Graphic  representation  of  the  effect  of  the  main  transduction  experiments 
on  cellular  lifespan  in  keratinocytes.  Infection  with  HPV  E7  combined 
with  transduction  of  hTERT  caused  keratinocyte  immortalisation.  In 
contrast,  hTERT  transduction  alone  extended  cellular  life  span  through  a 
long  slow-growth  phase.  Immortal  cells  emerged  only  through 
spontaneous  loss  of  p  16. 
The  corresponding  references  are  cited. 
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Recently,  Opitz  and  collaborators  (Opitz  et  al.  2001)  have  demonstrated  that  the 
transduction  of  dominant  negative  p53  and  of  cyclin  D1  in  normal  oral  keratinocytes  are 
each  individually  able  to  increase  the  proliferative  potential  of  these  cells  but  their  effects 
were  additive  when  combined.  Immortalisation  was  reached  only  later,  when  cells 
activated  an  alternative  mechanism  of  tel6mere  maintenance.  This  was  deduced  from  the 
fact  that  the  immortal  clones  were  invariably  negative  for  telomerase  activity,  but  their 
telomere  length  showed  a  considerable  increase  compared  to  the  growth  arrested  clones. 
This  report,  although  interesting,  is  nevertheless  difficult  to  interpret.  Cyclin  D1  is  a 
positive  regulator  of  cell  cycle,  and  it  exerts  its  effects  on  the  p16/Rb  pathway.  It  would 
therefore  be  plausible  to  assume  that  its  overexpression  might  have  the  same  effects  of  p16 
loss  or  Rb  degradation,  in  keeping  with  what  described  by  the  other  authors  (Kiyono  et  al. 
1998)  (Dickson  et  al.  2000)  (Rheinwald  et  al.  2002).  Nevertheless,  there  is  no  other 
evidence  in  literature  that  alternative  lengthening  of  telomere  mechanisms  are  used  to 
maintain  or  lengthen  telomeres  in  HNSCC. 
7.2  The  effects  of  culture  condition  on  cellular  replicative 
lifespan 
An  animated  scientific  debate  has  recently  arisen  about  whether  p16-dependent  growth 
arrest  is  due  to  inadequate  culture  conditions,  rather  than  an  active  role  for  p16  in  inducing 
cellular  senescence  per  se  (Ramirez  et  al.  2001).  According  to  these  authors,  human 
keratinocytes  could  be  directly  immortalised  by  hTERT  transduction  without  any  further 
requirements,  provided  that  they  were  cultured  on  a  feeder  layer  and  with  medium 
containing  5%  serum  as  originally  described  by  Rheinwald  and  Beckett  (Rheinwald  and 
Beckett  1981).  Growth  of  cells  in  chemically-defined  medium  with  0.25%  serum  on  a 
plastic  substrate  resulted  in  upregulation  of  p16  and  growth  arrest  both  before  and  after 
transduction  with  hTERT  expression  vector  (Ramirez  et  al.  2001).  In  addition  the  authors 
reported  that  the  p16  dependent  MO  growth  arrest  stage  observed  in  HMECs  could  be 
prevented  by  culturing  these  cells  on  a  feeder  layer  in  the  presence  of  10%  serum.  This 
suggests  that  p16  upregulation  mediates  a  premature  growth  arrest  state  due  to  inadequate 
culture  conditions,  both  in  keratinocytes  and  in  HMECs. 
However,  this  conclusion  is  presently  controversial.  Many  reports  from  different  groups 
underline  the  importance  of  p16/Rb  as  a  telomere  independent  growth  arrest  mechanism  in 
vitro  and  the  need  to  interfere  with  this  pathway  to  immortalise  different  types  of  human 
epithelial  cells  (see  paragraphs  1.2  and  1.3  of  this  chapter).  In  addition,  p16  loss  is Chapter  7  57 
frequently  found  in  HNSCCs  and  oral  premalignant  lesions  in  vivo,  as  discussed  in  chapter 
5  of  this  introduction.  It  seems  therefore  unlikely  that  the  involvement  of  p16  in  cellular 
senescence  is  merely  a  culture  artefact. 
7.3  Cellular  immortallsation  and  malignant  transformation 
The  acquisition  of  an  immortal  phenotype  is  considered  a  crucial  step  in  the  process  of 
carcinogenesis.  Nevertheless,  immortality  and  malignancy  are  not  synonymous.  In  oral 
cancer,  cellular  immortality  is  observed  in  about  1/3  of  premalignant  lesions  and  in  9/10 
carcinomas  (combined  data  from  K.  Parkinson's  and  our  group).  Therefore,  not  all 
immortal  cultures  are  cancers  and  cancers  are  not  necessarily  immortal.  In  keeping  with 
this,  Opitz  and  co-workers  (Opitz  et  al.  2001)  reported  that  exogenous  overexpression  of 
cyclin  D1  and  inactivation  of  p53,  together  with  spontaneous  activation  of  an  alternative 
lengthening  of  telomeres  mechanism,  leads  to  immortalisation  but  not  transformation  of 
oral  keratinocytes.  Although  the  acquisition  of  an  unlimited  proliferative  potential  occurs 
more  frequently  in  fully  developed  cancer  than  in  premalignancies,  additional  or  different 
genetic  events  must  be  involved  in  cancer  development. 
The  molecular  mechanisms  governing  human  cellular  transformation  have  recently  been 
investigated  by  Weinberg's  group.  The  authors  tested  the  ability  of  SV40  large-T  antigen, 
hTERT  and  H-ras  to  transform  normal  human  fibroblasts  (BJ  cells)  and  human  embryonic 
kidney  cells  (HEKs).  The  simultaneous  expression  of  all  three  oncogenes  permitted 
efficient  anchorage-independent  growth  in  soft  agar  and  rapid  turnour  formation  in  nude 
mice  (Hahn  et  al.  1999)(a).  In  a  later  study,  the  same  investigators  extended  their 
observation  to  HMECs  (Elenbaas  et  al.  2001).  This  cell  type  could  be  transformed  by 
expression  of  SV40  large-T  antigen,  hTERT  and  H-ras,  similarly  to  BJ  and  HEK  cells; 
however,  transformed  HMECs  showed  a  consistent  amplification  of  c-myc  locus,  which 
was  not  observed  in  similarly  treated  BJ  and  HEK  cells.  This  data  suggest  that  in  humans, 
multiple  pathways  involved  in  cellular  proliferation  and  lifespan  must  be  simultaneously 
disrupted  in  order  to  create  a  tumour  cell.  Nevertheless,  it  is  unlikely  that  SV40  large-T 
antigen  participates  in  this  transformation  process  solely  through  its  effects  on  p16/Rb  and 
p53  pathways,  since  Morales  and  collaborators  (Morales  et  al.  1999)  have  reported  that 
combined  expression  of  E6/E7,  hTERT  and  H-ras  was  not  sufficient  to  allow  normal 
human  fibroblasts  to  grow  in  soft  agar.  The  importance  of  telomerase  activity  in 
maintaining  the  transformed  phenotype  has  been  underlined  in  another  study  in 
Weinberg's  laboratory  (Hahn  et  al.  1999)(b),  in  which  inhibition  of  telomerase  activity Chapter  7  58 
through  infection  with  a  dominant  negative  hTERT  expression  vector  resulted  in  inhibition 
of  cellular  growth  and  loss  of  their  turnourigenic  capacity  in  nude  mice. 
7.4  Conclusions 
A  number  of  interventional  studies  have  been  carried  out  in  the  past  decade  to  clarify  the 
requirements  and  timing  of  cellular  immortalisation  in  different  human  cellular  settings. 
Shay  and  collaborators  (Shay  et  al.  1993)  have  proposed  that  two  mortality  checkpoints 
(Ml  and  M2)  need  to  be  by-passed  to  reach  immortality.  This  two-stage  mechanism 
applies  to  all  cell-types,  but  the  molecular  mechanisms  controlling  M1  and  M2  are  cell 
type  specific,  although  with  clear  similarities.  In  human  fibroblasts,  senescence  control  is 
mainly  regulated  by  telomere  erosion,  as  ectopic  activation  of  telomerase  efficiently 
immortalises  these  cells.  In  human  mammary  epithelial  cells,  inactivation  of  the  p16/Rb 
pathway  is  an  additional  requirement  for  immortalisation,  along  with  activation  of 
telomerase,  and  it  is frequently  a  spontaneous  event.  Similarly,  human  keratinocytes  can  be 
immortalised  by  disruption  of  p16/Rb  pathway  and  activation  of  telomerase,  but  it  has  been 
recently  suggested  that  p53  dysfunction  is  also  required  (Rheinwald  et  al.  2002).  In 
addition,  both  human  fibroblasts  and  human  epithelial  cells  require  additional  and  not 
completely  clarified  molecular  events  to  develop  a  malignant  phenotype. 59 
Materials  and  Methods 
8.1  Cell  culture 
All  cell  culture  work  was  performed  using  strict  aseptic  techniques  inside  a  laminar  flow 
hood  (Class  11  Microbiological  Safety  Cabinets,  Medical  Air  technology  Ltd.,  Manchester, 
UK).  Cell  culture  work  involving  the  use  of  retroviral  constructs  was  performed  in 
category  II  containment  suites.  Cells  were  incubated  at  37*C  in  a  dry  atmosphere 
containing  5%  (V/V)  C02  (Heraeus,  Essex,  UK). 
HeLa  cells  were  maintained  in  modified  Dulbecco's  medium  (Beatson  formulation)  (Gibco 
BRL  Europe  Life  Technologies,  Paisley,  UK)  supplemented  with  10%  foetal  bovine  serum 
(Harlan  Sera-Lab,  Crawley  Down,  Sussex,  UK)  and  1mM  glutamine  (Gibco  BRL  Europe 
Life  Technologies,  Paisley,  UK).  WI38  cells  were  maintained  in  modified  Dulbecco's 
medium,  supplemented  with  5%  foetal  bovine  serum  and  1mM  glutamine. 
The  derivation,  characterisation  and  maintenance  of  the  primary  human  keratinocyte 
cultures  have  been  described  previously  (Edington  et  al.  1995)  (McGregor  et  al.  1997).  All 
cells  were  maintained  on  irradiated  (60Gy  from  a  Co  60  radiation  source)  Swiss  373 
feeders.  The  growth  media  used  were  flavine  adenine  dinucleotide  (FAD)  growth  medium, 
composed  by  1:  3  Ham's  F12/Dulbecco's  modified  Eagles  medium  (DMEM)  (both  from 
Gibco  BRL  Europe  Life  Technologies,  Paisley,  UK)  supplemented  with  10%  foetal  bovine 
serum  (FBS),  0.4  ttg/ml  hydrocortisone  (Sigma-Aldrich,  Poole,  Dorset,  UK),  5  [tg/ml 
insulin  (Gibco  BRL  Europe  life  Technologies,  Paisley,  UK  ),  5  [tg/ml  transferrin  (Sigma- 
Aldrich,  Poole,  Dorset,  UK),  10-10M  cholera  toxin  (Sigma-Aldrich,  Poole,  Dorset,  UK),  1.8 
x  10-4  adenine  (Sigma-Aldrich,  Poole,  Dorset,  UK)  and  10  ng/ml  epidermal  growth  factor 
(Gibco  BRL  Europe  life  Technologies,  Paisley,  UK)  and  10H  growth  medium,  composed 
by  DMEM  supplemented  with  10%  FBS  and  0.4[tg/ml  hydrocortisone.  Each  culture  was 
tested  and  then  maintained  with  whichever  of  these  two  media  proved  best  for  their 
growth.  Immediately  prior  to  experimentation  all  keratinocyte  cultures  were  grown  on 
FAD  medium  to  avoid  complications  arising  from  growth  in  different  media.  The 
irradiated  3T3  feeders  were  carefully  removed  by  treatment  with  phosphate  buffered  saline 
(PBS)/0.02%  EDTA  for  15-20  seconds  and  vigorous  pipetting  before  analysis  of  the 
keratinocyte  cultures.  Swiss  3T3  cells  were  maintained  in  10C  medium  (Dulbecco's  MEM 
plus  10%  donor  calf  serum  (Sigma-Aldrich,  Poole,  Dorset,  UK). Chapter  8  60 
To  freeze  cell  stocks  for  storage,  semi-confluent  cultures  were  trypsinized,  pelleted  and  the 
pellet  resuspended  at  a  concentration  of  approximately  106  cells/ml  in  chilled  medium 
containing  50%  serum  and  10%(v/v)  dimethylsulfoxide  (DMSO)  (Fisher  Scientific,  USA). 
Suspensions  were  aliquoted  into  Iml  cryotubes  (Nunc,  Wiesbaden,  Denmark)  and  placed 
in  a  polystyrene  box  and  frozen,  well  insulated,  at  -70'C  overnight  to  ensure  a  slow  rate  of 
cooling.  The  ampoules  were  then  transferred  to  a  liquid  nitrogen  tank  until  required. 
Frozen  stocks  were  recovered  by  removing  the  ampoules  from  liquid  nitrogen  and  placed 
into  a  small,  covered  bucket  of  water  at  370C.  Once  thawed,  the  cells  were  added  to  10  ml 
of  the  appropriate  pre-warmed  growth  medium,  centrifuged,  resuspended  in  fresh  growth 
medium  and  transferred  to  90  mm  Falcon  culture  dishes  (Becton  Dickinson,  Franklin 
Lakes,  USA). 
8.2  Retrovirus  production  and  ectopic  expression  of  hTERT 
The  retroviruses  were  produced  by  infecting  the  amphotropic  packaging  line  Phoenix  A 
with  pBabeNeo  or  pBabest2  (hTERT)  retroviral  constructs  (Vaziri  and  Benchimol  1998) 
and  selecting  with  the  minimum  concentration  of  G418  (Invitrogen,  Paisley,  UK)  found  to 
kill  the  uninfected  cultures.  The  virus  titers  were  determined  using  3T3  cells:  one 
infectious  unit  corresponded  to  the  volume  of  retroviral  supernatant  capable  of  generating 
one  G418-resistant  colony.  Dysplasia  cultures  were  infected  at  about  80%  confluency  with 
1.35x  104  infectious  units/ml  in  the  presence  of  4  [tg/ml  of  polybrene  (Sigma  Chemicals, 
Poole,  UK).  The  dysplasia  cells  were  plated  on  G418-resistant  373  feeder  cells,  selected 
48h  later  with  200  [ig/ml  of  G418  and  cultured  under  constant  selection.  Pooled  G418- 
resistant  colonies  were  used  in  all  experiments  to  avoid  variability  due  to  clonal 
heterogeneity  of  the  population. 
8.3  Senescence  Associated  P-Galactosidase  (SABG)  assay. 
Cells  were  maintained  in  culture  for  a  minimum  of  three  weeks  to  confirm  proliferative 
growth  had  ceased.  The  3T3  feeder  layer  was  carefully  removed  and  the  cells  fixed  in  3% 
formaldehyde  (Fisher  Scientific,  USA)  in  PBS  for  2-5  minutes.  Subsequently,  cultures 
were  stained  essentially  as  described  by  Dimri  and  collaborators  (Dimri  et  al.  1995).  cells 
were  incubated  with  SABG  staining  solution  for  approximately  16h  at  37'C  in  a  humid 
box,  washed  with  milli-Q  H20  (Millipore  MilliQ  System,  UK)  and  stored  in  milli-Q  H20 
until  visualised  with  a  light  microscope  and  photographed. Chapter  8 
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The  proliferative  index  of  colonies  was  determined  by  Bromo  deoxy  Uridine  (BrdU) 
labelling  as  previously  described  by  Munro  and  collaborators  (Munro  et  al.  2001).  After 
incubating  the  cells  for  48h  with  10[tM  BrdU  (Sigma  Chemicals,  Poole,  UK),  the 
irradiated  3T3  feeders  were  carefully  removed  and  the  cells  fixed  in  1:  1  acetone/methanol 
(Fisher  Scientific,  USA)  for  10  minutes.  Subsequently,  cells  were  washed  in  PBS  for  10 
minutes,  permeabilised  in  0.25%  Tween  20  (Sigma  Chemicals,  Poole,  UK)  in  PBS  for  10 
minutes  in  a  humidity  box  and  denatured  in  1M  HCI  (Fisher  Scientific,  USA)  at  60'  for  5 
minutes.  After  blocking  with  10%  FBS,  cultures  were  incubated  with  an  anti-BrdU 
antibody  (Harlan  Sera-Lab,  Loughborough,  UK)  at  4'C  overnight.  The  following  day,  cells 
were  incubated  with  an  FITC-conjugated  anti-rat  IgG  (Sigma  Chemicals,  Poole,  UK)  at  a 
dilution  of  1/125  for  1  hour  in  the  dark  in  a  humidity  box.  After  each  antibody  incubation, 
cells  were  washed  with  10%  FBS/1xKRH/Tween  80  as  previously  described  (Munro  et  al. 
2001).  The  nuclei  were  counterstained  with  propidium  iodide  (lng/ml),  finally  the  cells 
were  mounted  with  Vectashield  (Vector  Laboratories,  Peterborough,  UK)  and  visualised 
with  a  fluorescence  microscope. 
8.5  TUNEL  assay 
Apoptosis  was  measured  by  the  Terminal  deoxynucleotidyl  transferase-mediated  dUTP 
nick  end-labelling  (TUNEL)  assay  using  the  ApoTag@  kit  (Intergen,  Oxford,  UK).  After 
careful  removal  of  the  irradiated  3T3  feeders,  cells  were  processed  according  to  the 
manufacturer's  protocol.  Cells  were  fixed  for  10  minutes  in  1%  paraformaldehyde  (TAAB 
laboratories,  UK)  and  washed  2x5  minutes  in  PBS.  The  cells  were  post-fixed  in  pre- 
cooled  Ethanol/Acetic  Acid  (James  Burrough  Ltd.,  UK  and  Fisher  Scientific,  USA 
respectively)  for  5  minutes  at  -20"C,  drained  and  washed  as  above.  The  nuclei  were 
counterstained  with  propidium  iodide  (lng/ml),  the  cells  were  mounted  in  Vectashield  and 
visualised  on  a  fluorescence  microscope. 
8.6  RNA  Analysis 
RNA  extraction  and  Northern  blotting  was  carried  out  as  previously  described  (McGregor 
et  al.  1997).  The  hTERC  probe  was  kindly  provided  by  Dr.  Fiona  McGregor  (Beatson 
Institute,  UK).  The  RAR-P  probe  was  made  from  a  plasmid  containing  the  full  length 
RAR-P2  cDNA  sequence  provided  by  ProL  P.  Chambon  (Strasbourg,  France). Chapter  8 
8.7  Western  Blot  Analysis 
62 
Protein  extraction  and  Western  blotting  was  carried  out  as  described  previously  (McGregor 
et  al.  1997).  Primary  antibody  incubations  were  carried  out  using  the  following  antibodies: 
pl6"k4A(C-20:  Santa  Cruz  Biotechnology,  Santa  Cruz,  CA,  USA);  EGF-R  (Santa  Cruz 
Biotechnology);  c-erbB2  (Ab-17:  Neomarkers,  Fremont,  CA,  USA),  PLK1  (Transduction 
Laboratories,  Lexington,  KY,  USA);  cyclin  D1  (AW,  Oncogene  Research  Products, 
Boston,  MA,  USA);  p53  (DO1,  SantaCruz  Biotechnology);  ser  15  phospho-specific  p53 
(16GS,  New  England  Biolabs,  Hitchin,  Hertfordshire,  UK).  Membranes  were  re-probed 
with  a  polyclonal  antibody  against  total  ERKsl&2  (ERK1(C-16)-G,  Santa  Cruz 
Biotechnology)  or  a-Tubulin  (Sigma-Aldrich,  Poole,  Dorset,  UK)  to  ensure  even  loading 
and  transfer  since  they  were  found  to  be  uniformly  expressed  in  all  keratinocyte  cultures 
regardless  of  proliferative  fate.  Unless  otherwise  stated,  protein  was  extracted  from 
cultures  during  the  proliferative  phase  of  growth. 
8.8  p53  sequencing. 
This  was  performed  using  proof-reading  DNA  polymerase  (Quiagen,  Crawley,  UK)  and 
the  following  primers:  exon  2,2F/2R  for  amplification  and  sequencing;  exon  3,3F/4R  for 
amplification  and  sequencing;  exon  4,3F/4R  for  amplification,  3F/4F/4R  for  sequencing; 
exons  5&6,5F/5R  for  amplification  and  sequencing;  exon  7,7F/8R  for  amplification, 
7F/7R  for  sequencing;  exons  8&9,7F/8R  for  amplification,  8F/8R  for  sequencing;  exon 
10,1OF/1OR  for  amplification  and  sequencing;  and  exon  11,11F/11R  for  amplification, 
11F/11BR  for  sequencing.  Primer  sequences  are  as  follows:  2F  (5'- 
CrCAAAGAAGTGCATGGCrGG-3');  2R  (5'-CAGGAAGTCrGAAAGACAAGAGC- 
Y);  3F  (5'-GAAGCGAAAATTCATGGGACrGAC-3');  4R  (5'- 
CATIPGAAGTCrCATGGAAGCCA-3');  4F  (5'-ACCrGGTCCTCrGACrGCrCr-3'); 
5F  (5'-  CGTGTTCCAGTTG=ATCFG-3');  5R  (5'-GGAGGGCCACrGACAACCA- 
3');  7F  (5'-AGGCGCACTGGCCTCATCTT-3');  7R  (5'- 
AGGGGTCAGCGGCAAGCAGA-3');  8F  (5'-TTGGGAGTAGATGGAGCCr-3');  8R 
(5'-AA=CCACTrGATAAGAGGTC-3');  1OF  (5'- 
GTACTGTGAATATACTTACTTCTCC-3');  1OR  (51- 
CAAAGAAGTATCCACACrCGTC-3');  11F  (5'-CACrCATGTGATGTCATCrCrCC- 
Y);  11R  (5'-CAAGACrrGACAACrCCCrC-3');  11BR  (5'- 
ATCrAAGCrGGTATGTCCrACrC-3').  Sequencing  of  fragments  in  both  directions  was 
performed  according  to  the  manufacturer's  protocols  (ABI  prism  big  dye  terminator Chapter  8  63 
reaction  kit,  Applied  Biosystems,  Foster  City,  CA,  USA).  Where  a  mutation  was  found,  the 
result  was  confirmed  using  an  independent  PCR  amplification  product. 
8.9  Telomerase  assay. 
Telomerase  activity  was  measured  in  cell  lysates  containing  100-200ng  of  protein,  using 
the  TRAPeze  telomerase  detection  kit  (Intergen,  Oxford,  UK)  according  to  the 
manufacturer's  recommendations.  The  feeder  layer  of  irradiated  3T3  fibroblasts  was 
carefully  removed  before  analysis  to  eliminate  any  residual  contaminating  activity  from 
these  cells.  W138  and  HeLa  cells  were  used  as  negative  and  positive  controls,  respectively. 
The  PCR  products  were  analysed  by  electrophoresis  on  a  12.5%  polyacrylamide  gel  and 
visualised  using  ethidium  bromide  staining. 
8.10  Semi-quantitative  reverse  transcription  (RT)/polymerase 
chain  reaction  (PCR)  assay  for  hTERT  mRNA. 
This  assay  was  performed  using  the  GeneAmp  RNA  PCR  core  reagent  kit  (Perkin  Elmer, 
Branchberg,  NJ,  USA)  according  to  the  manufacturer's  protocols.  The  hTERT  primers 
used  were  MS113  (5'-AGAGTGTCrGGAGCAAGTTGC-3')  and  MS114  (5'- 
CGTAGTCCATGTTCACAATCG-3'),  yielding  a  183-bp  fragment  corresponding  to 
nucleotides  1789-1971,  as  described  by  Dome  and  collaborators  (Dome  et  al.  1999).  The 
levels  of  GAPDH  mRNA  were  also  measured  as  an  internal  control,  and  the  primers  used 
were  AAGGCTGAGAACGGGAAGCITGTCATCAAT  and 
AGCCCCAGCCITCrCCATGGTGGTGAAGAC. 
8.11  Quantitative  reverse  transcription  (RT)/polymerase  chain 
reaction  (PCR)  assays  for  hTERT  mRNA. 
This  was  performed  using  the  Taqman  reverse  transcription  reagents  and  Taqman  PCR 
core  reagent  kit  (Perkin  Elmer,  Branchberg,  NJ,  USA),  according  to  the  manufacturer's 
protocols.  This  method  measures  the  number  of  PCR  cycles  required  to  obtain  exponential 
amplification  of  specific  PCR  product  and  comparing  this  with  a  standard  curve.  For  each 
experiment,  an  initial  amplification  reaction  was  carried  out  to  measure  the  quantity  of  7S 
rRNA  present  in  each  sample,  as  an  internal  control.  To  obtain  a  standard  curve,  four 
known  quantities  of  7S  rRNA  were  reverse-transcribed  and  then  PCR  amplified:  lOng, 
lng,  100pg,  10pg.  The  7S  rRNA,  the  primers  and  the  probe  for  cDNA  PCR  amplification Chapter  8  64 
were  supplied  in  the  Taqman  Ribosomal  RNA  control  kit,  Perkin  Elmer,  Branchberg,  NJ, 
USA).  Similarly,  5ng  of  RNA  extracted  from  each  sample  and  measured  by  optical  density 
were  reverse  transcribed  and  PCR  amplified.  The  values  obtained  from  the  quantification 
of  the  samples  were  always  interpolated  within  those  obtained  for  the  corresponding 
standard  curve.  Subsequently,  our  gene  of  interest  hTERT  was  quantified  in  the  same  set  of 
samples.  Initially,  hTERT  DNA  was  excised  from  an  hTERT  expression  construct  cloned 
in  a  pBluescript  KS  plasmid  vector  (kindly  provided  by  Dr.  Lisa  Bryce,  Beatson  Institute 
for  Cancer  Research)  and  quantified  by  optical  density.  To  obtain  a  standard  curve,  four 
known  quantities  of  hTERT  DNA  were  reverse  trancribed:  1pg,  100fg,  10fg,  lfg.  The 
cDNA  was  then  PCR  amplified  using  the  primers  ACAGCACTTGAAGAGGGTGCA  and 
TrCCCGATGCTGCCTGAC  and  the  fluorescent  probe  FAM- 
TGCGGGAGCIPGTCGGAAGCA-  TAMRA  (VH  Bio  Ltd.,  Newcastle  upon  Tyne,  UK). 
Similarly,  1[tg  of  RNA  extracted  from  each  sample  and  measured  by  optical  density  was 
reverse  transcribed  and  PCR.  As  described  for  rRNA,  the  values  obtained  from  the  hTERT 
quantification  of  the  samples  were  always  interpolated  within  those  obtained  for  the 
corresponding  standard  curve.  Finally,  the  relative  levels  of  hTERT  to  ribosomal  RNA  and 
the  standard  deviation  was  calculated. 
8.12  TRF  measurement. 
TRF  measurement  was  carried  out  essentially  as  described  by  Munro  and  collaborators 
(Munro  et  al.  2001).  4  [tg  of  genomic  DNA  was  digested  with  RsaI  and  HinJ7  restriction 
enzymes  (Roche  diagnostics,  Indianapolis,  USA),  separated  on  a  0.7%  agarose  gel  and 
transferred  to  a  Hybond  N  membrane  (Amersham  International,  Amersham,  UK)  in 
20xSSC.  The  blot  was  prehybridised  for  15  minutes  at  420C  in  PerfectHyb  Plus  solution 
(Sigma  Chemicals,  Poole,  UK),  hybridised  for  4  hours  at  420C  with  a  radiolabelled 
oligonucleotide  probe  (ITAGGG)3  using  the  same  hybridisation  solution  and  subsequently 
washed  in  6xSSC/1%SDS  at  42*C.  The  molecular  weight  markers  used  for  determining 
the  size  of  the  TRFs  were  X/hindIll  and  1Kb  ladders  (Gibco  BRL  Europe  Life 
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9  Features  of  the  primary  human  keratinocyte 
cultures  used  in  this  work:  a  descriptive 
summary 
This  project  was  designed  and  developed  with  the  aim  of  investigating  two  main  aspects  of 
oral  cancer  development:  1)  what  molecular  markers  are  involved  in  the  transition  from 
normal  oral  mucosa  to  dysplastic  lesions  and  subsequently  to  squamous  cell  carcinoma, 
and  2)  which  molecular  changes  are  required  for  keratinocyte  immortalisation  and  the 
timing  and  hierarchy  of  their  occurrence. 
In  order  to  answer  these  two  questions,  an  in  vitro  model  of  oral  cancer  progression 
rendered  available  by  previous  work  in  our  Institute  was  used  (Edington  et  al.  1995) 
(McGregor  et  al.  1997).  The  purpose  of  this  introductory  chapter  is  to  describe  the 
derivation  and  characterization  of  the  primary  cultures  from  normal  oral  mucosa,  mortal 
dysplasias,  immortal  dysplasias  and  squamous  cell  carcinomas  used  in  this  work,  and  their 
features  are  summarised  in  Table  1.  The  oral  dysplasias  were  all  derived  and  analysed  by 
previous  work  in  our  group.  In  addition,  several  primary  cultures  derived  from  HNSCC 
biopsies  were  kindly  made  available  by  K.  Parkinson's  group  at  the  Beatson  Institute  and 
extensively  used  throughout  this  project. 
9.1  Features  of  the  biopsy  samples 
All  of  the  biopsy  samples  utilised  for  the  derivation  of  corresponding  cultures  were  excised 
at  the  Canniesburn  Hospital  or  Glasgow  Dental  Hospital  and  School  by  our  collaborator, 
Dr.  E.  Felix,  and  their  histological  features  assessed  by  Prof.  G.  McDonald  at  the  Glasgow 
Dental  School.  Biopsies  from  normal  oral  mucosa  were  obtained  from  three  healthy 
volunteers  (FNB,  FNB3,  FNB5,  FNB6),  one  of  whom  donated  two  biopsy  from  different 
sites  of  the  oral  cavity  (FNB  and  FNB3).  Two  additional  biopsies  were  obtained  from 
morphologically  normal  tissue  adjacent  to  turnours  and  the  corresponding  cultures  made 
(NB1  and  NB5). 
The  fifteen  biopsies  of  dysplasias  were  obtained  from  different  sites  of  the  oral  cavity, 
mostly  from  those  that  are  known  to  carry  a  high  risk  of  malignant  transformation  like 
tongue  and  floor  of  mouth  but  in  one  case  from  buccal  mucosa. Chapter  9  66 
Type  Dysplasia  #  Site  Dvsplasia  Mo!  jq1& 
Patholow  phenotype 
(m  PlDs) 
Leukoplakias  D41  Posterolateral  mild  3.5 
tongue 
D6  Posterior  Moderate/  25 
tongue  severe 
D8  Ventral  mild/  9 
tongue  moderate 
D25  Floor  of  severe  28 
mouth 
D30  Floor  of  mild  30 
mouth 
D47  Floor  of  moderate  20 
mouth 
D17  Buccal  mild/  45 
mucosa  moderate 
D48  Ventral  moderate/  25.5 
tongue  severe 
D20  Lateral  moderate  immortal 
tongue 
D34  Postero-  moderate  immortal 
lateral  tongue 
D9  Ventral  mild/  immortal 
tongue  moderate 
D4  Ventral  early  SCC  immortal 
tongue/f  loor 
of  mouth 
D38  Lateral  mild  immortal 
tongue 
Erythroleukoplakias  D19  Lateral  severe/CIS  immortal 
tongue 
D35  Floor  of  severe/CIS  immortal 
mouth/ 
ventral 
I  tongue  II 
Table  1:  Features  of  the  dysplasias  used  in  this  work. Chapter  9  67 
Macroscopically,  thirteen  of  the  dysplasias  appeared  like  leukoplakias,  i.  e.  white 
hyperkeratotic  patches  on  the  oral  mucosa,  and  two  appeared  like  erythroleukoplakias,  i.  e. 
red  velvety  lesions  with  areas  of  leukoplakia  admixed.  Microscopically,  they  were 
classified  as  mild,  moderate,  severe  dysplasias  and  carcinoma  in  situ  (CIS)  depending  on 
several  internationally  adopted  criteria:  increased  nuclear/cytoplasmic  ratio,  altered  nuclear 
polarization,  irregular  epithelial  stratification,  increased  number  of  mitotic  figures,  nuclear 
hyperchromatism,  enlargement  of  nucleoli,  abnormal  keratinisation,  reduced  cellular 
cohesion  and  invasion  of  the  lamina  propria  (see  chapter  1). 
Only  limited  amount  of  information  was  available  regarding  the  clinical  outcome  of  the 
excised  dysplasias,  due  to  strict  regulations  on  patients  right  to  privacy  and  confidentiality 
issues.  Three  of  the  dysplasias,  D19,  D35  and  D48,  evolved  into  fully  developed  squamous 
cell  carcinomas  within  three  years  of  onset.  In  particular,  D19  had  a  very  poor  clinical 
outcome,  with  lymph-node  invasion,  requiring  lateral  neck  dissection. 
9.2  Establishment  of  primary  cultures 
Primary  cultures  were  derived  from  biopsies  using  the  irradiated  3T3  feeder  layer  system 
developed  and  optimised  by  Rheinwald  and  Beckett  (Rheinwald  and  Beckett  1981).  This 
system  has  been  shown  to  facilitate  growth  of  keratinocytes  from  normal  oral  mucosa  as 
well  as  malignant  lesions  maintaining  the  characteristics  of  the  original  tumours.  The 
growth  medium  utilised  for  the  establishment  of  the  cultures  was  either  flavine  adenine 
dinucleotide  growth  medium  (FAD)  supplemented  with  10%  foetal  bovine  serum  (FBS), 
0.4  Itg/ml  hydrocortisone,  5  [tg/mI  insulin,  5  [tg/ml  transferrin,  10'10M  cholera  toxin,  1.8  x 
10-4  adenine  and  10  ng/ml  epidermal  growth  factor,  or  DMEM  supplemented  with  10% 
FBS  and  hydrocortisone  (10H).  Each  culture  was  tested  and  then  maintained  with 
whichever  of  these  two  media  proved  best  for  their  growth.  Other  media  formulations  had 
been  previously  tested  in  our  Institute  (Edington  et  al.  1995),  but  the  elimination  of 
hydrocortisone  or  FBS  had  proved  detrimental  for  growth  of  carcinoma  cultures. 
Another  culture  medium  often  utilised  for  growth  of  keratinocytes  is  the  K-sfm  serum-free 
chemically-defined  medium,  supplemented  with  25  gg/ml  bovine  pituitary  extract,  0.2 
ng/ml  EGF  and  0.4  mM  CaC12.  This  medium  was  found  to  be  inadequate  for  the  growth  of 
carcinoma  cultures  because  of  the  absence  of  serum,  as  explained  above,  and  therefore  not 
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The  possibility  to  derive  primary  cultures  from  all  stages  of  oral  cancer  progression  and 
compare  their  features  offers  an  invaluable  advantage  over  other  epithelial  cancer 
progression  models,  like  colon  cancer,  where  cells  from  normal  colonic  mucosa  can  be 
grown  only  with  extreme  difficulty,  and  breast  cancer,  where  the  same  difficulty  is 
encountered  in  growing  primary  neoplastic  cells.  Another  advantage  offered  by  this  culture 
system  is  that  it  prevents  the  premature  growth  arrest  occurring  when  keratinocyte  are 
grown  in  a  chemically  defined  medium  on  plastic  culture  dishes,  without  the  3T3  feeder 
layer  (Ramirez  et  al.  2001). 
The  3T3  feeder  layer  was  removed  and  replaced  on  a  weekly  basis  or  immediately  before 
each  assay.  Keratinocytes  were  harvested  when  they  had  reached  approximately  80%  of 
confluence  in  culture  dishes  and  during  the  exponential  phase  of  their  growth. 
Standardization  of  these  two  parameters  was  considered  necessary  to  ensure  that  all  of  the 
molecular  changes  observed  amongst  the  cultures  were  possibly  related  to  different  stages 
of  cancer  progression  rather  than  different  ages  in  culture  or  different  percentages  of 
confluence. 
9.3  In  vitro  features  of  primary  cultures 
9.3.1  Proliferative  potential 
All  of  the  primary  cultures  successfully  derived  from  oral  biopsies  as  described  above  were 
serially  passaged  in  tissue  culture  plates  and  monitored  for  life-span.  The  four  cultures 
obtained  from  healthy  volunteers  (FNB,  FNB3,  FNB5,  FNB6)  proliferated  for  10,3,20 
and  11.5  population  doublings  (PD)  respectively,  after  which  they  showed  a  rapid 
deterioration  of  their  growth  rate.  The  two  cultures  derived  from  apparently  normal  tissue 
adjacent  to  turnours  (NB1  and  NB5)  reached  growth  arrest  after  20.5  and  13  PD 
respectively.  Combining  our  data  with  Ken  Parkinson's  data,  a  total  of  19  dysplasias  were 
available,  13  classified  as  leukoplakias,  2  as  erythroleukoplakias  and  4  as  erythroplakias. 
5/13  of  the  leukoplakias  and  both  the  erythroleukoplakias  showed  an  unlimited 
proliferative  potential:  they  were  still  proliferating  after  having  completed  100  PD  and 
were  therefore  considered  immortal.  The  remaining  8  leukoplakias  and  4  erythroplakias 
reached  a  growth  arrest  status  after  between  4  and  30  PD,  with  the  exception  of  D17  that 
had  a  considerably  extended  life  span  and  proliferated  for  45  PD  (table  1).  No  clear 
correlation  could  be  observed  between  proliferative  potential  and  grade  of  dysplasia  (mild, 
moderate,  severe,  CIS)  or  smoking/drinking  habits.  Both  of  the  erythroleukoplakias 
cultures  isolated  in  our  group  were  immortal,  but  this  does  not  appear  to  be  a  general  trend Chapter  9  69 
as  four  other  erythroplakia  cultures  previously  isolated  in  the  Institute  were  mortal 
(Edington  et  al.  1995).  Also,  there  was  also  no  clear  correlation  between  immortal 
phenotype  and  clinical  outcome:  only  two  of  the  seven  dysplasias  that  evolved  into  SCC 
were  immortal  in  culture. 
9.3.2  Senescence  or  crisis? 
As  discussed  in  chapter  7,  human  epithelial  cells  proliferate  for  a  finite  number  of 
population  doublings  and  then  enter  a  growth  arrest  state  called  M1  (mortality  stage  1  or 
senescence).  This  phenomenon  is  characterized  by  a  decline  in  the  number  of  cells  actually 
dividing,  while  the  others  exit  from  cell  cycle  and  arrest  in  GO.  They  remain  metabolically 
active,  resistant  to  apoptosis  and  acquire  some  peculiar  features  like  enlarged  and  flattened 
shape  with  occasional  multinuclei,  decrease  in  nuclear/cytoplasm  ratio  (Dimri  et  al.  1995). 
Abrogation  of  Rb/p16  and  p53  tumour  suppression  pathways  are  capable  of  overcoming 
the  M1  block  and  extending  cellular  life  span.  Cells  then  encounter  a  second  proliferative 
checkpoint  called  M2  (mortality  stage  2  or  crisis),  characterised  by  increased  cell  death  and 
karyotypic  abnormalities.  Only  a  small  number  of  cells  are  able  to  overcome  M2  and 
acquire  unlimited  growth  potential,  and  this  event  is  thought  to  be  dependent  upon 
reactivation  of  telomerase  and  maintenance  of  telomere  length.  In  order  to  understand  the 
role  of  different  molecular  markers  in  the  multistep  process  that  leads  to  keratinocyte 
immortality,  it  was  of  crucial  importance  to  assess  whether  the  growth  arrest  observed  in 
all  the  mortal  cultures  was  due  to  senescence  or  crisis. 
Three  assays  were  used  to  answer  this  question.  The  first  assay,  Senescence  Associated  0- 
Galactosidase  (SABG)  staining,  is  positive  in  cells  undergoing  growth  arrest  irrespectively 
of  their  senescence  or  crisis  status  (Dimri  et  al.  1995)  (Romanov  et  al.  2001).  The  second 
assay,  Bromodeoxyuridine  (BrdU)  incorporation  over  a  48h  period,  is  an  index  of  DNA 
synthesis  and  therefore  cellular  proliferation.  It  better  distinguishes  between  the  two 
mortality  checkpoints,  since  -20%  of  normal  senescent  keratinocytes  are  positive  in  this 
assay  compared  to  >80%  of  keratinocytes  in  crisis  QC  Parkinson,  personal 
communication).  The  third  assay,  TUNEL  assay,  is  specific  for  DNA  fragmentation  that 
occurs  during  cellular  apoptosis,  which  is  a  typical  feature  of  cellular  crisis  but  not 
senescence. 
All  of  the  mortal  dysplasias  were  maintained  in  culture  for  a  minimum  of  three  weeks  after 
their  growth  rate  had  decreased  and  then  analysed  by  the  assays  described  above.  SABG 
staining  was  positive  for  all  of  the  cultures.  BRDU  incorporation  was  found  in  <2%  of Chapter  9  70 
cells,  with  the  exception  of  D17  that  had  a  slightly  higher  percentage  of  BRDU 
incorporation  (10-20%).  Virtually  no  apoptosis  could  be  detected  by  TUNEL  assay.  Figure 
15  shows  a  representative  example  of  these  stainings  in  D17.  These  combined  results 
suggest  that  all  of  our  mortal  dysplasia  cultures  enter  growth  arrest  status  because  they 
reach  senescence  rather  than  crisis. 
9.3.3  Invasive  potential 
In  order  to  assess  at  what  stage  of  oral  cancer  progression  cells  acquire  invasive  potential, 
an  in  vitro  matrigel  invasion  assay  was  performed  with  or  without  the  presence  of  EGF  as  a 
chemoattractant  in  the  medium  above  the  matrigel  (McGregor  et  al.  2002).  The  percentage 
of  cultures  of  normal  oral  mucosa,  mortal  and  immortal  dysplasias  capable  of  invasion  was 
negligible  (<0.5%).  However,  the  percentage  of  SCC  and  lymph-node  metastasis  showing 
invasion  was  significantly  higher  (2%),  particularly  with  the  metastatic  culture  (6%). 
Therefore,  the  invasive  potential  appears  to  be  acquired  at  the  carcinoma  stage  of  oral 
cancer  progression,  and  increases  further  in  metastasis. 
9.3.4  Chapter  summary 
A  description  of  the  features  of  primary  human  keratinocyte  cultures  previously 
established  and  extensively  used  in  this  work  is  presented  in  this  chapter. 
A  series  of  oral  biopsies  from  normal  mucosa,  macroscopically  normal  mucosa 
adjacent  to  tumours  and  premalignant  lesions  were  collected  from  high-risk  sites 
and  corresponding  cultures  established. 
Half  of  the  dysplasias  were  mortal  in  culture  and  the  remaining  half  were  immortal. 
The  acquisition  of  immortality  can  therefore  be  an  early  event  in  oral  cancer 
progression. 
The  growth  arrest  status  reached  by  the  mortal  dysplasias  was  due  to  senescence 
rather  than  crisis. 
The  acquisition  of  invasive  potential  is  a  feature  of  SCC  and  metastatic  lesions, 
thus  a  later  event  in  oral  carcinogenesis. Chapter  9 
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Fig.  15:  SABG  staining,  BRDU  incorporation,  TUNEL  assay  in  D17. 
D17  was  maintained  in  CUlture  for  a  minimurn  of  three  weeks  to  confirill 
cessation  of  proliferative  growth.  In  order  to  Understand  if  the  growth 
arrest  StatUS  WaS  (We  to  senescence  or  crisis,  SABG  sta  ining,  BRDLJ 
I 
incorporation  and  the  TUNEL  assay  were  performed,  as  111LIStrated  above. 
A)  Cells  that  have  reached  growth  arrest,  b0th  dUe  to  senescence  or  to 
crisis,  stain  positive  for  SA-ýGal.  staining,  whereas  actively  proliferating 
cells  stain  negative. 
B)  Actively  proliferating  cells  incorporate  BRDLJ  (green  label),  whereas 
cells  that  have  reached  growth  arrest  are  only  ViSLIallSed  by  tile  nUclear 
DNA  staining  with  propidium  iodode  (red  label).  The  percentage  of  cells 
scoring  positive  for  BRDLJ  incorporation  was  assessed  on  a  1111111111LI111  Ot 
500  cells. 
C)  Apoptotic  cells  are  visuallsed  by  the  DNA  fragments  label  (green)  and 
the  nuclear  DNA  by  the  PI-OPRI11.1111  iodide  staining  (red).  Virtually  no 
apoptotic  cells  are  visible  in  any  of  the  colonies. 
Tile  positive  SABG  staining,  the  low  percentagge  of  cells  still  proliferating 
and  therefore  incorporating  the  green  BRDLJ  label  (2  1%)  and  tile  absence 
of  apoptotic  cells  incorporating  the  green  DNA-fragments  label  (TLJNEL 
assay)  are  characteristics  of  senescence  rather  than  crisis. 
Similar  evidence  was  obtained  for  all  tile  other  mortal  dysplasias  (Janis 
Fleming,  personal  CO  11111M  nicat  ion). 
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10  Analysis  of  markers  differentially  expressed  at 
different  stages  of  oral  cancer  progression. 
Our  unique  series  of  primary  cultures  from  normal  oral  mucosa,  mortal  dysplasias, 
immortal  dysplasias  and  squamous  cell  carcinomas  represents  an  ideal  system  to  carry out 
a  detailed  analysis  on  several  features  of  oral  carcinogenesis  in  vitro.  The  first  and  main 
advantage  offered  by  this  system  is  the  possibility  to  analyse  those  molecular  changes 
occurring  in  the  transition  from  normal  oral  mucosa  to  premalignant  lesions  and  squarnous 
cell  carcinomas.  Another  clear  advantage  is  the  availability  of  detailed  information 
regarding  the  proliferative  life  span  for  all  of  the  cultures.  The  acquisition  of  unlimited 
proliferative  potential  is  a  frequent,  even  if  not  universal,  feature  of  cancer  cells  and,  as 
previously  reported  by  our  group,  it  most  commonly  occurs  at  the  dysplasia  stage  of  oral 
cancer  progression.  Comparing  molecular  features  of  mortal  and  immortal  dysplasias  could 
therefore  be  of  crucial  importance  in  understanding  those  phenomena  implicated  in  cellular 
immortality.  Finally,  information  about  the  clinical  outcome  of  some  of  the  dysplasias 
from  which  our  cultures  were  derived  could  prove  useful  in  identifying  markers  of 
potential  prognostic  significance  for  early  oral  lesions. 
A  large  number  of  literature  reports  describe  several  molecular  events  occurring  during 
oral  cancer  progression.  This  study  had  several  purposes:  understanding  the  stage  of  oral 
cancer'progression  at  which  these  molecular  changes  occur,  investigating  the  potential 
correlations  between  these  markers  and  the  mortal/immortal  proliferative  potential  and 
clarifying  the  molecular  differences  between  erythroplakias  and  leukoplakias.  For  this 
reason,  a  representative  panel  of  cultures  from  normal  oral  mucosa,  mortal  dysplasias, 
immortal  dysplasias  and  SCC  was  selected  and  analysed  for  expression  of  the  following 
markers: 
Retinoic  Acid  Receptor  0  (RARP) 
*  Epidermal  Growth  Factor  Receptor  (EGFR)  and  c-erbB2 
*  Polo-like  Kinase  (PLK) 
o  Cyclin  Dl 
o  p16 
o  p53 
e  Telornerase  activity,  hTERC  and  hTERT. Chapter  10  73 
For  two  of  these  markers  (p16  and  RARP),  an  involvement  in  oral  cancer  had  already  been 
suggested  through  previous  work  carried  out  in  our  group  and  this  was  confirmed  at  the 
outset  of  my  study. 
10.1  RAR  P  is  lost  in  immortal  dysplasias  and  SCC 
Retinoids  (vitamin  A  analogues)  and  their  nuclear  receptors  are  known  to  play  a  central 
role  in  maintaining  appropriate  cellular  growth  and  differentiation  in  non  keratinising 
epithelia  like  the  oral  cavity  mucosa.  Several  studies  carried  out  in  vivo  have  reported  a 
progressive  decreAse  in  RARP  expression  in  samples  from  normal,  premalignant  and 
malignant  head  and  neck  epithelia  (Xu  et  al.  1994)  (Lotan  et  al.  1995).  In  vitro,  loss  of 
RARP  seems  to  be  a  frequent  finding  in  SCC  (Hu  et  al.  1991).  Interventional  studies 
carried  out  by  Wan  and  collaborators  (Wan  et  al.  1999)  were  also  able  to  demonstrate  that 
transfection  of  an  RARP  expression  vector  in  HN  cancer  cells  restores  their  sensitivity  to 
suppression  of  squamous  differentiation  by  retinoids. 
Previous  studies  carried  out  in  our  group  have  thoroughly  analysed  the  expression  of 
RARP  in  our  series  of  normal  samples,  premalignant  lesions  and  carcinomas  (McGregor  et 
al.  1997)  (McGregor  et  al.  2002)  and  shown  differential  regulation  of  this  marker  at 
different  stages  of  oral  cancer  progression.  RARP  mRNA  is  detectable  in  vivo  in  samples 
from  normal  oral  mucosa.  In  cultures  derived  from  those  biopsies  RARP  mRNA  was  not 
expressed  if  the  cells  were  cultured  in  a  retinoid-free  medium,  but  expression  was  restored 
upon  retinoid  treatment.  Also,  when  these  cultures  were  analysed  at  different  stages  of 
their  life  span,  expression  of  the  receptor  increased  as  cells  approached  senescence 
(McGregor  et  al.  2002).  Therefore,  expression  of  RARP  in  cultures  from  normal  oral 
mucosa  appears  to  be  retinoic'acid-dependent  when  cells  are  actively  proliferating, 
whereas  it  becomes  constitutive  at  later  stages  of  their  life  span  even  in  the  absence  of 
retinoids.  In  mortal  dysplasia  cultures,  RARP  expression  is  constitutively  active  and  its 
expression  is  detectable  independently  of  retinoid  treatment  (McGregor  et  al.  1997).  One 
interesting  exception  to  this  general  principle  is  D17,  a  mortal  culture  that  senesces  after  a 
considerably  extended  lifespan.  The  characteristics  of  this  particular  cell  line  will  be 
discussed  in  greater  detail  in  later  chapters.  In  all  of  our  immortal  dysplasias  and 
carcinomas,  RARP  mRNA  expression  is  undetectable  in  vitro  and  can  not  be  restored  with 
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Taking  into  account  all  these  observations,  the  pattern  of  RARP  expression  in  normal  oral 
mucosa  and  mortal  dysplasias  in  vitro  is  not  completely  clear.  Normal  cultures  might  lack 
receptor  expression  as  a  result  of  absence  of  exposure  to  the  ligand.  This  is  suggested  by  its 
presence  in  normal  biopsies  which  would  be  exposed  to  physiological  levels  of  circulating 
retinoids  and  by  its  expression  upon  retinoid  treatment.  As  cells  approach  senescence, 
higher  levels  of  RARP  expression  might  be  required  to  mediate  the  arrest  of  proliferative 
growth  and  terminal  differentiation.  Mortal  dysplasias  show  a  different  pattern  of 
regulation  of  RARP  expression,  as  they  are  able  to  express  high  levels  of  receptor  in  the 
complete  absence  of  ligand.  A  possible  explanation  to  this  phenomenon  is  that  mortal 
dysplasias  behave  like  senescent  normal  cells,  but  have  acquired  some  as  yet  unknown 
features  that  allow  them  to  proliferate  for  longer.  Conversely,  the  association  between  loss 
of  expression  of  RARP  and  immortal  phenotype  in  culture  appears  quite  strong,  as  it 
occurred  with  just  one  exception  in  our  oral  premalignant  lesions. 
The  constitutive  expression  of  RARP  mRNA  in  mortal  dysplasias  and  its  loss  in  immortal 
dysplasias  and  SCC  was  confirmed  at  the  outset  of  my  project  (fig.  16).  RARP  protein 
expression,  although  potentially  more  specific,  could  not  be  assessed  because  of  the 
unavailability  of  a  specific  antibody. 
10.2  Epidermal  Growth  Factor  Receptor  is  upregulated  in  SCC 
The  EGF  Receptor  family  is  composed  of  4  members  EGF-R,  c-erbB2,3  and  4;  of  these 
EGF-R  homodimers  or  EGF-R/c-erbB-2  heterodimers  form  receptors  for  EGF.  The  EGF 
Receptor  complex  and  its  ligands  EGF  and  TGFa  are  involved  in  cellular  growth  and 
differentiation.  As  for  many  other  growth  factor  receptors,  over-expression  of  EGF 
receptor  complex  could  be  a  potential  mechanism  enabling  cells  to  acquire  a  proliferative 
advantage  and  respond  to  low  amount  of  ligands.  A  vast  body  of  literature  (Grandis  and 
Tweardy  1993)  (Todd  et  al.  1989)  (Ishitoya  et  al.  1989)  including  work  done  from  our 
Institute  (Stanton  et  al.  1994)  has  demonstrated  that  EGF-R  is  up-regulated  in  HNSCC, 
both  in  vitro  and  in  vivo.  EGF-R  expression  has  also  been  analysed  in  oral  premalignant 
lesions,  both  in  vitro  and  in  vivo  (Grandis  et  al.  1998)(d),  and  its  up-regulation  in  these 
lesions  appears  to  be  correlated  with  increasing  degrees  of  dysplasia.  It  has  also  been 
suggested  that  c-erbB-2  may'be  a  better  prognostic  index  for  oral  cancer  development  than 
EGF-R  subunit  itself  (Xia  et  al.  1999). Chapter  10 
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Fig.  16:  RARP  expression  in  a  panel  of  cultures  from  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  squamous  cell 
carcinomas. 
Northern  blot  showing  RARP  niRNA  expression  in  a  randomly  selected 
group  of  cultures  from  normal  oral  mucosa,  mortal  dysplasias,  immortal 
dysplasias  and  squamous  cell  carcinomas.  The  level  of  Ribosomal  RNA 
subunit  7S  was  also  determined  to  ensure  equal  loading  of  samples.  Cells 
were  cultured  in  a  Retinoid-free  (i.  e.  not  supplemented)  standard  medium 
and  samples  were  collected  within  the  exponential  growth  phase  for  each 
culture.  Names  of  individual  cultures  are  shown  on  the  upper  part  of  the 
figure. 
As  shown  in  this  figure,  in  the  absence  of  RA  treatment,  RARP  is 
constitutively  expressed  in  the  mortal  dysplasias  and  virtually 
undetectable  in  the  normal  culture,  all  of  the  immortal  dysplasias  and 
SCCS. 
Data  presented  is  representative  of  2  independent  experiments. 
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EGF-R  expression  was  analysed  by  Western  Blotting  in  selected  cultures  of  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  SCCs  (fig.  17  A).  After  quantification 
of  the  EGFR  bands  and  normalisation  for  the  loading  control,  the  average  values  were  0.5 
for  the  normal  samples,  2.2  for  the  mortal  dysplasias,  3.3  for  the  immortal  dysplasias  and 
7.9  for  the  SCCs.  Amongst  the  immortal  dysplasias,  D19  showed  particularly  high  levels 
of  expression  of  EGFR,  similar  to  those  observed  in  SCCs.  Although  the  significance  of 
this  finding  is  difficult  to  assess  at  present,  it  is  useful  to  point  out  that  D19  was  an 
erythroleukoplakia  that  evolved  to  SCC.  Overall,  this  experiment  suggested  that  an  up- 
regulation  of  EGF-R  expression  could  occur  in  the  transition  from  normal  oral  mucosa  to 
dysplasias,  regardless  of  their  proliferative  fate,  with  a  further  up-regulation  in  SCCs, 
although  the  presence  of  only  two  samples  from  normal  oral  mucosa  and  two  samples  from 
SCCs  in  the  blot  did  not  allow  to  draw  significant  conclusions.  In  a  subsequent  experiment, 
all  our  normal  samples  and  mortal  dysplasias  were  analysed  (fig.  17  B).  The  difference 
between  levels  of  EGFR  expression  in  FNB5  and  FNB6  observed  in  the  previous 
experiment  was  not  as  marked  in  this  second  experiment.  The  levels  of  EGFR  expression 
in  mortal  dysplasias  were  fairly  consistent  in  the  two  experiments,  but  a  slight  degree  of 
inter-experiment  variation  could  still  be  observed,  particularly  for  D6.  The  average  values 
calculated  were  0.8  for  normal  samples  and  1.4  for  mortal  dysplasias.  Therefore,  the  lower 
levels  of  EGFR  expression  in  normal  oral  mucosa  compared  to  mortal  dysplasias  suggested 
by  the  previous  experiment  was  not  a  consistent  finding. 
A  similar  conclusion  emerged  from  the  analysis  of  levels  of  expression  of  c-erbB2,  the 
favourite  binding  partner  for  EGF-R.  No  major  differences  were  observed  between  normal 
samples  (1.7  on  average)  and  mortal  dysplasias  (2.4  on  average)  in  the  first  experiment 
(fig.  18  A).  Similarly,  only  slight  differences  could  be  observed  amongst  the  different 
groups  in  the  second  experiment  (fig.  18  13):  the  only  normal  sample  analysed  had  a  value 
of  1.0,  the  three  mortal  dysplasias  had  an  average  value  of  1.7,  the  three  immortal 
dysplasias  an  average  value  of  0.9  and  the  two  SCCs  an  average  value  of  1.3.  Again,  strong 
conclusions  could  not-been  drawn  due  to  the  low  number  of  normal  samples  and  SCCs 
included  in  the  blot.  In  addition,  a  moderate  degree  of  variation  could  be  observed  in  levels 
c-erbB2  expression  for  D30  and  D25  in  the  two  separate  experiments,  and  the  significance 
of  this  finding  is  unknown. Chapter  10 
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Fig.  17:  EGFR  expression  in  a  panel  of  cultures  from  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  SCCs. 
A)  The  expression  of  EGFR  was  assessed  through  western  blot  in  a 
selected  panel  of  cultures  from  normal  oral  mucosa,  mortal  dysplasias, 
immortal  dysplasias  and  squarnous  cell  carcinomas.  The  names  of 
individual  cultures  are  shown  on  the  upper  part  of  each  figure.  ERK  1,2 
levels  were  also  measured  to  ensure  equal  sample  loading.  The 
quantification  of  the  EGFR  bands  normalised  for  the  loading  control  is 
shown  in  the  bottom  part  of  each  figure.  EGFR  appeared  to  be 
overexpressed  in  dysplasias  compared  to  normal  samples,  with  further 
upregulation  in  carcinomas.  To  test  the  consistency  of  this  finding,  EGFR 
expression  was  assessed  in  a  wider  panel  of  normal  samples  and  mortal 
dysplasias  (B).  OC-Tubulin  was  used  as  a  loading  control. 
As  shown  above,  EGFR  protein  expression  is  upregulated  in  SCCs  but  not 
in  premalignant  lesions. 
Data  presented  is  representative  of  2  and  3  independent  experiments  (A 
and  B  respectively). 
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Fig.  18:  c-erbB2  expression  in  a  panel  of  cultures  from  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  squamous  cell 
carcinomas. 
Western  blots  comparing  c-erbB2  expression  in  all  of  our  normal  samples 
and  mortal  dysplasias  (A)  and  in  a  randornly  selected  group  of  cultures 
from  normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and 
squamous  cell  carcinomas  (B).  ot-Tubulin  and  ERK  1,2  were  used  as  a 
loading  control  (A  and  B  respectively). 
Names  of  individual  cultures  are  shown  on  the  upper  part  of  each  figure. 
The  quantification  of  the  c-erbB2  bands  normalised  for  the  loading 
control  is  shown  in  the  bottom  part  of  each  figure. 
No  consistent  changes  in  protein  expression  can  be  observed  in  the  panel 
of  samples  analised,  with  the  exception  on  FNB  6  in  (B),  which  could  be 
due  to  sample  underloading. 
Data  presented  is  representative  of  2  independent  experiments. 
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To  exclude  that  the  differences  in  EGFR  or  c-erbB2  expression  between  normal  cultures 
were  not  due  to  unintended  differences  in  culture,  four  different  samples  of  normal  oral 
mucosa  were  analysed  at  different  stages  of  their  proliferative  life  span  comprising 
senescence  and  at  different  percentages  of  confluence  in  culture  plates  (fig.  19).  The  levels 
of  EGF-R  expression  were  virtually  unchanged  at  all  different  culture  ages  in  both  FN133 
and  FNB6.  Higher  levels  of  EGF-R  expression  appeared  to  be  associated  with  senescence 
in  FNB;  opposedly,  the  levels  of  EGF-R  expression  appeared  downregulated  in  the 
senescent  FNB5  sample.  In  FNB,  EGF-R  levels  remained  unchanged  when  the  cells 
formed  a  confluent  monolayer  in  the  culture  plate.  Overall,  these  findings  suggest  that  no 
consistent  variation  of  EGF-R  expression  appears  to  be  related  to  either  culture  age  or 
percentage  of  confluence  in  culture  plates  in  the  samples  analysed. 
Summarizing  what  reported  in  literature  (see  chapter  3)  EGFR  is  not  expressed  in  cultures 
from  normal  oral  mucosa  and  is  upregulated  in  cultures  from  SCC,  but  no  data  are 
available  describing  changes  of  EGFR  expression  in  oral  dysplasias  in  vitro.  In  vivo,  EGFR 
is  barely  detectable  in  samples  from  normal  oral  mucosa,  where  it  is  confined  to  the  basal 
epithelial  layers;  its  ligand  TGFcc  is  expressed  at  low  levels  only  in  the  suprabasal 
epithelial  layers.  In  contrast,  both  the  receptor  and  its  ligand  are  expressed  at  high  levels  in 
all  layers  of  the  SCC  epithelium,  particularly  at  tumour  margins.  This  is  consistent  with  the 
development  of  an  autocrine  pathway,  where  cells  produce  both  the  receptor  and  its  ligand 
becoming  independent  from  exogenous  supplementation.  This  mechanism  confers  tumour 
cells  a  proliferative  advantage  over  their  normal  counterparts  and  would  explain  the  higher 
expression  of  both  EGFR  and  TGFa  at  tumour  margins.  In  dysplasias,  only  slight 
increases  of  EGFR  have  been  described  in  vivo,  not  exceeding  2.5-fold. 
On  the  basis  of  the  new  experimental  findings  described  in  this  section,  the  EGFR 
upregulation  in  oral  cancer  progression  appears  to  occur  at  the  SCC  stage:  a  4.5  and  11.5 
upregulation  was  found  in  two  different  carcinoma  samples  compared  to  a  normal  sample. 
in  keeping  with  the  development  of  an  autocrine  pathway,  cultures  from  SCC  grow  well  in 
medium  not  supplemented  with  EGF,  whereas  cultures  from  normal  oral  mucosa  and 
dysplasias  do  not.  No  consistent  difference  was  found  in  the  expression  of  EGFR  between 
samples  from  normal  oral  mucosa  and  dysplasias.  The  discrepancy  between  the  data 
reported  in  literature  in  vivo  and  our  findings  in  vitro  might  be  due  to  the  fact  that  cells 
from  normal  oral  mucosa  do  not  normally  proliferate  in  vivo,  but  are  forced  to  proliferate 
in  culture  and  therefore  to  express  EGFR.  Alternatively,  the  cultures  isolated  from  normal 
oral  mucosa  could  be  composed  mainly  by  basal  layer  cells,  that  do  express  EGFR  like 
cells  from  the  basal  layers  of  dysplasias  and  carcinomas. A 
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Fig.  19:  EGFR  expression  in  samples  of  normal  oral  mucosa  at 
different  ages  and  percentage  of  confluence  in  culture. 
In  order  to  determine  whether  EGFR  expression  varied  depending  on  age 
in  culture  or  percentage  of  confluence,  all  of  our  samples  from  normal 
oral  mucosa  were  grown  under  standard  culture  condition  and  harvested  at 
several  different  proliferative  ages  towards  senescence.  Sample  collection 
was  also  standardised  at  80%  of  confluence,  with  the  exception  of  sample 
indicated  as  FNB  C  that  was  harvested  after  cells  had  formed  a  complete 
monolayer. 
On  the  upper  part  of  each  figure  are  indicated  names  of  individual  cultures 
and  number  of  population  doublings  completed  in  culture  or  senescence 
status. 
The  expression  of  EGFR  was  assessed  by  western  blotting.  (x-tubulin  was 
used  as  a  loading  control.  The  quantification  of  the  EGFR  bands 
normalised  for  the  loading  control  is  shown  in  the  bottom  part  of  each 
figure.  No  consistent  variations  in  EGFR  expression  were  observed  in  all 
of  the  cultures  analysed  depending  on  different  stage  of  replicative  life 
span  or  different  percentage  of  confluence. 
80 Chapter  10 
10.3  Cell  cycle  regulators 
10.3.1  Polo-Like-Kinase  expression  does  not  show  consistent  variations 
81 
PLK  is  a  cell  cycle  regulator,  involved  in  the  transition  from  G2/M  phase  (see  chapter  5.2). 
One  report  in  literature  describes  PLK  (Knecht  et  al.  1999)  expression  to  be  elevated  in 
oral  SCC  in  vivo,  but  no  studies  are  available  so  far  on  their  expression  in  oral  dysplasias 
or  in  cultures  from  either  SCC  or  dysplasias.  Therefore,  our  model  was  ideal  to  address  this 
question. 
PLK  protein  expression  was  analysed  through  Western  Blotting  (fig.  20  A)  in  the  usual 
panel  of  samples,  the  bands  quantified  and  normalised  for  the  loading  control.  The  normal 
sample  had  a  value  of  1,  and  the  average  values  calculated  for  each  group  were  8.7  for  the 
mortal  dysplasias,  9.4  for  the  immortal  dysplasias  and  16.4  for  the  SCCs.  D19,  an 
erythroleukoplakia  that  evolved  to  SCC,  showed  levels  of  PLK  expression  comparable  to 
those  found  in  carcinomas,  although  the  significance  of  this  finding  is  difficult  to  assess. 
An  indication  that  PLK  might  be  upregulated  in  the  transition  from  normal  oral  mucosa  to 
early  premalignant  lesions,  and  further  in  SCCs  emerged  from  this  experiment,  although 
only  1  normal  sample  and  2  SCCs  were  analysed.  However,  a  more  extensive  analysis  of 
this  marker  in  normal  samples  and  mortal  dysplasias  did  not  show  major  differences 
between  the  two  groups  (fig.  20  B):  the  two  normal  samples  used  in  this  second  experiment 
showed  a  great  variability  in  their  levels  of  PLK  expression  (6.6  on  average),  and  the 
mortal  dysplasias  were  13.17  on  average.  The  apparent  marked  difference  between  levels 
of  PLK  expression  in  FNB5  and  FNB6  were  not  confirmed  in  the  following  experiments, 
so  the  interpretation  of  this  finding  is  unclear. 
When  PLK  protein  expression  was  analysed  in  samples  from  normal  oral  mucosa  at 
different  stages  of  their  life  span  and  percentages  of  confluence  (fig.  21),  no  relevant  age- 
specific  changes  were  found,  but  a  downregulation  of  this  protein  could  be  observed  in  a 
sample  extracted  from  a  confluent  monolayer  of  cells.  This  finding  requires  confirmation, 
but  if  substantiated  it  suggests  an  involvement  of  PLK  in  regulatory  mechanisms  governing 
cellular  proliferation  rather  than  replicative  senescence  or  premalignant-malignant 
transformation. Chapter  10 
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Fig.  20:  Polo-Like  Kinase  expression  in  a  panel  of  cultures  from 
normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and 
squamous  cell  carcinomas. 
A)  The  expression  of  PLK  was  assessed  by  western  blot  in  a  panel  of 
cultures  from  normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias 
and  squamous  cell  carcinomas.  The  names  of  the  cultures  are  shown  on 
the  upper  part  of  each  figure.  ERK  1,2  were  also  measured  to  ensure  equal 
sample  loading.  The  quantification  of  the  PLK  bands  normalised  for  the 
loading  control  is  shown  in  the  bottom  part  of  each  figure.  Allowing  for  a 
slight  underloading  in  samples  at  the  extremities  of  the  blot,  PLK 
overexpression  appeared  to  be  a  feature  of  dysplasias  and  carcinomas, 
compared  to  normal  oral  mucosa.  To  determine  whether  this  was  a 
consistent  difference  in  expression  levels,  a  wider  variety  of  samples  from 
normal  oral  mucosa  and  mortal  dysplasias  was  analysed  (B).  As  shown  in 
the  figure,  PLK  protein  overexpression  in  neoplastic  lesions  was  not 
confirmed  in  this  second  experiment. 
Data  presented  is  representative  of  3  and  4  independent  experiments  (A 
and  B  respectively). 
82 Chapter  10 
FNB3  FNB  A 
Tn 
1V 
LD  ulý 
t-ý  Eci 
z 
Tp  c 
Lo  CD 
r-,  ff) 
PLK  qmý 
ERKs 
1.00  0.92  0.91  0.72  0.16  0.83  0.79 
B  FNB6  FNB5 
zi  7m  Z 
3  :3  'V  1:  3  'W  h  3 
1:  2  c  ui  LO  Lö 
LD  ui  (V  -. 
ßý  m  in 
v 
ýr- 
N 
w- 
Lli 
-r-  (n 
PLK  ýWmwww  -ownwo  "ý  quoraw 
ERKs  =ýý  qmý  qmý  ý  -Wwvý 
1.00  0.91  1.29  1.05  1.03  1.18  1.08  1.22  1.21 
Fig.  21:  Polo-Like-Kinase  expression  in  samples  of  normal  oral 
mucosa  at  different  ages  and  percentage  of  confluence  in  culture. 
PLK  protein  expression  was  monitored  in  four  different  cultures  of 
normal  oral  mucosa  at  different  proliferative  ages  in  culture,  comprising 
senescence.  Protein  extracts  were  obtained  from  cultures  at  80%  of 
confluence,  with  the  exception  of  sample  FNB  C  that  was  harvested  after 
the  cells  had  formed  a  complete  monolayer.  On  the  upper  part  of  each 
figure  are  indicated  name  of  individual  cultures  and  number  of  population 
doublings  completed  in  culture  or  senescence  status.  Levels  of  PLK 
protein  were  assessed  through  Western  Blotting,  using  ERK  1,2  as  a 
loading  control.  The  quantification  of  the  PLK  bands  normalised  for  the 
loading  control  is  shown  in  the  bottom  part  of  each  figure. 
No  consistent  variation  in  PLK  expression  was  observed  in  all  of  the 
cultures  analysed  regardless  of  the  stage  of  replicative  life  span.  A  slight 
downregulation  of  PLK  protein  expression  was  observed  in  the  sample 
obtained  from  the  confluent  monolayer  (FNB  Q. 
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10.3.2  No  major  changes  are  found  in  Cyclin  Dl  expression 
Cyclin  D1  is  a  key  regulator  of  the  Gl/S  phase  of  cell  cycle  in  response  to  growth  factor 
stimulation.  Cyclin  D1/cdk4  complexes  lead  to  phosphorylation  of  Rb  protein,  release  of 
E2F  transcription  factor  and  ultimately  enhancement  of  mitogenesis  (see  chapter  4.1). 
Amplification  of  the  cyclin  D1  locus  and  protein  overexpression  have  been  frequently 
reported  in  HNSCC  in  vivo  (Berenson  et  al.  1989)  (Bartkova  et  al.  1995)  (Callender  et  al. 
1994),  but  very  little  data  are  available  on  this  cell  cycle  regulating  protein  in  premalignant 
oral  lesions  or  in  SCC  derived  cell  cultures  (see  chapter  5.1). 
To  clarify  the  exact  stage  of  oral  cancer  progression  at  which  the  involvement  of  cyclin  D1 
occurs  in  vitro,  protein  expression  was  analysed  through  Western  Blotting  in  several 
samples  of  normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and  SCCs.  As 
shown  in  fig.  22,  despite  some  degree  of  variation  observed  amongst  samples,  overall  no 
stage  specific  changes  were  observed.  The  average  values  calculated  after  normalisation 
for  the  loading  control  were  4.1  for  normal  samples  and  4.9  for  mortal  dysplasias  in  the 
first  experiment  (panel  A);  1.0  for  the  normal  sample,  2.0  for  mortal  dysplasias,  0.9  for 
immortal  dysplasias  and  1.9  for  SCCs  in  the  second  experiment  (although  only  two  SCC 
samples  were  analysed)  (panel  B). 
It  emerges  from  the  literature  reports  (see  chapter  5.1)  that  amplification  of  cyclin  D1  locus 
and  protein  overexpression  occur  in  25-48%  of  premalignant  lesions  or  SCC  in  vivo,  but 
the  data  published  on  in  vitro  findings  is  inconclusive.  When  grown  in  culture,  cells  are  all 
stimulated  to  grow,  and  this  could  mask  the  differences  between  protein  expression  in 
normal  samples  and  neoplastic  lesions  observed  in  vitro. Chapter  10 
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Fig.  22:  Cyclin  DI  expression  in  a  panel  of  cultures  from  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  squamous  cell 
carcinomas. 
Western  blots  comparing  cyclin  DI  expression  in  all  of  our  normal 
samples  and  mortal  dysplasias  (A)  and  in  a  group  of  cultures  from  normal 
oral  mucosa,  normal  mucosa  adjacent  to  tumour  (NB  1),  mortal  dysplasias, 
immortal  dysplasias  and  squamous  cell  carcinomas  (B).  Names  of 
individual  cultures  are  shown  on  the  upper  part  of  each  figure.  ERK  1,2 
were  used  as  a  loading  control.  The  quantification  of  the  cyclin  DI  bands 
normalised  for  the  loading  control  is  shown  in  the  bottom  part  of  each 
figure. 
As  shown  in  the  figures,  protein  expression  does  not  show  major  changes 
in  the  panel  of  samples  analysed. 
Data  presented  is  representative  of  a  single  experiment  (A)  and  2 
independent  experiments  (B). 
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10.3.3  p16  is  lost  in  immortal  dysplaslas  and  SCC 
p16  protein  is  an  upstream  regulator  of  the  cyclin  D1/cdk4  complex,  regulating  its  function 
through  an  inhibitory  effect  on  cdk4  (see  chapter  4.3).  Loss  or  mutation  of  this  gene  in 
HNSCCs,  both  in  vitro  and  in  vivo  has  been  reported  by  a  large  number  of  studies,  as 
described  in  chapter  5.3.  p16  inactivation  was  also  described  in  oral  leukoplakias  in  vivo 
(Papadimitrakopoulou  et  al.  1997).  p16  also  plays  a  crucial  role  in  initiating  and 
maintaining  the  programme  of  cellular  senescence  and  its  loss  is  necessary,  even  though 
not  sufficient,  for  keratinocyte  immortalisation  (see  chapter  7).  Previous  work  carried  out 
in  our  Institute  has  described  loss  of  protein  expression  in  immortal,  but  not  senescent, 
HNSCC  cell  lines  (Loughran  et  al.  1996).  In  our  oral  dysplasias  ,  loss  of  p16  expression 
was  also  related  to  the  acquisition  of  the  immortal  phenotype  (McGregor  et  al.  1997),  with 
the  interesting  exception  of  D17  culture  that  has  lost  p16  expression  as  well  as  RARP 
expression,  as  previously  reported  in  this  chapter,  but  still  senesces,  even  if  after  a 
considerably  extended  life  span.  The  features  of  D17  mortal  culture  will  be  a  focus  of  the 
present  study  discussed  in  greater  detail  in  later  chapters. 
In  order  to  consolidate  the  basis  of  this  project  it  appeared  worthwhile  to  include  such  a 
crucial  player  amongst  the  molecular  markers  investigated  for  differential  expression 
during  oral  cancer  progression,  even  if  only  as  a  reiteration  of  previous  findings  in  our 
group.  p16  protein  expression  was  analysed  through  Western  Blotting  in  a  small 
representative  group  of  our  samples.  Cellular  extracts  were  obtained  during  the  exponential 
phase  of  growth  of  each  culture,  to  avoid  changes  in  protein  expression  due  to  cells 
approaching  the  senescence  status. 
In  agreement  with  what  previously  described,  p16  was  present  in  normal  samples  and 
mortal  dysplasias  but  undetectable  in  immortal  dysplasias  and  SCCs  (fig.  23).  This 
corroborates  the  extensively  described  and  important  role  played  by  p16  in  cellular 
immortalisation. Chapter  10 
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Fig.  23:  p16  expression  in  a  panel  of  cultures  from  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  squamous  cell 
carcinomas. 
Western  Blot  showing  p16  protein  expression  in  a  group  of  cultures  from 
normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and 
squamous  cell  carcinomas.  The  samples  were  obtained  from  each  culture 
during  the  exponential  phase  of  growth.  Names  of  individual  cultures  are 
shown  on  the  upper  part  of  the  figure.  ERK  1,2  was  also  measured  to 
ensure  equal  loading  of  samples.  The  quantification  of  the  p16  bands 
normalised  for  the  loading  control  is  shown  in  the  bottom  part  of  the 
figure. 
The  figure  shows  p16  protein  expression  in  samples  frorn  normal  mucosa 
and  mortal  dysplasias,  but  not  in  immortal  dysplasias  and  carcinomas. 
Data  presented  is  from  a  single  experiment,  but  confirms  previous 
findings  in  the  group. 
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10.3.4  p53  is  overexpressed  in  immortal  dysplaslas  and  SCC 
p53  mediates  cell  cycle  arrest  or  apoptosis  in  response  to  a  variety  of  cellular  stresses 
(DNA  damage,  hypoxia,  viral  and  cellular  oncogenes)  (see  chapter  4.4).  Elevated  p53 
protein  levels  often  occur  when  p53  is  mutated  (mainly  missense  mutations)  that  cause 
protein  stabilization  through  an  increase  in  its  half  life.  It  is  also  generally  accepted  that  an 
abrogation  of  p53  and  Rb  tumour  suppressor  gene  pathways,  in  conjunction  with 
telomerase  up-regulation,  are  required  for  keratinocyte  immortality  (see  chapter  7). 
Several  studies  carried  out  in  vivo  have  reported  an  increased  frequency  of  p53 
overexpression  in  the  transition  from  mild  to  moderate  to  severe  dysplasias  (Sauter  et  al. 
1994)  and  increased  incidence  of  p53  mutations  during  HNSCC  progression  (Boyle  et  al. 
1993).  p53  overexpression  has  also  been  associated  with  immortal  but  not  senescent 
phenotype  in  HNSCC  cell  lines  (Edington  et  al.  1995). 
p53  protein  expression  was  analysed  through  Western  Blotting  in  normal  samples, 
premalignant  lesions  and  SCCs.  Consistently  low  levels  of  protein  were  found  in  all  of  the 
normal  samples  (2.7  on'  average)  and  mortal  dysplasias  (3.3  on  average),  with  the 
exception  of  D17  (9.45)  (fig.  24  A).  As  reported  earlier  in  this  chapter,  this  mortal 
dysplasia  senesces  after  a  considerably  extended  life  span  and,  also  in  contrast  to  all  other 
mortal  dysplasias,  has  lost  expression  of  RARP  and  p16.  p53  protein  expression  was  also 
considerably  elevated  in  immortal  dysplasias  (15.6  on  average)  and  SCCs  (16.7  on 
average)  (fig.  24  B). 
Thus  p53  protein  analysis  suggested  a  strict  correlation  between  p53  over-expression  and 
immortal  phenotype  as  early  as  the  premalignant  stage  of  oral  cancer  progression.  What 
remained  to  be  tested  was  the  actual  correspondence  between  protein  over-expression  and 
gene  mutation.  Genomic  DNA  was  obtained  from  all  of  our  mortal  and  immortal 
dysplasias  and  the  entire  p53  coding  region  (exons  2-11)  was  sequenced  (table  2).  In  all  of 
the  mortal  dysplasias,  comprising  D17,  the  wild  type  status  of  p53  was  confirmed.  The 
immortal  dysplasias  harboured  point  mutations,  affecting  the  DNA  binding  domain  of  the 
protein  or,  in  one  example,  the  tetramerization  domain.  These  mutations  were 
heterozygous  in  3  of  the  cultures  and  homozygous  in  the  remaining  3.  Mutations  were 
defined  as  homozygous  when  no  expression  of  the  normal  allele  could  be  detected  upon 
sequencing. Chapter  10 
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Fig.  24:  p53  expression  in  a  panel  of  cultures  from  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplasias  and  squamous  cell 
carcinomas. 
Western  blots  illustrating  the  expression  of'  p53  protein  in  normal  oral 
mucosa,  mortal  dysplasias,  immortal  dysplaslas  and  squanious  cell 
carcinomas.  ERK  1,2  were  used  as  a  loading  control.  A)  p53  expression 
levels  are  fairly  homogeneous  in  all  nornial  samples  and  mortal  dysplasias 
analysed,  with  the  exception  of  D17  which  shows  high  levels  of  p53 
expression.  As  described  in  the  text,  this  culture,  although  still  mortal, 
shows  a  considerably  extended  life  span  compared  to  all  other  mortal 
cultures.  B)  p53  overexpression  is  evident  in  all  of  the  immortal 
dysplasias  and  carcinomas  analysed,  as  a  synoninious  of  protein 
stabilization  due  to  gene  mutation. 
Names  of  individual  cultures  are  shown  on  the  upper  part  of  each  figure. 
Data  presented  is  representative  of'  4  and  2  independent  experiments  (A 
and  B  respectively). 
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D38 
(immortal) 
WT 
D17  (mortal)  WT 
D6  (mortal)  WT 
D8  (mortal)  WT 
D25  (mortal)  WT 
D30  (mortal)  WT 
D41  (mortal)  WT 
D47  (mortal)  WT 
D48  (mortal)  WT 
Table  2:  p53  sequencing  in  cultures  from  mortal  dysplasias  and 
immortal  dysplasias. 
The  entire  coding  region  of  p53  (exons  2-11)  was  sequenced  in  all  our 
dysplasias,  in  collaboration  with  Janis  Fleming.  This  table  illustrates  the 
exon  and  nucleotide  number  where  the  mutation  was  found,  the 
consequent  nucleotide  and  aminoacid  change,  the  zigosity  status  and  the 
protein  domain  affected  by  the  mutation.  WT  indicates  the  wild  type 
status  of  the  p53  gene. 
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Nevertheless,  this  type  of  analysis  does  not  allow  to  discriminate  between  a  trace  generated 
by  two  identical  alleles  (in  which  case  the  mutation  would  be  truly  homozygous)  and  a 
trace  generated  by  a  single  allele,  the  other  one  being  deleted  (in  which  case  it  would  be 
more  appropriate  to  define  the  mutation  as  hemizygous).  The  only  exception  to  the  general 
trend  of  all  immortal  cultures  harbouring  mutations  in  p53  gene  was  the  immortal  culture 
D38,  which  retained  wild  type  p53.  The  significance  of  this  finding  will  be  discussed  later 
in  the  context  of  other  data  in  the  general  discussion  chapter  of  this  work. 
This  findings  are  in  concordance  with  the  generally  accepted  crucial  role  played  by  the  p53 
tumour  suppressor  protein  in  acquisition  of  cellular  immortality.  Mutations  occurring  in 
our  immortal  SCC  cell  lines  have  already  been  reported  and  in  the  majority  of  cases  they 
were  homozygous  (Edington  et  al.  1995).  This  work  has  extended  the  observation  to  a 
wide  spectrum  of  oral  premalignant  lesions,  where  p53  overexpression  and  gene  mutation 
are  related  to  the  transition  from  mortal  to  immortal  phenotype.  An  apparent  discordance 
seems  to  exist  between  levels  of  p53  protein  expression  and  wild  type  status  of  p53  gene  in 
D17  culture.  One  possible  explanation  for  this  finding  is  that  the  loss  of  p16  expression 
observed  in  D17  allows  cells  to  bypass  the  initial  growth  arrest  checkpoint  regulated  by 
p16.  They  undergo  further  telomere  shortening,  up-regulate  p53  and  indeed  activate  it 
through  phosphorylation  at  serine  residue  15  (Webley  et  al.  2000),  this  event  finally 
leading  to  growth  arrest.  Alternatively,  the  over-expressed  p53  might  be  transcriptionally 
inactive  because  of  a  concomitant  increase  in  the  levels  of  mdm-2,  consistent  with  an  auto- 
regulating  feedback  loop  (Blaydes  et  al.  1997).  Increased  levels  of  p53  have  also  been 
reported  in  post-selection  human  mammary  epithelial  cells  (HMECs),  that  have 
spontaneously  lost  expression  of  p16  (Romanov  et  al.  2001). 
10.4  Telomerase 
A  vast  body  of  literature  has  been  produced  over  the  past  years  on  the  role  of  telomerase  in 
cellular  immortalisation  and  cancer  progression  (see  chapter  6.2).  In  the  specific  field  of 
oral  carcinogenesis,  telomerase  activity  has  been  reported  in  a  large  percentage  of  SCCs 
and  in  a  smaller  percentage  of  oral  leukoplakias  in  vivo  (Miyoshi  et  al.  1999)  (Mutirangura 
et  al.  1996). 
In  view  of  this  evidence  in  the  literature,  telomerase  activity  and  levels  of  the  two 
components  of  telomerase  hTERT  and  hTERC  were  analysed  in  cultures  from  normal  oral 
mucosa,  oral  premalignant  and  malignant  lesions. Chapter  10  92 
10.4.1  Telomerase  activity  is  high  in  immortal  dysplaslas  and  SCC 
The  levels  of  telomerase  activity  were  investigated  using  the  serniquantitative  method 
TRAPeze  assay.  This  assay  is  a  two  step  system  utilising  the  polymerase  chain  reaction 
(PCR).  In  the  first  step  of  the  reaction,  telomerase  adds  a  number  of  telomeric  repeats 
(GGTTAG)  onto  the  3'  end  of  a  substrate  oligonucleotide  (TS)  provided  with  the  assay  kit. 
In  the  second  step,  the  extended  products  are  amplified  by  PCR  using  the  TS  and  RP 
(reverse)  primers,  generating  a  ladder  of  products  with  6  base  pair  increments.  The 
TRAPeze  telomerase  detection  kit  also  includes  an  internal  standard,  a  36bp  band  (S-IC), 
in  every  lane.  The  internal  control  band  appears  weaker  in  those  samples  with  high 
telomerase  activity  because  amplification  of  the  TRAP  products  and  the  S-IC  band  are 
semi-competitive.  Being  based  on  PCR  amplification  of  substrates,  this  assay  can  be 
saturated  by  the  amounts  of  telomerase  in  the  samples,  rendering  a  precise  quantitation  of 
the  enzyme  activity  very  difficult.  For  this  reason,  different  amounts  of  protein  extracts 
from  our  samples  were  tested  in  separate  experiments.  W138  and  Hela  cells  were  included 
as  negative  and  positive  control,  as  described  in  literature  (Kim  et  al.  1994).  When  200ng 
of  protein  extract  were  used,  telomerase  activity  was  found  to  be  undetectable  or  barely 
detectable  in  normal  oral  mucosa  and  mortal  dysplasias  and  readily  detectable  in  immortal 
dysplasias  and  SCCs  (fig.  25).  A  second  experiment  using  100ng  of  whole  cell  extract 
from  the  same  samples  (fig.  26)  revealed  that  the  telomerase  activities  of  immortal 
dysplasias  and  SCCs  varied  considerably,  some  of  them  showing  higher  levels  than  HeLa 
(D19,  D20,  D35,  D38). 
This  finding  suggests  a  close  correlation  between  telomerase  activity  and  cellular 
immortalisation  at  the  dysplasia  stage  of  oral  cancer  progression.  The  percentage  of  our 
oral  dysplasia  cultures  that  are  telomerase  positive  (50%)  is  similar  to  the  figure  previously 
reported  in  vivo  (Miyoshi  et  al.  1999)  (Mutirangura  et  al.  1996)  (Sumida  et  al.  1999). 
To  gain  further  insight  into  the  mechanisms  of  telomerase  activation,  the  two  components 
of  telomerase,  hTERC  (RNA  template)  and  hTERT  (reverse  transcriptase)  were 
subsequently  analysed. Chapter  10 
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Fig.  25:  Telomerase  activity  in  cultures  from  normal  oral  mucosa  (N), 
mortal  dysplasias  (MD),  immortal  dysplasias  (ID)  and  squamous  cell 
carcinomas  (SCQ- 
TRAP  assay  illustrating  telomerase  activity  in  a  large  group  of  cultures 
from  normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and 
squanious  cell  carcinomas.  The  gels  show  PCR  products  generated  from 
200ng  of  protein  extracts  after  staining  with  ethidium  bromide.  The 
internal  control  (S-IC)  is  visible  as  a  36bp  band  and  its  intensity  is 
inversely  correlated  to  the  telomerase  activity  in  the  sample.  In  the  upper 
panel,  protein  extract  from  a  positive  control  provided  in  the  assay  kit 
before  and  after  heat  inactivation  were  used  respectively  as  positive  and 
negative  controls.  In  the  lower  panels,  protein  extracts  from  HeLa  and 
W138  were  used  as  positive  and  negative  controls  respectively.  Names  of 
individual  cultures  are  shown  on  the  upper  part  of  each  figure. 
Telomerase  activity  was  consistently  found  barely  detectable  or 
undetectable  in  normal  samples  and  mortal  dysplasias  and  readily 
detectable  in  immortal  dysplasias  and  carcinornas. 
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Fig.  26:  Telomerase  activity  in  cultures  from  normal  oral  mucosa  (N), 
mortal  dysplasias  (MD),  immortal  dysplasias  (ID)  and  squamous  cell 
carcinomas  (SCQ  using  100  ng.  of  protein  extract. 
In  order  to  avoid  overlooking  differences  amongst  samples  that  showed 
high  levels  of  telomerase  activity  (see  previous  experiment),  lower 
amounts  of  protein  extracts  were  analysed  for  all  of  the  cultures.  The  gels 
show  PCR  products  generated  from  100ng  of  protein  extracts  after 
staining  with  ethidium  bromide.  HeLa  and  W138  were  used  as  positive 
and  negative  controls  respectively.  Names  of  individual  cultures  are 
shown  on  the  upper  part  of  each  figure. 
Telornerase  activity  levels  were  found  to  be  undetectable  in  normal 
samples  and  mortal  dysplasias.  In  immortal  dysplasias  and  SCCs 
telomerase  activities  were  considerably  variable,  some  of  them  being 
barely  detectable  with  this  amount  of  extract  and  others  showing  higher 
levels  than  HeLa. 
94 Chapter  10  95 
10.4.2  No  major  changes  are  observed  in  hTERC 
The  levels  of  telomerase  RNA  component  were  analysed  by  Northern  Blotting  in  cultures 
of  biopsies  from  all  different  stages  of  oral  cancer  progression  (fig.  27  A).  No  major 
changes  were  apparent  amongst  all  samples.  In  order  to  compensate  for  slight  differences 
in  total  quantities  of  RNA,  optical  densities  of  the  bands  obtained  for  both  hTERC  and  7S 
loading  control  were  calculated.  The  relative  hTERC  RNA  levels  obtained  after 
normalization  against  7S  RNA  levels  (fig.  27  B)  revealed  only  minor  variations  amongst 
individual  samples  and  no  specific  changes  when  samples  where  grouped  according  to 
stage  of  progression  (fig.  27  Q. 
Although  hTERC  is  a  crucial  component  of  telomerase  holoenzyme  and  its  expression  is 
necessary  for  telomerase  function,  these  data  suggest  that  an  up-regulation  of  hTERC  is  not 
the  explanation  for  the  increase  in  telomerase  activity  in  immortal  dysplasias  and  SCCs. 
10.4.3  hTERTis  highly  upregulated  in  immortal  dysplaslas  and  SCC 
hTERT  mRNA  expression  was  initially  investigated  by  serniquantitative  RT-PCR  since 
our  attempts  to  measure  hTERT  through  northern  blotting  were  repeatedly  unsuccessful, 
due  to  its  extremely  low  levels  even  in  SCCs.  At  the  point  in  the  project  when  this  work 
was  performed,  specific  hTERT  antibodies  were  still  unavailable:  although  hTERT  protein 
expression  had  been  reported  in  one  study  in  situ  (Kolquist  et  al.  1998),  there  was  not 
enough  evidence  on  the  reproducibility  of  this  finding. 
Several  splicing  or  insertion  variants  of  hTERT  mRNA  have  been  described  (Kilian  et  al. 
1997)  some  of  which  act  as  dominant  negatives  (Colgin  et  al.  2000).  In  the  light  of  these 
reports,  the  primer  set  chosen  for  RT-PCR  amplification  of  hTERT  mRNA  does  not 
encompass  any  regions  where  splicing  or  insertion  variants  have  been  described.  The 
levels  of  hTERT  in  normal  oral  mucosa  and  mortal  dysplasias  were  undetectable  or  barely 
detectable  (fig.  28).  A  low  level  of  expression  could  be  detected  in  the  mortal  dysplasia 
D6,  which  was  also  the  mortal  dysplasia  that  showed  a  barely  detectable  telomerase 
activity  (fig.  28  and  25).  In  all  of  the  immortal  dysplasias  and  SCCs  analysed,  hTERT 
mRNA  levels  of  expression  were  considerably  higher  than  those  found  in  mortal  dysplasias 
and  normal  oral  mucosa  (fig.  28). A 
hTEPC 
7S 
B 
E'  F4  FNB6  D30  D25  D6  D34  D38  D19  B,  )6  B6. 
_ 
amb,.  soft  mm  dm  im  am  dm  so  40M  an 
dOW 
C'  I  Normal  k4ortal  Immortal 
--juarnf--o-is.  Mucosa  Dysplasias  Dysplasias  Carcinomas 
2,0, 
14  t5  E 
E 
C3 
0 
Ocill 
u 
&.  -i 
II 
FNB6  D30  D25  D6  jý54  L)38  L).  'j  B56  B68 
C 
t  -ý  It  ;  #2  1,,..  '  i  alp, 
ki 
04 
62- 
N  MD  ID  scc 
F4 
Fig.  27:  Levels  of  telomerase  RNA  component  h,  rERC  in  cultures  of 
normal  oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and 
squamous  cell  carcinomas. 
A)  Northern  Blot  analysing  levels  of  hTERC  in  a  panel  of  samples  from 
normal  oral  inucosa,  mortal  dysplasias,  immortal  dysplasias  and 
squarnous  cell  carcinomas.  Ribosomal  subunit  7S  RNA  was  also 
measured  to  ensure  equal  loading  of  samples.  Names  of  individual 
cultures  are  shown  on  the  upper  part  of  each  figure.  Data  presented  is 
representative  of  2  independent  experiments. 
B)  and  C)  Graphical  comparison  of  the  levels  of  hTERC  as  assessed  by 
Northern  Blot  after  ineasurernent  of  the  optical  densities  of  the  bands  and 
nornialization  against  the  7S  loading  control.  Data  is  presented  for 
individual  samples  in  B)  and  for  groups  in  C). 
No  significant  variation  in  hTERC  levels  was  found  arnongst  all  samples 
even  after  norinalization. 
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Fig.  28:  Expression  of  telomerase  enzyme  component  hTERT  in 
samples  of  normal  oral  mucosa,  mortal  dysplasias,  immortal 
dysplasias  and  squamous  cell  carcinomas. 
The  levels  of  hTERT  were  analysed  by  RT-PCR  in  a  panel  of  samples 
from  normal  oral,  mortal  dysplasias,  immortal  dysplasias  and  squarnous 
cell  carcinomas.  The  gels  show  the  PCR  products  generated  after 
amplification  with  MS113  and  MS114  primers  (see  Materials  and 
Methods)  and  stained  with  ethidiurn  bromide.  GAPDH  rnRNA  levels 
were  also  measured  as  an  internal  control. 
Names  of  individual  cultures  are  shown  on  the  upper  part  of  each  figure. 
Data  presented  is  representative  of  5  independent  experiments 
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This  suggested  a  close  correlation  between  levels  of  hTERT  mRNA  expression  and 
telomerase  activity,  its  only  limitation  being  the  semi-quantitative  method  used.  It 
therefore  appeared  worthwhile  to  confirm  this  data  by  the  more  accurate  Real  Time 
Quantitative  RT-PCR  technique.  An  illustration  of  the  principles  of  this  technique  is 
presented  in  fig.  29. 
A  series  of  preliminary  experiments  were  performed  to  optimise  the  methods  and  ensure 
reproducibility  and  accuracy  of  this  technique,  which  at  that  stage  had  not  been  extensively 
utilised  in  the  Institute.  In  order  to  obtain  equal  amounts  of  cDNA  after  reverse 
transcription  for  all  of  our  samples,  total  RNA  was  quantified  by  optical  densitometry.  To 
aid  quantitation  and  reproducibility,  an  internal  control  RNA  was  also  measured  in  each 
experiment  along  with  quantification  of  our  target  gene  hTERT.  7S  ribosomal  RNA  was 
preferred  to  GAPDH  as  an  internal  control  after  a  preliminary  experiment  showed  a  lower 
variability  of  the  former  amongst  different  RNA  samples.  The  primer  set  chosen  for 
Quantitative  RT-PCR  amplification  of  hTERT  mRNA  anneals  to  a  region  where  no 
splicing  or  insertion  variants  have  been  described.  After  quantification  of  7S  rRNA  and 
hTERT  in  each  sample,  the  relative  amounts  of  hTERT/rRNA  were  finally  calculated. 
Typical  amplification  curves  obtained  for  a  standard  curve,  a  mortal  dysplasia,  an  immortal 
dysplasia  and  a  SCC  are  shown  in  fig.  30  A  and  B. 
The  data  presented  in  fig.  31  shows  the  average  of  the  results  obtained  for  the  entire  panel 
of  dysplasias  in  three  separate  experiments  performed  as  described  above.  In  keeping  with 
the  findings  reported  for  semi-quantitative  RT-PCR,  hTERT  is  highly  upregulated  in 
immortal  dysplasias  and  SCCs  compared  to  mortal  dysplasias  and  normal  oral  mucosa. 
Despite  a  substantial  heterogeneity  amongst  immortal  dysplasias,  levels  of  hTERT  in  the 
lowest  expressing  immortal  dysplasia  (D34)  are  still  10  fold  higher  than  those  of  the  mortal 
dysplasia  expressing  the  highest  levels  of  hTERT  mRNA  (D6).  One  important  observation 
emerging  from  these  results  is  that  the  cultures  with  the  highest  telomerase  activity  are  the 
ones  that  express  the  highest  levels  of  hTERT  mRNA  (see  fig.  26  and  28).  This  suggests 
that  hTERT  overexpression  and  therefore  telomerase  activity  upregulation  occur  at  the 
dysplasia  stage  of  oral  cancer  progression  and  is  related  to  the  acquisition  of  the  immortal 
phenotype. Chapter  10 
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Fig.  29:  Quantitative  Real  Time  PCR. 
In  the  Real  time  quantitative  PCR  a  set  of  primers  and  an  oligonucleotidic 
probe  are  designed  to  anneal  with  the  target  gene.  The  taqnian  probe  is 
covalently  linked  with  a  fluorescent  dye  at  its  5'  end  and  with  a  quencher 
dye  at  its  3'  end.  The  quencher  dye  suppresses  the  fluorescence  of  the 
reporter  until  cleaved  by  the  amplitaq  gold  enzyme,  which  has  a  5'-3' 
nuclease  activity.  Therefore,  the  fluorescence  of  the  reporter  dye 
progressively  increases  during  the  amplification  reaction. 
The  instrument  compares  the  intensity  of  the  fluorescent  signal  at  each 
cycle  to  a  standard  curve.  The  fewer  cycles  it  takes  to  reach  a  detectable 
level  of  fluorescence,  the  greater  the  initial  copy  number  of  the  target 
gene. 
99 1010 
B 
i 
02468  10  12  14  16  119  20  22  24  26  20  30  32  34  36  36  40 
Cycle 
Fig.  30:  Amplification  curves  obtained  for  hTERT  through 
Quantitative  Real  Time  PCR. 
In  most  quantitative  PCR  detection  systems  the  fluorescent  signal 
obtained  dufing  the  first  15  amplification  cycles  is  considered  as  a  passive 
reference  signal.  In  successive  amplification  cycles,  the  instrument  detects 
the  increase  in  signal  associated  with  exponential  growth  of  PCR  product 
and  defines  a  threshold  value.  The  fewer  cycles  it  takes  to  reach  the 
threshold  value,  the  greater  the  initial  copy  number  of  the  target  gene. 
A)  Example  of  an  amplification  reaction  carried  out  to  obtain  a  standard 
curve.  Four  samples  of  known  template  amount  (I  pg,  I  00fg,  I  Ofg,  I  fg  of 
hTERT  insert)  were  amplified  in  triplicate,  each  generating  overlapping 
curves.  B)  Example  of  an  amplification  reaction  of  three  different  samples 
containing  an  unknown  quantity  of  hTERT,  each  analysed  in  triplicate. 
The  three  curves  correspond  to  one  immortal  dysplasia  (D19),  one 
carcinoma  (1368)  and  one  mortal  dysplasia  (D30).  The  values  obtained 
from  this  quantification  are  interpolated  within  those  obtained  for  the 
corresponding  standard  curve. 
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Fig.  31:  Levels  of  hTERT  in  samples  of  normal  oral  mucosa  (N), 
mortal  dysplasias  (MD),  immortal  dysplasias  (ID)  and  squamous  cell 
carcinomas  (SCC)  measured  through  Real  Time  quantitative  PCR. 
Summary  illustrating  the  levels  of  hTERT  niRNA  in  samples  of  normal 
oral  mucosa,  mortal  dysplasias,  immortal  dysplasias  and  squallious  cell 
carcinomas.  The  relative  amounts  of  hTERT  are  expressed  after 
normalization  for  7S  ribosomal  RNA  measured  independently  in  each 
sample.  Hela  and  W138  were  used  as  positive  and  negative  controls 
respectively.  Standard  deviations  are  also  shown. 
Names  of  individual  cultures  are  shown  on  the  lower  part  of  each  figure. 
Data  presented  is  the  average  of  3  independent  expefiments  for  each 
panel. 
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10.5  Chapter  Summary 
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eA  unique  series  of  primary  cultures  from  normal  oral  mucosa,  mortal  dysplasias, 
immortal  dysplasias  and  squamous  cell  carcinomas  was  used  to  analyse  several 
molecular  markers  involved  in  oral  cancer  progression. 
e  No  consistent  variations  were  found  in  expression  of  cell  cycle  regulators  Polo  like 
Kinase  and  Cyclin  Dl. 
*  Four  molecular  changes  are  related  to  the  acquisition  of  the  immortal  phenotype  in 
oral  dysplasias:  loss  of  RARP  and  p16  expression,  p53  mutations  and  activation  of 
telomerase. 
e  Telomerase  activation  is  associated  with  upregulation  of  hTERT  mRNA  expression 
rather  than  hTERC  levels. 
9  Epidermal  Growth  Factor  Receptor  subunit  EGF-R  overexpression  occurs  at  the 
squamous  cell  carcinoma  stage  of  oral  cancer  progression.  No  significant  changes 
were  found  in  Epidermal  Growth  Factor  Receptor  subunit  c-erbB2. 103 
11  Functional  interventional  studies  of 
keratinocyte  immortalisation 
As  described  in  chapter  10,  our  observational  studies  had  thus  far  identified  four  molecular 
changes  associated  with  the  acquisition  of  the  immortal  phenotype  in  oral  dysplasias:  loss 
of  RARP  and  p16  expression,  mutation  of  p53  and  activation  of  telomerase.  This  scientific 
evidence  was  informative,  but  did  not  allow  to  determine  what  molecular  events  are 
required  for  immortalisation  and  what  others  are  consequential  to  it.  In  addition,  the 
literature  provides  contrasting  evidence  on  this  topic,  some  authors  reporting  that 
telomerase  activation  is  sufficient  to  immortalise  normal  epithelial  cells  (Bodnar  et  al. 
1998)  (Ramirez  et  al.  2001)  and  others  reporting  that  loss  of  p16  is  required  in  addition  to 
telomerase  activation  in  order  to  immortalise  epithelial  cells  (Kiyono  et  al.  1998)  (Dickson 
et  al.  2000)  (Romanov  et  al.  2001).  This  section  of  our  work  was  aimed  at  addressing  these 
issues  in  oral  neoplastic  keratinocytes. 
11.1  Features  of  our  mortal  clysplasias 
The  vast  majority  of  our  mortal  dysplasias  (7/8)  proliferated  for  5-30  population  doublings 
and  then  reached  a  growth  arrest  status  due  to  senescence  (see  chapter  9).  They  showed 
none  of  the  molecular  changes  associated  with  immortality:  they  expressed  RARP  and  p16, 
had  wild  type  p53  and  no  telomerase  activity. 
The  remaining  mortal  culture,  D17,  showed  cellular  and  molecular  features  that  could  be 
considered  intermediate  between  the  mortal  and  the  immortal  phenotype.  It  proliferated  for 
a  considerably  extended  life  span  (45  PD)  but  still  eventually  reached  growth  arrest  due  to 
senescence.  In  addition,  it  had  lost  expression  of  RARP  and  p16,  like  immortal  cultures, 
but  had  no  telomerase  activity  and  retained  wild  type  p53,  like  mortal  cultures.  The  loss  of 
RARP  and  p16  in  D17  is  not  to  be  considered  a  cultural  artefact,  as  loss  of  expression  of 
these  two  molecular  markers  has  been  shown  in  vivo  in  the  biopsy  from  which  D17  was 
derived  (K  Hunter,  personal  communication).  D17  was  therefore  an  example  of  a  naturally 
occurring  dysplasia  that  had  acquired  per  se  two  of  the  four  molecular  features  associated 
with  the  immortal  phenotype  but  still  remained  mortal,  suggesting  that  loss  of  p16/RARP 
is  not  sufficient  for  keratinocyte  immortalisation. 
Our  series  of  typical  mortal  cultures  and  our  intermediate  phenotype  culture  D17  provided 
a  useful  model  to  test  whether  telomerase  activation  was  sufficient  to  confer  cellular Chapter  11  104 
immortality  or  it  needed  to  occur  in  combination  with  other  molecular  changes,  like  p53 
mutation,  loss  of  expression  of  p16  and/or  RARP. 
11.2  Ectopic  expression  of  hTERT  in  two  typical  mortal  cultures 
and  in  D17 
To  test  this  hypothesis,  amphotrophic  retroviral  vectors  transducing  either  the  hTERT  gene 
(pBabeEST)  or  the  Neomycin  resistance  gene  (pBabeNeo)  were  used  to  infect  D17  along 
with  the  typical  mortal  dysplasia  D30.  In  parallel,  Janis  Fleming  in  the  group  has 
performed  the  same  experiments  on  another  typical  mortal  dysplasia,  D25. 
The  retroviral  vectors  were  produced  by  infecting  the  packaging  cell  line  Phoenix  A  with 
pBabeNeo  (neomycin  resistance  gene)  or  pBabeEst  (hTERT)  constructs,  selecting  with 
G418  and  titrating  the  virus  production  so  that  equal  amounts  of  infectious  units  could  be 
used  to  infect  different  cultures.  A  series  of  preliminary  experiments  were  carried  out  to 
establish  the  minimum  concentration  of  Neomycin  (G418)  that  was  able  to  kill  the 
uninfected  D30,  D25  and  D17  cultures.  This  concentration  (200  [tg/ml)  was  later  used  to 
select  the  infected  cultures  and  to  maintain  retroviral  expression.  After  infection,  the  G418- 
resistant  colonies  (typically  50-70)  were  pooled  and  used  for  all  of  the  subsequent 
experiments  to  avoid  variations  due  to  clonal  heterogeneity  of  the  population.  The  number 
of  G418-resistant  colonies  obtained  after  infection  with  the  hTERT  construct  was  similar 
to  that  obtained  with  the  empty  vector. 
The  typical  mortal  dysplasia  culture  D30  had  an  expected  life  span  of  30  population 
doublings  and  was  infected  at  8.5,9,17  and  18  population  doublings  in  four  separate 
experiments.  D25  had  an  expected  life  span  of  25  population  doublings  and  was  infected  at 
7,9  and  18  population  doublings  in  three  separate  experiments.  The  atypical  mortal 
dysplasia  culture  D17  had  an  expected  life  span  of  45  population  doublings  and  was 
infected  after  having  reached  34.5  and  39  population  doublings  in  two  separate 
experiments.  In  each  experiment,  8  plates  of  cells  were  seeded  at  a  concentration  of  5x105 
cells  and  treated  as  follows:  two  were  infected  with  the  hTERT  vector,  two  were  infected 
with  the  NEO  vector,  two  were  used  as  uninfected  controls  and  two  were  left  uninfected 
but  treated  with  the  same  concentration  of  G418  used  to  select  the  infected  plates,  to 
confirm  that  no  non-infected  clones  survived  selection. Chapter  11  105 
11.2.1  Assessing  the  functionality  of  hTERT  vector 
In  order  to  assess  whether  infection  with  the  hTERT  vector  resulted  in  activation  of 
telomerase,  protein  extracts  were  obtained  from  each  culture  and  checked  for  telomerase 
activity  as  soon  as  a  sufficient  number  of  cells  were  available.  As  shown  in  figures  32  and 
33,  no  telomerase  activity  could  be  detected  in  D17  and  D30  uninfected  cultures  and  NEO 
infectants.  Enzyme  activity  was  readily  detectable  in  the  hTERT  infectants,  testifying  for 
telomerase  activation  upon  hTERT  transduction. 
A  point  that  remained  to  be  clarified  was  whether  or  not  telomerase  activation  had  any 
effect  on  telomere  maintainance  or  elongation.  To  address  this  question,  genomic  DNA 
was  extracted  from  the  uninfected  D17  and  D30  cultures  at  different  stages  of  their  life 
span,  comprising  senescence,  from  the  NEO  infectants  when  they  had  reached  growth 
arrest  and  from  the  EST  infectants.  TRIF  lengths  were  measured  for  all  samples  through 
Southern  Blotting  (fig.  34  and  35).  In  both  cases,  telomeres  underwent  progressive 
shortening  with  continuous  passage  in  culture,  and  were  significantly  and  progressively 
elongated  in  the  hTERT  infectants  but  not  in  the  "mock"  infectants. 
It  is  evident  from  these  results  that  infection  with  the  hTERT  vector  but  not  with  the 
"empty"  vector  is  effective  in  maintaining/elongating  the  telomeres  as  well  as  activating 
telomerase. 
11.22  Monitoring  for  proliferative  fate  of  the  cultures 
The  uninfected  controls  and  infected  cultures  for  D30,  D25  and  D17  were  subsequently 
monitored  for  life  span  by  successive  passaging  in  culture  plates. 
With  both  D30  and  D25  dysplasias,  no  difference  in  growth  rate  or  proliferative  fate  was 
observed  amongst  the  uninfected  cultures,  the  cultures  infected  with  the  empty  vector  and 
those  transduced  with  hTERT.  The  uninfected  and  infected  cultures  of  both  dysplasias 
showed  a  very  slow  proliferation  rate  from  as  early  as  discreet  colonies  were  visible.  They 
were  maintained  in  culture  for  three  weeks,  during  which  time  the  colonies  failed  to  reach 
confluence,  suggesting  that  growth  arrest  status  had  been  reached.  Fig  36  shows  a 
representative  example  of  SABG  positive  staining  in  uninfected  and  hTERT  transduced 
D30  colonies  after  cessation  of  proliferative  growth.  BRDU  incorporation  assay  could  not 
be  carried  out  because  of  the  limited  amount  of  material  available. Chapter  11 
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Fig.  32:  Telomerase  activity  in  D-jo  cultures  before  and  after  infection 
with  WFERT  expression  vector. 
TRAPeze  assay  was  performed  on  400ng  of  protein  extract.  The  gels 
show  the  PCR  products  generated  after  staining  with  ethidiurn  bromide. 
Protein  extracts  were  obtained  from  the  uninfected  control  at  18  PD,  from 
the  empty  vector  infectant,  transduced  with  the  neoinicin  resistance  gene 
alone  (NEO)  at  24  PD  and  from  the  hTERT  infectant  (EST)  at  24  PD. 
W138  cells  were  included  as  negative  control,  HeLa  cells  and  D17  EST 
infectants  were  included  as  positive  controls. 
Telotyierase  activity  is  readily  detectable  in  the  hTERT  infectant  and 
undetectable  in  the  uninfected  control  and  in  the  mock  infectant. 
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Fig.  33:  Telomerase  activity  in  D17  cultures  before  and  after  infection 
with  h,  rER,  r  expression  vector. 
TRAPeze  assay  was  performed  on  200ng  of  protein  extract.  The  gels 
show  the  PCR  products  generated  after  staining  with  ethidium  bromide. 
Protein  extracts  were  obtained  from  the  uninfected  control  at  different 
stages  of  its  life  span  (the  number  of  population  doublings  is  indicated  for 
each  sample),  from  the  empty  vector  infectant  transduced  with  the 
neomicin  resistance  gene  alone  (Neo)  at  54  population  doublings  and 
from  the  hTERT  infectant  (EST)  at  55  population  doublings.  W138  and 
HeLa  cells  were  included  as  telomerase  negative  and  positive  controls 
respectively. 
Telomerase  activity  is  readily  detectable  in  the  hTERT  infectant  and 
undetectable  in  all  of  the  uninfected  controls  and  in  the  mock  infectant. 
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Fig.  34:  Telomere  length  in  D30  cultures  before  and  after  infection 
with  hTERT  expression  vector. 
Southern  blot  illustrating  TRF  length  measurements  in  D30.  Genoniic 
DNA  samples  were  obtained  from  D30  cultures  at  different  stages  of  their 
life  span  (the  number  of  population  doublings  is  indicated  for  each 
sample),  after  infection  with  the  empty  vector  (NEO)  and  with  the  hTERT 
transducing  vector  (EST).  I  Kb  DNA  fragments  and  X/Hindlll  were  used 
as  reference  molecular  weight  inarkers. 
As  shown  in  the  figure,  telomeres  underwent  a  progressive  shortening 
with  increasing  age  in  culture,  but  were  considerably  elongated  after 
hTERT  ectopic  activation. 
The  ratio  of  telomeric  TTAGGG  repeats  versus  total  nuclear  DNA  is 
lower  in  cells  with  short  telomeres  than  in  cells  with  long  telonleres. 
Therefore,  the  measurement  of  teloinere  length  in  different  samples  using 
equal  amounts  of  total  nuclear  DNA  results  in  lower  intensity  of  signals 
for  cells  with  shorter  telomeres.  This,  along  with  a  limited  sample 
availability,  might  explain  the  weaker  signal  observed  in  the  senescing 
D30  NEO  infectant. 
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Fig.  35:  Telomere  length  in  D17  cultures  before  and  after  infection 
with  hTERT  expression  vector. 
Southern  blot  illustrating  TRF  length  ineasurements  in  DIT  Genomic 
DNA  samples  were  obtained  from  D17  cultures  at  different  stages  of  their 
life  span  towards  senescence  (the  number  of  population  doubling  is 
indicated  for  each  sample),  after  infection  with  the  empty  vector  (NEO) 
and  with  the  hTERT  transducing  vector  (EST).  I  Kb  and  ýJl-lind  III  DNA 
fragments  were  used  as  reference  molecular  weight  markers. 
As  shown  in  the  figure,  telomeres  underwent  a  progressive  shortening  as 
cultures  approached  senescence,  but  were  considerably  elongated  after 
hTERT  ectopic  expression.  The  weaker  signal  observed  in  the  D  17 
uninfected  control  and  NEO  infectant  is  due  to  the  senescent  status  of  the 
cultures. 
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Fig.  36:  SABG  staining  in  D30  uninfected  control  and  EST  int'vdant. 
Cells,  were  maintained  in  Culture  for  a  1111111mum  of  three  weeks  after  theý 
appeared  to  be  stationary  to  confirm  cessation  of  proliferative  growth. 
Subsequently,  they  were  fixed,  stained  and  photographed  with  a  IOX 
magnifying  lens. 
The  positive  SABG  staining  confirms  the  growth  arrest  status  reached  by 
both  the  Uninfected  control  and  the  EST  infectant. 
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With  D17,  no  substantial  difference  was  observed  between  the  growth  rates  of  uninfected 
D17  and  Neo  infectants.  However,  the  cells  infected  with  the  hTERT  vector  kept 
proliferating  beyond  120  PD,  at  which  point  the  cells  were  considered  immortal.  As 
expected,  the  uninfected  D17  reached  growth  arrest  after  45  PD.  The  NEO  infectant 
stopped  growing  but  having  completed  56  PD  in  culture.  One  possible  explanation  for  the 
difference  between  the  number  of  population  doublings  completed  at  growth  arrest  by  the 
D17  uninfected  culture  and  the  NEO  infectant  could  come  from  the  method  used  for 
counting  the  number  of  PD  in  infected  cultures.  G418  resistant  colonies  started  emerging 
from  selection  and  were  counted  as  soon  as  visible  under  light  microscopy.  The 
assumption  was  made  that  each  colony  was  derived  from  expansion  of  a  single  resistant 
cell.  The  number  of  resistant  cells  so  obtained  was  then  utilised  for  estimating  the 
population  doublings  completed  in  culture  when  cells  were  subsequently  harvested  and 
counted.  This  method  involves  some  approximations,  not  taking  into  account  1)  those 
resistant  cells  that  are  not  visible  upon  observation  under  the  light  microscope  and  2)  the 
possibility  that  one  single  colony  could  derive  from  more  than  one  resistant  cell.  Both 
these  factors  could  lead  to  the  overestimation  of  cellular  proliferation. 
When  the  uninfected  D17  and  the  NEO  infectants  entered  a  slow  growth  phase,  they  were 
maintained  in  culture  for  a  minimum  of  three  weeks  to  confirm  proliferative  growth  had 
ceased.  At*that  stage,  hTERT  infectants  had  reached  85  PD.  Plates  from  all  three  cultures 
were  assayed  for  SABG  staining,  BRDU  incorporation  and  TUNEL  assay  to  better  define 
if  the  terminal  growth  arrest  reached  by  the  controls  and  the  mock  infectants  was  due  to 
senescence  or  crisis,  as  discussed  in  chapter  9.3  (fig.  37).  Both  these  cultures  stained 
positive  for  SABG,  had  a  low  BRDU  incorporation  index  (-  20%)  and  showed  virtually  no 
apoptosis  as  assessed  by  TUNEL  assay,  suggesting  they  had  arrested  in  senescence  rather 
than  in  crisis.  The  hTERT  infectants  stained  negative  for  SABG,  had  a  high  BRDU 
incorporation  index  (84%)  and  showed  no  apoptosis,  as  expected  from  rapidly  proliferating 
cells,  indicating  that  these  cells  had  bypassed  the  replicative  senescence  checkpoint. Chapter  11 
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Fig.  37:  SABG  staining,  BRDU  incorporation  and  TUNEL  assay  in 
D17  before  and  after  infection  with  the  hTERTexpression  vector. 
Tile  alin  of  this  experiment  was  to  Linderstand  If  proliterative  senescence 
in  D17  Lininfected  control  and  NEO  infectants  could  be  overcome  bý 
infection  with  hTERT. 
SABG  staining  (A),  BRDLJ  incorporation  (B)  and  TUNEL  assay  (C)  were 
performed  on  D  17  Uninfected  controls,  NEO  and  hTERT  infectants.  When 
this  experiment  was  carried  out,  D17  Lininfected  control,,  -,  and  NEO 
infectants  had  been  stationary  in  culture  for  three  weeks. 
A)  D17  Lininfected  controls  and  NEO  infectants  stain  positive  for  SABG 
staining,  whereas  liTERT  infectants  stained  negative. 
B)  The  percentage  of  cells  scoring  positive  for  BRDLJ  incorporation  wzIs 
assessed  on  a  minimurn  of  500  cells:  21  11c  Of  Uninfected  controls,  2211c  ot 
Neo  infectants  and  84"Ic  of  hTERT  infectants. 
C)  VINLIZIlly  110  ZIPOPtOtiC  Cells  M-e  visible  in  either  D17  Lininfected 
controls,  NEO  infectants  or  hTERT  infectants. 
These  combined  results  suggest  that  when  the  three  assays  were  carried 
OLIt  D17  uninfected  controls  and  Neo  infectants  11ZILI  reached  senescence, 
whereas  hTERT  infectants  have  bypassed  this  momility  checkpoint  and 
were  actively  proliferating. 
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11.23  Investigating  p53  status  and  phosphorylation  at  serine  15  In  D17 
In  our  previous  work  we  have  shown  that  p53  mutations  are  often  associated  with  the 
acquisition  of  immortality  in  naturally  occurring  oral  dysplasias.  It  still  remained  unclear  if 
in  a  scenario  like  the  one  just  described,  where  immortality  is  acquired  after  ectopic 
expression  of  hTERT,  a  selective  pressure  exists  towards  inactivation  of  p53.  Therefore, 
genomic  DNA  samples  were  obtained  from  hTERT  infectants  after  they  had  completed  86 
PD  in  culture  and  the  whole  p53  coding  region  was  sequenced.  No  mutations  were  found, 
indicating  that  mutation  of  p53  gene  is  not  an  obligatory  requirement  for  the  acquisition  of 
immortality  when  telomerase  is  activated  exogenously. 
Wild  type  p53  has  been  reported  to  downregulate  hTERT  mRNA  expression  in  carcinoma 
cells,  but  this  could  not  be  observed  with  mutant  p53  (Xu  et  al.  2000).  Therefore,  mutation 
of  p53  could  be  necessary  to  allow  telomerase  activation  and  immortalisation  in  a  naturally 
occurring  context,  but  not  when  hTERT  is  ectopically  expressed.  Another  possible 
explanation  is  that  the  elongation  of  critically  short  telomeres  as  obtained  through 
exogenous  telomerase  activation  abolishes  the  stimulus  leading  to  p53  mediated  growth 
arrest  and  therefore  the  necessity  to  mutate  p53  in  order  for  cellular  proliferation  to 
continue. 
It  was  recently  shown  that  p53  response  to  the  DNA  damage-like  signal  generated  by 
telomere  erosion  acts  through  phosphorylation  of  its  serine-residue  15  in  human  fibroblasts 
(Webley  et  al.  2000).  Therefore,  it  seemed  worthwhile  to  investigate  p53  expression  and 
serine-residue  15  phosphorylation  in  D17  during  its  normal  aging  process  and  after 
immortalisation  (and  telomere  elongation)  with  hTERT. 
D17  was  serially  passaged  in  culture  and  analysed  at  different  stages  of  its  life-span 
comprising  senescence.  At  each  time  point  chosen  for  this  experiments  the  cellular  biology 
features  of  D17  were  assessed  through  SABG  staining  and  BRDU  incorporation  assay  (fig. 
38).  As  shown  in  the  figure,  the  combined  outcome  of  these  two  assays  indicates  that  D17 
is  actively  proliferating  at  12.5,22  and  32.5  PD  and  has  reached  senescence  at  45  PD. 
Protein  samples  were  extracted  from  plates  grown  in  parallel  with  the  ones  utilised  for  the 
stainings  and  analysed  through  Western  Blotting  (fig.  39). Chapter  11 
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Fig.  38:  SABG  staining  and  BRDU  incorporation  in  D17  at  different 
culture  ages. 
D17  was  grown  in  CLIlture  and  harvested  at  different  stages  of  its  life  span. 
SABG  staining  (left  panels)  and  BRDU  incorporation  (right  panels)  were 
performed  at  the  same  time  as  the  collection  of  samples  to  assess 
variations  in  p53  expression  and  p53-serineI5  phosphorylation  with 
increasing  age  in  culture. 
For  each  sample,  the  nUmber  of  population  (IOLiblings  completed  III  CLIKII-e 
and  tile  percentage  of  cells  scoring,  positive  for  BRDU  incorporation  are 
indicated  oil  the  left  and  right  part  of  tile  figure  respectively. 
Taken  together,  these  results  confirin  that  D17  is actively  proliferating  at 
12.5,23  and  32.5  PD  and  has  reached  senescence  at  45  PD. 
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Fig.  39:  p53  and  p53  phosphorylation  at  serine15  in  D17. 
Western  blots  illustrating  the  expression  of  total  p53  protein  and  p53 
phosphorilation  at  serine  residue  15  (detected  through  a  phospho  specific 
antibody)  in  D  17  at  different  culture  ages  and  after  infection  with  hTERT 
expression  vector.  ERK  1,2  were  also  measured  to  ensure  equal  loading  of 
samples. 
As  illustrated  in  the  upper  panel,  the  expression  of  total  p53  protein  is 
fairly  uniform  at  all  the  different  culture  ages  analysed. 
In  the  lower  panel,  p53  phosphorylation  at  serine  residue  15  increases  as 
cultures  approach  senescence,  and  decreases  after  infection  with  hTERT 
expression  vector.  This  trend  closely  mirrors  that  of  telomere  length, 
suggesting  a  telomere  shortening  dependent  mechanism  of  p53  activation 
through  phosphorilation  at  serine  residue  15. 
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As  shown  in  the  figure,  p53  protein  expression  is fairly  homogeneous  amongst  all  samples 
analysed.  In  contrast,  p53  phosphorylation  at  serine  residue  15  increases  as  cells  approach 
senescence,  but  this  stimulus  seems  to  be  abrogated  upon  telomere  elongation  following 
infection  with  hTERT.  This  result  suggests  that  in  human  keratinocytes,  as  well  as  human 
fibroblasts,  signalling  through  phosphorylation  of  serine  15  residue  of  p53  is  triggered  in 
response  to  the  critical  shortening  of  telomeres  occurring  during  senescence. 
Overall,  these  results  suggest  that  telomerase  activation  through  ectopic  expression  of 
hTERT  and  telomere  maintainance/elongation  are  not  sufficient  per  se  to  immortalise 
naturally  occurring  mortal  dysplasias.  In  order  for  cells  to  acquire  unlimited  proliferative 
potential  in  culture,  other  molecular  changes  like  loss  of  RARP  and/or  p16  are  necessary. 
11.3  Chapter  summary 
*  In  our  series  of  primary  cultures  from  oral  dysplasias,  four  molecular  changes  were 
consistently  associated  with  the  immortal  phenotype:  loss  of  expression  of  RARP 
and  p16,  mutation  of  p53  and  activation  of  telomerase. 
9  One  atypical  dysplasia  (D17)  senesced  after  a  considerably  extended  life  span  (45 
PD)  and  had  molecular  features  that  were  intermediate  between  mortal  and 
immortal  phenotype:  loss  of  expression  of  RARP  and  p16,  wild  type  p53  and  no 
telomerase  activity. 
0  D17  was  immortalised  by  retroviral  transduction  of  hTERT.  This  was  associated 
with  activation  of  telornerase  and  elongation  of  telorneres. 
Immortal  hTERT  transduced  D17  clones  retained  wild-type  p53,  suggesting  that 
p53  mutations  are  not  an  absolute  requirement  for  cellular  immortalisation  when 
telomerase  is  activated  exogenously. 
*  Immortalisation  of  D17  was  associated  with  abrogation  of  the  increase  in  levels  of 
p53  phosphorylation  at  serine  residue  15,  that  otherwise  occurs  during  dysplasia 
senescence. 
e  Two  typical  mortal  dysplasias  (D30  and  D25)  that  express  RARP  and  p16  were  not 
immortalised  by  retroviral  transduction  of  hTERT,  despite  activation  of  telornerase 
and  elongation  of  telorneres. 117 
12  General  discussion 
12.1  Features  of  the  growth  arrest  status  observed  in  our  mortal 
dysplasia  cultures 
In  recent  years,  considerable  progress  has  been  made  in  defining  the  cellular  and  molecular 
features  of  replicative  senescence  in  different  types  of  cells.  As  already  described  in  the 
introduction  section,  human  keratinocytes  are  known  to  reach  a  first  mortality  checkpoint, 
called  M1  or  senescence,  characterised  by  positivity  for  SABG  staining,  a  low  proliferation 
index  as  assessed  by  BRDU  incorporation  index,  and  low  apoptosis  index  as  assessed  by 
the  TUNEL  assay.  This  growth  arrest  status  is  associated  with  overexpression  of  p16, 
although  it  is  not  yet  clear  if  this  tumour  suppressor  protein  plays  a  role  in  initiating  the 
senescence  programme,  or  whether  its  overexpression  is  a  consequence  of  sub-optimal 
culture  conditions.  During  the  onset  of  keratinocyte  senescence,  telomere  shortening 
causes  an  activation  of  p53  through  phosphorylation  of  its  serine  residue  15.  This  causes  a 
G1  growth  arrest  mediated  by  p2l.  A  recent  report  suggests  that  p53  also  participates  in 
M1  through  a  telomere  length-independent  mechanism,  associated  with  increased  levels  of 
p14"F  expression  (Rheinwald  et  al.  2002).  If  senescence  is  bypassed,  keratinocytes 
encounter  a  second  mortality  check-point  (M2)  called  crisis,  still  characterised  by 
positivity  for  SA-P-gal  staining,  but  showing  a  high  index  of  cellular  proliferation  and 
apoptosis  by  BRDU  and  TUNEL  assays,  respectively.  Crisis  is  thought  to  be  governed  by 
critical  telomere  shortening  causing  a  high  degree  of  genetic  instability,  which  can  be 
overcome  by  activation  of  telomerase. 
Our  in  vitro  model  of  oral  premalignant  lesions  has  proved  very  useful  in  further  defining 
the  molecular  changes  associated  with  these  two  different  mortality  check-points. 
Surnmarising  data  from  previous  work  in  the  group  and  that  described  in  this  thesis,  all  of 
our  8  mortal  dysplasia  cultures  are  invariably  telomerase  negative.  The  majority  of  these 
dysplasias  (7/8)  expressed  RARP,  p16,  and  wild  type  (WT)  p53  and  reached  senescence 
after  5-30  population  doublings.  The  remaining  mortal  dysplasia,  D17,  had  lost  expression 
of  p16  and  RARP  but  retained  WT  p53,  and  still  senesced,  although  after  an  extended  life 
span  (45PD).  In  addition  to  this,  Ken  Parkinson's  group  in  the  Institute  has  described  a 
mortal  carcinoma  culture  (BICR  7)  which  is  telomerase  negative,  has  lost  expression  of 
p16  and  has  mutated  p53  (no  data  is  available  on  RARP  expression).  Interestingly,  this 
culture  reached  growth  arrest  in  a  crisis-like  state.  On  purely  observational  grounds,  these 
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premalignant/malignant  lesions  is  still  associated  with  a  senescence  like  growth  arrest 
status,  whereas  features  of  crisis  are  observed  when  p53  mutation  occurs  together  with  loss 
of  p16.  This  is  in  keeping  with  the  interventional  studies  recently  published  by  Rheinwald 
and  collaborators  (Rheinwald  et  al.  2002),  suggesting  that  both  p16  and  p53  functions  have 
to  be  disrupted  to  evade  M1  growth  arrest  in  normal  keratinocytes. 
12.2  Molecular  changes  associated  with  immortality 
Senescence  control  is  widely  regarded  as  a  tumour  suppressor  mechanism.  This  process 
breaks  down  during  turnourigenesis,  yielding  cells  that  have  acquired  an  unlimited 
proliferative  potential.  Our  analysis  has  revealed  that  this  event  occurs  at  early  stages  of 
oral  cancer  progression,  since  7/15  of  our  dysplasias  are  immortal  in  culture.  Four 
molecular  changes  are  consistently  found  in  association  with  the  immortal  phenotype:  loss 
of  expression  of  RARP  and  p16,  mutation  of  p53  and  activation  of  telomcrase.  Only  one 
immortal  dysplasia  (D38)  represents  an  exception  to  this  general  rule,  and  will  be 
discussed  separately. 
1ZZ  1  The  role  of  RARP  in  cellular  immortality  and  cancer 
The  initial  suggestion  that  retinoids  might  prevent  the  development  of  cancer  came  from 
the  observation  that  prolonged  vitamin  A  deprivation  in  humans  predisposes  to  epithelial 
cancers.  Direct  evidence  for  the  specific  involvement  of  RARP  in  prevention  of  malignant 
transformation  was  obtained  through  an  interventional  study.  Transgenic  mice  expressing 
an  antisense  RARP2  transgene  were  generated,  and  reported  to  be  more  prone  to 
developing  lung  turnours  than  the  non-transgenic  mice  (Berard  et  al.  1996).  Nevertheless, 
the  specific  pathways  linking  retinoids  and  their  receptors  to  cancer  formation  remain 
unclear. 
Retinoids  are  known  to  inhibit  aberrant  squamous  differentiation  in  HNSCC  keratinocytes 
in  vitro,  and  strong  evidence  points  out  RARP  as  the  mediator  of  this  effect.  In  fact, 
transfection  of  RARP2  in  a  human  RARP  negative  HNSCC  cell  line  restored  its  sensitivity 
to  the  downregulation  of  squamous  differentiation  markers  induced  by  RA  treatment  (Wan 
et  al.  1999).  Although  abnormal  differentiation  is  a  common  feature  of  malignant  lesions 
arising  in  the  oral  cavity  mucosa,  the  link  between  the  effects  of  retinoids  in  suppressing 
squarnous  differentiation  and  preventing  carcinogenesis  has  not  yet  been  elucidated.  It  is 
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differentiation  markers  that  are  peculiar  to  oral  epithelial  cells,  like  keratin  19  in  the  basal 
layer  or  keratin  4  and  13  in  the  suprabasal  layers.  Although  some  reports  suggest  a 
correlation  between  RARP  and  keratin  19  expression  in  normal  oral  keratinocytes,  the 
same  is  not  true  for  SCC  from  the  oral  cavity,  where  keratin  19  expression  was  detected 
even  in  cell  lines  that  have  lost  expression  of  RARP  (Crowe  et  al.  1991)  (Hu  et  al.  1991). 
Keratin  4  and  13  expression  is  found  in  the  suprabasal  layer,  which  is  composed  of  cells 
that  have  already  committed  to  differentiate  (Fuchs  1990),  so  they  could  be  reasonable 
candidates  as  downstream  targets  of  RARP.  This  potential  avenue  has  not  been 
investigated  as  yet. 
The  effects  of  retinoids  on  cellular  growth  are  even  more  complicated.  In  HNSCC,  they 
inhibit  cellular  proliferation  in  vitro,  but  this  effect  is  not  necessarily  mediated  by  RARP. 
In  fact,  ectopic  expression  of  RARP2  in  HNSCC  cells  lacking  endogenous  expression  does 
not  significantly  affect  their  growth  rate  in  response  to  retinoid  treatment  (Wan  et  al. 
1999).  Our  studies  are  novel  in  relating  expression  of  RARP  to  the  proliferative  potential 
of  premalignant  and  malignant  lesions  from  the  oral  cavity.  In  our  in  vitro  model,  cultures 
from  normal  oral  mucosa  express  higher  levels  of  RARP  when  they  are  exhausting  their 
proliferative  potential,  independently  of  retinoic  acid  treatment.  Mortal  dysplasias  express 
RARP  even  at  early  passages  in  culture,  like  senescent  normal  cells.  We  have  speculated 
that  RARP  expression  could  be  required  to  mediate  growth  arrest  in  normal  oral 
keratinocytes,  but  in  the  context  of  dysplastic  lesions  it  might  be  no  longer  sufficient  to 
exert  this  effect.  This  change  in  the  regulation  of  RARP  expression  is  not  due  to  expression 
of  different  RARP  isoforms,  as  both  normal  oral  mucosa  and  mortal  dysplasias 
predominantly  expressed  the  RARP2  isoform  (Judith  Brown  and  Paul  Harrison,  personal 
communication).  In  keeping  with  this  hypothesis,  we  have  demonstrated  a  striking 
association  between  loss  of  RARP  and  cellular  immortality:  this  molecular  event  had 
occurred  in  our  immortal  dysplasias  with  no  exceptions.  Loss  of  RARP  has  been  reported 
in  vivo  both  in  oral  dysplasias  (44%  of  cases)  and  in  oral  carcinomas  (65%  of  cases). 
Therefore,  our  finding  is  unlikely  to  be  a  culture  artefact.  Our  work  provides  evidence 
suggesting  that  RARP  might  be  involved  in  regulating  the  mortal  to  immortal  transition. 
Functional  experiments  are  required  to  determine  if  loss  RARP  is  causal  or  merely 
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1ZZ2  Involvement  of  p16  and  p14ARFIn  Immortality  and  cancer 
The  INK4a  locus  codifies  for  two  distinct  proteins  both  involved  in  regulation  of  cellular 
replicative  senescence  and  turnour  suppression:  p16  and  p14  ARF.  As  a  turnour  suppressor 
protein,  p16  is  often  lost  or  inactivated  in  several  different  types  of  turnours  and  in  HNSCC 
(Cairns  et  al.  1995)  (Califano  et  al.  1996)  (Reed  et  al.  1996).  Evidence  for  its  direct 
involvement  in  carcinogenesis  is  provided  by  an  animal  model:  mice  engineered  to  bear  a 
germline  homozygous  deletion  of  the  INK4a  locus  are  known  to  develop  turnours  with  a 
higher  frequency  than  their  normal  counterparts  (Serrano  et  al.  1996).  The  functional 
relevance  of  p16  expression  in  regulating  cellular  growth  has  also  been  assessed  in  vitro. 
Transfection  of  a  p16'NK4  cDNA  into  several  carcinoma  cell  lines  resulted  in  growth 
inhibition,  and  a  strong  selection  pressure  develops  against  the  p16  expressing  transfectants 
with  continuous  passage  in  culture  (Okamoto  et  al.  1994). 
In  previous  chapters  of  this  thesis  I  have  discussed  the  role  of  p16  in  regulating  growth 
arrest  at  M1  (replicative  senescence)  and  the  possibility  that  p16  overexpression  might  be 
due  to  inadequate  culture  conditions  (see  chapter  7.2).  In  our  cultures  from  normal  oral 
mucosa,  p16  is  expressed  at  high  levels  since  the  earliest  available  passages  in  culture  and 
no  further  upregulation  of  protein  expression  occurs  at  later  stages  of  their  proliferative 
lifespan.  This  is  in  contrast  with  the  accumulation  of  p16  reported  in  human  mammary 
epithelial  cells  when  approaching  MO  and  in  keratinocytes  when  approaching  senescence 
(Kiyono  et  al.  1998)  (Munro  et  al.  1999)  (Romanov  et  al.  2001).  A  possible  explanation  to 
this  is  the  adult  age  of  the  donors  from  whom  our  cultures  were  derived.  Alternatively, 
upregulation  of  p16  might  be  involved  in  the  initiation  of  replicative  senescence  at  an 
earlier  stage  than  the  dysplasias  we  were  able  to  obtain. 
With  the  exception  of  D17,  our  mortal  dysplasias  express  high  levels  of  p16  throughout 
their  proliferative  lifespan,  like  normal  cultures.  It  is  very  unlikely  that  p16  overexpression 
in  our  cultures  is  due  to  inadequate  culture  conditions,  as  they  were  all  established  and 
maintained  on  a  layer  of  irradiated  feeder  cells  in  the  presence  of  serum  in  the  growth 
medium.  Therefore,  p16  might  be  genuinely  involved  in  regulating  Ml  growth  arrest  in  our 
cultures  from  normal  oral  mucosa  and  mortal  dysplasias. 
our  dysplasias  showed  a  strong  association  between  acquisition  of  immortal  proliferative 
potential  and  loss  of  p16  expression,  the  only  exception  being  D38.  This  is  in  agreement 
with  a  large  body  of  literature  indicating  that  abrogation  of  the  p16/Rb  pathway  is  an 
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keratinocytes,  along  with  telomerase  activity  (Kiyono  et  al.  1998)  (Dickson  et  al.  2000) 
(Romanov  et  al.  2001).  The  evidence  using  our  oral  dysplasias  is  strengthened  by  work 
carried  out  by  another  group,  describing  loss  of  p16  expression  in  38%  of  oral  dysplasia 
biopsies  in  vivo  (Papadimitrakopoulou  et  al.  1997).  This  percentage  is  very  similar  to  the 
figure  we  have  reported  in  oral  dysplasia  cultures,  correlated  with  cellular  immortality. 
However,  a  recent  report  by  Rheinwald  and  collaborators  (Rheinwald  et  al.  2002)  has 
provided  evidence  that  p16  dysfunction  is  insufficient  per  se  to  significantly  extend  the 
proliferative  life  span  of  normal  epidermal  and  oral  keratinocytes.  In  order  to  interfere  with 
the  p16-related  growth  arrest  mechanism,  the  authors  have  transduced  keratinocytes  with  a 
p16-insensitive  mutantcdk4  expression  vector.  Similarly,  only  a  10  PD  life  span  extension 
was  observed  in  normal  human  fibroblasts  using  p16-insensitive  cdk4  and/or  cdk6  mutants 
(Morris  et  al.  2002).  One  possible  limitation  of  this  approach  is  that  it  does  not  abolish  all 
of  the  functions  of  p16,  but  only  those  mediated  by  cdk4  and/or  cdk6.  Rheinwald  and 
collaborators  (Rheinwald  et  al.  2002)  also  report  that  p16  dysfunction  combined  with 
telomerase  activation  fails  to  immortalise  these  cell  types  in  the  presence  of  functional  p53. 
ARF 
In  these  experiments,  abrogation  of  the  p16  pathway  lead  to  accumulation  of  p14 
ultimately  resulting  in  stabilization  of  p53  and  growth  arrest.  Therefore,  p53  might 
participate  to  the  replicative  senescence  control  through  two  different  mechanisms,  one 
mediated  by  p14ARF  and  the  other  mediated  by  telomere  shortening.  Interference  with  both 
p16  and  p53  functions  may  allow  senescence  to  be  bypassed,  with  cellular  immortalisation 
being  achieved  through  a  concomitant  activation  of  telomerase. 
The  p14ARF  status  of  all  our  naturally  occurring  immortal  dysplasias  has  not  been 
investigated,  although  p16  and  p14A"  are  known  to  be  frequently  co-deleted  or  inactivated 
in  immortal  SCC  cultures  (45%  and  20%  of  cases  respectively)  (Munro  et  al.  1999).  The 
intermediate  phenotype  culture  D17  lacked  expression  of  p16  (and  RARP)  and  was 
successfully  immortalised  by  ectopic  activation  of  telomerase,  despite  retaining  a 
functional  p53.  In  fact,  D17  has  also  lost  expression  of  p14  ARF  (Janis  Fleming  and  Paul 
Harrison,  personal  communication)  and  is  therefore  presumably  unable  to  activate  p53 
through  the  proposed  telomere  length  independent  mechanism.  Thus  the  requirements  for 
D17  immortalisation  are  consistent  with  the  recent  conclusions  of  Rheinwald  and 
collaborators  (Rheinwald  et  al.  2002). Chapter  12 
MZ3  The  atypical  immortal  culture  D38 
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In  previous  chapters,  D38  has  often  been  referred  to  as  an  atypical  immortal  dysplasia.  In 
fact,  it  is  the  only  example  amongst  our  immortal  dysplasia  cultures  that  does  not  conform 
to  the  molecular  phenotype  associated  with  the  acquisition  of  an  unlimited  proliferative 
potential.  D38  has  lost  RARP  expression  and  activated  telomerase,  like  the  other  6 
immortal  dysplasias,  but  it  differs  from  them  in  having  retained  expression  of  p16  and  wild 
type  p53. 
As  discussed  in  previous  sections,  abrogation  of  the  p16/Rb  pathway  is  frequently  reported 
in  literature  as  a  necessary  requirement  for  immortalisation  of  human  epithelial  cells. 
Therefore,  detecting  high  levels  of  p16  expression  in  an  immortal  dysplasia  is  unusual.  The 
entire  coding  region  of  p16  was  sequenced  in  previous  work  from  our  group,  but  no 
mutations  could  be  found  (Fiona  McGregor  and  Paul  Harrison,  personal  communication). 
p16  is  a  turnour  suppressor  protein  that  negatively  regulates  the  activity  of  cdk4/cyclin  D1 
complexes,  ultimately  resulting  in  inhibition  of  the  phosphorylation  of  Rb  and  the 
consequent  release  of  E213  transcriptional  activity.  D38  shows  normal  levels  of  expression 
of  cyclin  D1,  but  the  activity  of  the  cyclin  D1/cdk4  complex  has  not  been  tested.  A 
naturally  occurring  cdk4  point  mutant 
(cRR24C)  that  retains  its  kinase  activity  despite 
having  lost  the  ability  to  bind  p16  has  recently  been  used  to  abolish  p16  control  on  the  cell 
cycle  (Rheinwald  et  al.  2002).  Thus  it  is  not  excluded  that  cyclin  D1/cdk4  complex  in  D38 
is  constitutively  active,  or  that  cdk4  bears  a  mutation  rendering  it  p16  insensitive  but 
functionally  active.  Inactivation  of  p16  or  pRb  have  been  reported  as  mutually  exclusive 
events  in  HNSCC  (Okarni  et  al.  1999).  It  is  also  not  known  whether  Rb  is  lost  in  D38, 
which  would  render  the  upstream  Rb  control  pathways  ineffective.  These  are  all 
hypotheses  that  need  to  be  tested.  Alternatively,  the  molecular  phenotype  of  D38  could 
imply  that  inactivation  of  p16  is  not  a  crucial  step  in  cellular  immortalisation,  whereas  loss 
of  RARP  or  other  as  yet  unknown  molecular  changes  might  be  required  instead.  However, 
at  present,  this  is  a  radical  interpretation. 
The  finding  of  WT  p53  in  D38  was  not  as  surprising.  As  discussed  above,  the  selective 
pressure  to  mutate  p53  derives  from  its  ability  to  sense  critical  telomere  shortening  and 
mediate  a  G1  cell  cycle  arrest  before  severe  telomere  dysfunction  occurs.  Activation  of 
telomerase  could  per  se  reverse  the  telomere  shortening  mechanism  associated  with 
senescence  and  thus  render  inactivation  of  p53  unnecessary.  The  recent  evidence  that  p53 
is  also  involved  in  regulating  proliferative  senescence  through  a  telomere-independent 
p14ARF-mediated  mechanism  (Rheinwald  et  al.  2002)  raises  the  possibility  that  D38  might Chapter  12  123 
harbour  a  mutations  in  exon  10  of  the  INK4A  locus,  which  uniquely  encodes  for  p14  ARF 
and  is  essential  for  its  function.  In  this  case  inactivation  of  the  p14  ARF/p53  pathway  would 
be  obtained  through  loss  of  p14  ARF  expression  in  alternative  to  mutation  of  p53. 
12.3  Attempts  to  immortalise  mortal  dysplaslas 
Our  in  vitro  model  of  oral  cancer  progression  has  identified  several  molecular  changes  that 
occur  in  association  with  cellular  immortality.  However,  although  informative,  such 
analysis  was  not  sufficient  to  distinguish  the  events  that  are  merely  consequential  from 
those  that  have  a  causal  importance  in  the  process  of  immortalisation.  In  addition,  the 
literature  reports  addressing  this  question  are  frequently  in  confliction,  so  that  an  univocal 
conclusion  cannot  be  drawn.  To  briefly  summarize  the  two  main  points  of  debate  in  this 
field,  Shay's  group  reports  that  transduction  of  hTERT  is  sufficient  to  immortalise  normal 
keratinocytes,  p16  overexpression  being  a  result  of  inadequate  culture  conditions  (Ramirez 
et  al.  2001)  whereas  Rheinwald's  group  provides  evidence  that  p16  is  upregulated 
independently  of  culture  conditions  in  cells  approaching  senescence,  and  its  loss  is 
required  in  addition  to  telomerase  activation  to  achieve  keratinocyte  immortalisation 
(Rheinwald  et  al.  2002). 
As  previously  described,  only  1/8  of  our  mortal  dysplasias  showed  any  of  the  changes  that 
were  found  in  immortal  dysplasias.  D17  was  atypical,  as  it  showed  loss  of  RARP  and  p16 
and  a  considerably  extended  life  span.  This  suggests  that  the  acquisition  of  two  out  of  four 
of  the  molecular  changes  associated  with  immortality  is  still  not  sufficient  to  confer  an 
unlimited  proliferative  potential.  D17  was  therefore  an  ideal  model  to  test  whether  ectopic 
activation  of  telomerase  was  sufficient  to  immortalise  naturally  occurring  oral  dysplasias, 
or  whether  other  changes  like  p53  mutation  and  loss  of  RARP  and  p16  are  also  required. 
Initially,  a  retroviral  hTERT  expression  vector  was  transduced  in  two  typical  mortal 
dysplasia  cultures,  that  retained  normal  p16  and  RARP  expression.  Despite  maintaining 
them  under  adequate  culture  conditions,  activation  of  telomerase  and  the  consequent 
telomere  elongation  did  not  allow  these  cultures  to  proliferate  beyond  their  expected  life 
span.  In  contrast,  ectopic  activation  of  telomerase  in  D17  under  the  same  conditions  caused 
immortalisation,  suggesting  that  when  loss  of  RARP  and/or  p16  occur  in  concomitance 
with  telomerase  activation,  oral  dysplasias  become  immortal. 
Another  important  point  emerging  from  the  analysis  of  D17  is  that  mutation  of  p53  is  not 
an  absolute  requirement  for  immortalisation.  In  fact,  the  D17  hTERT  infectants  never Chapter  12  124 
selected  in  favour  of  p53  mutation,  and  were  shown  to  retain  wild-type  p53  after  having 
completed  120  population  doublings  in  culture.  Certainly,  activation  of  telomerase/ 
telomere  elongation  in  D17  abrogated  the  increased  phosphorylation  of  p53  at  serine  15 
that  otherwise  occurs  at  senescence.  This  could  be  an  efficacious  mechanism  to  bypass  the 
selective  pressure  against  wild  type  p53  in  indefinitely  proliferating  cells.  The  most  recent 
findings  from  our  group  have  added  p14  ARF  as  an  additional  player  in  this  scenario.  It 
could  be  speculated  that  in  D17  the  concomitant  dysfunction  of  p16  and  p14  ARF  allows  the 
cells  to  proliferate  for  longer,  undergoing  further  telomeric  attrition  and  ultimately 
reaching  a  further  senescence  checkpoint  that  involves  telomere  mediated  phosphorylation 
of  p53  at  serine  15. 
12.3.1  p53  mutation  and  telomerase  activation  in  immortality  and  cancer 
The  involvement  of  both  p53  and  telomerase  in  human  carcinogenesis  is  widely  accepted 
and  described  in  a  copious  body  of  literature.  The  human  Li  Fraumeni  syndrome,  due  to  an 
inherited  heterozygous  mutation  of  p53,  is  known  to  be  characterized  by  predisposition  of 
affected  individuals  to  various  types  of  cancers.  Similarly,  p53  knock  out  mice  are  more 
prone  to  developing  turnours  than  their  normal  counterparts.  Furthermore,  an  early 
intervention  experiment  presented  evidence  that  functional  p53  inhibits  the  growth  of 
cancer  cells:  when  WT  p53  was  transfected  in  a  colon  carcinoma  cell  line  that  had 
inactivated  p53,  a  substantial  inhibition  of  cell  growth  and  colony  forming  efficiency  was 
noticed,  as  assessed  by  H3  thymidine  incorporation,  along  with  a  selection  pressure  to 
mutate  the  exogenous  p53  (Baker  et  al.  1990).  More  recent  efforts  have  lead  to  the 
generation  of  transgenic  mice  that  overexpress  hTERT  in  their  basal  keratinocytes.  These 
mice  showed  an  increased  susceptibility  to  chemically  induced  skin  carcinogenesis 
(Gonzalez-Suarez  et  al.  2000;  Gonzalez-Suarez  et  al.  2001).  Not  surprisingly,  expression 
of  a  mutant  form  of  hTERT  in  human  cancer  cell  lines  resulted  in  inhibition  of  their  growth 
(Hahn  et  al.  1999)(b). 
Our  most  recent  data  has  identified  a  close  correlation  between  mutation  of  p53,  activation 
of  telomerase  activity  (through  hTERT  upregulation)  and  cellular  immortality.  Telomerase 
activity  was  observed  in  immortal  dysplasias  with  no  exceptions,  whereas  the  atypical 
culture  D38  was  the  only  one  retaining  wild  type  p53  along  with  an  immortal  phenotype. 
I 
The  interactions  between  p53  and  hTERT  have  not  yet  been  fully  elucidated.  The  hTERT 
promoter  lacks  p53  consensus  binding  sites  (Cong  et  al.  1999),  but  p53  might  regulate 
hTERT  via  interfering  with  the  hTERT  transcriptional  activator  Sp-1:  recent  evidence  has Chapter  12  125 
demonstrated  that  wild  type  p53  is  able  to  form  complexes  with  Sp-1  and  thus  could 
prevent  it  from  binding  to  the  hTERT  promoter  (Xu  et  al.  2000).  In  the  same  experiments, 
transfection  of  wild  type  p53  into  Burkitt  lymphoma  cells  lacking  a  functional  p53  resulted 
in  a  rapid  dowregulation  of  hTERT  transcription.  On  the  other  hand,  the  critical  shortening 
of  telomeres  observed  as  a  result  of  cellular  senescence  activates  p53  through 
phosphorylation  of  its  serine  residue  15,  which  mediates  a  p53-dependent  G1  arrest  in 
response  to  DNA  damage  (Webley  et  al.  2000).  This  can  be  circumvented  by  telomerase 
activation,  as  demonstrated  with  D17  in  the  present  studies. 
This  background  information  suggests  at  least  two  possible  routes  to  cellular  immortality: 
through  hTERT/telomerase  activation  and/or  through  mutation  of  p53.  By  spontaneously 
mutating  p53,  cells  may  acquire  the  ability  to  release  the  interference  on  Sp-1  mediated 
hTERT  transcription  by  WT  p53,  and  thus  activate  telomerase.  Alternatively,  telomerase 
activation  might  remove  the  selection  pressure  to  inactivate  p53  by  correcting  telomere 
dysfunction,  and  therefore  abrogate  the  cascade  of  events  that  leads  to  p53-mediated  cell 
cycle  arrest.  Although  these  two  options  are  not  mutually  exclusive,  the  second  is  probably 
not  of  frequent  occurrence  in  human  keratinocytes  since  spontaneous  activation  of 
telomerase  has  never  been  reported  in  this  cell  type. 
Activation  of  telomerase  does  not  have  to  be  considered  solely  in  association  with  loss  of 
function  of  p53.  Several  telomerase  positive  and  negative  regulators  of  hTERT 
expression/telomerase  activity  have  been  described  in  literature  (discussed  in  chapter  6.2), 
and  loss  of  expression  of  a  telomerase  inhibitor  or  gain  of  function  of  a  telomerase 
activator  could  be  responsible  for  telomerase  activation  in  our  immortal  cultures.  The 
expression  of  c-Myc  and  Madl,  reported  to  be  respectively  a  positive  and  a  negative 
regulator  of  hTERT,  was  previously  analysed  in  all  of  our  cultures  from  mortal  and 
immortal  dysplasias,  but  no  changes  were  found  (Judith  Brown  and  Paul  Harrison, 
personal  communication). 
12.3.2  Proposed  future  experiments 
Using  D17  to  investigate  the  genetic  basis  of  keratinocyte  immortalisation  offers  several 
clear  advantages,  along  with  a  few  disadvantages.  This  culture  has  peculiar  features  in 
vitro,  as  it  has  spontaneously  acquired  two  of  the  molecular  changes  associated  with  the 
immortal  phenotype  and  retains  an  extended  but  still  limited  proliferative  potential. 
Finding  these  molecular  changes  in  a  naturally  occurring  dysplasia  is  certainly  more 
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oncogenes,  whose  biological  effects  are  not  clearly  and  completely  defined.  The 
availability  of  the  frozen  biopsy  sample  from  which  this  culture  was  derived  enabled  us  to 
prove  that  loss  of  RARO  and  p16  have  occurred  in  vivo  (Keith  Hunter  and  Paul  Harrison, 
personal  communication),  thus  allowing  us  to  rule  out  the  possibility  of  a  cultural  artefact. 
Nevertheless,  we  can  not  exclude  that  other  as  yet  unknown  molecular  events  have  taken 
place  in  D17  and  might  play  a  role  in  determining  its  cellular  or  molecular  phenotype.  In 
addition  to  our  earlier  findings,  most  recent  experiments  on  D17  have  identified  loss  of 
expression  of  p14A",  which  might  be  involved  in  mediating  the  p53  regulatory  effects  on 
replicative  senescence,  as  recently  reported  observations  suggest  (Rheinwald  et  al.  2002). 
It  remains  to  be  clarified  whether  all  three  molecular  changes  in  D17  are  required  in 
addition  to  hTERT  expression  for  immortalisation.  In  fact,  we  have  not  observed  any 
mortal  dysplasias  that  have  lost  just  RARP  or  p16;  their  p14  ARF  status  needs  to  be 
investigated  through  further  experiments. 
Several  interventional  procedures  could  be  carried  out  in  the  future  to  clarify  these  points. 
RARP  expression  could  be  exogenously  abolished  in  a  typical  mortal  dysplasia,  creating  a 
situation  where  the  molecular  status  of  our  four  markers  of  interest  is  RARP-,  pl6+, 
telomerase-  and  wt  p53.  An  RARP2  mutant  (R269Q)  acting  with  dominant  negative  effects 
has  been  described  in  literature,  but  its  inhibitory  function  is  exerted  on  all  RAR  subtypes. 
If  this  mutant  were  to  be  used,  it  would  be  impossible  to  distinguish  between  the  effects 
due  to  loss  of  expression  of  RARP  and  those  due  to  loss  of  expression  of  RARa/y.  A 
Similar  problem  would  be  encountered  using  expression  vectors  transducing  RARP4.  This 
RARP  isoform  lacks  a  DNA  binding  domain  but  retains  its  ability  to  interact  with  RXRs, 
rendering  them  unavailable  for  binding  with  other  functional  RARs.  Alternatively, 
antisense  mRNA  or  RNA  interference  approaches  could  be  used.  An  antisense  construct 
specific  for  the  RARP2  isoforin  has  been  designed  and  utilised  by  Berard  and  co-workers; 
(Berard  et  al.  1996),  and  it  proved  successful  in  reducing  the  levels  of  expression  of 
RARP2  message  in  transgenic  mice.  A  novel  technique  has  been  recently  developed,  using 
duplexes  of  21-nucleotide  RNAs,  known  as  short  interfering  RNAs  (si-RNAs):  they  have 
proved  to  efficiently  inhibit  endogenous  gene  expression  when  introduced  in  mammalian 
cells  (Sui  et  al.  2002)  (Yu  et  al.  2002).  Considering  what  reported  in  literature,  it  is  very 
unlikely  that  the  sole  abrogation  of  RARP  function  would  create  an  immortal  phenotype, 
unless  ectopic  RARP  loss  of  expression  resulted  in  activation  of  telomerase.  Our 
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from  normal  oral  mucosa  and  our  mortal  dysplasia  D17  do  not  express  RARP  but  still  have 
no  detectable  telomerase  activity. 
Alternatively,  RARP  expression  could  be  induced  in  an  immortal  dysplasia,  to  investigate 
if  the  artificial  RARP+,  p16-,  telomerase+  and  mutated  p53  combination  restores  the 
mortal  phenotype.  If  this  were  the  case,  it  would  be  then  interesting  to  assess  whether  or 
not  normal  p16  expression  and  wt  p53  are  required  in  addition  to  RARP  for  cells  to  be 
mortal.  This  information  could  be  gathered  by  comparing  the  effects  of  RARP  ectopic 
expression  in  a  typical  mortal  dysplasia  and  in  our  atypical  mortal  dysplasia  D38,  which 
retains  p16  and  wt  pS3.  Such  experiments  have  already  been  attempted  in  the  group  by 
transfection  methods  before  the  retroviral  infection  technique  was  developed,  but  proved 
inconclusive  because  of  the  very  low  transfection  efficiencies.  A  retroviral  vector 
expressing  RARP2  (LNSP)  has  recently  been  generated  and  utilised  in  HNSCC  cell  lines 
by  Lotan's  research  group,  which  had  also  encountered  similar  difficulties  with 
transfection  approaches.  The  only  potential  disadvantage  of  using  this  system  would  be  the 
long  period  of  time  between  the  infection  procedure  and  the  manifestation  of  those 
biological  effects  imputable  to  RARP  expression.  This  would  not  enable  us  to  distinguish 
between  its  direct  effects  and  those  mediated  by  other  unidentified  effectors.  An  inducible 
RARP  expression  system  could  be  used  instead.  Recently,  an  ecdysone-inducible 
mammalian  expression  system  has  been  optimised  by  Van  Craenenbroeck  and  co-workers 
(Van  Craenenbroeck  et  al.  2001).  This  system  entails  transfection  with  an  expression 
vector  transducing  a  retinoid  X  receptor  (RXR)  and  a  modified  ecdysone  receptor, 
controlled  by  the  constitutive  RSV  (Rous  sarcoma  virus)  and  CMV  (cytomegalovirus) 
promoters  respectively.  After  addition  of  ecdysone,  the  two  receptors  heterodimerize  and 
bind  to  the  ecdysone-responsive  elements,  resulting  in  transcription  of  the  gene  of  interest. 
Although  this  system  could  potentially  be  useful,  it  has  several  drawbacks.  The  exogenous 
expression  of  RXR  receptor  might  alter  the  physiological  balance  between  the  levels  of 
expression  of  RXR/RAR  subunits.  In  addition,  RARP  expression  would  need  to  be 
maintained  for  a  long  period  of  time  before  senescence  would  be  expected  to  occur, 
rendering  difficult  to  discriminate  between  its  direct  and  indirect  effects.  Also,  if  RARP 
were  to  trigger  senescence,  a  selection  against  those  clones  expressing  RARP  could  be 
expected.  Nevertheless,  this  approach  could  still  prove  useful  in  identifying  other  possible 
target  genes  of  RARP.  This  could  be  accomplished  by  comparing  the  mRNA  expression  of 
a  culture  pre  and  post  transfection  with  the  inducible  RARP  expression  system  through 
microarray  analysis.  This  quite  novel  approach  would  be  in  keeping  with  our  group's Chapter  12  128 
ongoing  work  to  identify  genes  implicated  in  mortality  control  through  microarray  analysis 
of  our  panel  of  mortal  and  immortal  dysplasias. 
As  discussed  earlier  in  this  chapter,  a  certain  degree  of  "cross  talk"  seems  to  occur  between 
p53  and  telomeres/telomerase  activity.  In  keeping  with  this,  we  have  observed  that  wild 
type  p53  is  found  in  association  with  low  or  undetectable  telomerase  activity  and  mortal 
phenotype,  and  mutated  p53  is  associated  with  high  telomerase  activity  and  immortal 
phenotype.  To  clarify  whether  the  association  between  these  markers  is  direct  or  only 
coincidental,  we  propose  to  interfere  with  p53  function  in  our  atypical  mortal  dysplasia 
D17,  which  lacks  p16  and  RARP  expression.  We  could  then  investigate  if  p53  inactivation 
is  able  to  upregulate  telomerase  activity  and/or  induce  immortalisation.  Two  approaches 
could  be  utilised  to  inactivate  p53:  infection  with  HPV  E6  or  with  a  retroviral  vector 
expressing  a  dominant  negative  p53  construct.  The  first  approach  would  probably  be  less 
specific,  since  HPV  E6  is  known  to  activate  telomerase  independently  of  its  effects  on  p53 
degradation  (Klingelhutz  et  al.  1996).  However,  a  large  panel  of  well-characterized  Arg175 
p53  mutants  (Tyr175,  Trp175,  Asp175  and  Phe175),  along  with  Tyr141,  His175  and 
Trp248  mutants  (these  last  two  being  mutational  hotspots  in  human  cancer)  have 
completely  lost  their  transactivating  functions  and  can  inhibit  wild  type  p53  activity 
(Hachiya  et  al.  1994)  (Blagosklonny  et  al.  2001).  It  has  to  be  kept  in  mind  that  the 
dominant  negative  effects  of  p53  mutants  are  promoter  selective,  as  a  consequence  of 
selective  loss  of  transactivation  functions  (Blagosklonny  et  al.  2001).  Therefore,  it  would 
probably  be  more  informative  to  investigate  the  effects  of  a  combination  of  different 
mutants  using  retroviruses  with  different  selectable  markers. 
12.4  Relevance  of  these  molecular  changes  in  vivo 
The  evidence  generated  by  our  studies  has  shed  new  light  on  two  aspects  of  oral  cancer 
progression:  what  molecular  changes  are  involved  at  different  stages  and  in  what  temporal 
sequence  they  have  to  occur  to  yield  to  keratinocyte  immortalisation.  Using  an  in  vitro 
model  to  study  a  biological  process  that  takes  place  in  vivo  offers  several  advantages:  it 
allows  a  wider  range  of  observations  by  expanding  the  cellular  population  in  culture;  it  is 
amenable  for  interventional  procedures.  In  turn,  the  interpretation  of  in  vitro  results 
requires  caution,  as  established  cell  cultures  are  different  from  their  tissue  of  origin  in  that 
they  are  extrapolated  from  the  natural  anatomic  setting  and  somehow  inevitably  modified 
to  allow  growth  in  tissue  culture. Chapter  12  129 
One  of  the  features  that  makes  our  in  vitro  model  of  oral  cancer  progression  particularly 
valuable  is  the  availability  of  frozen  biopsy  material  corresponding  to  six  of  the  established 
cell  cultures  (3  mortal  and  3  immortal  dysplasias).  This  will  allow  verification  of  whether 
the  observations  made  in  vitro  actually  correspond  to  events  that  have  taken  place  in  the 
original  tumour  sample,  giving  a  new  significance  to  our  observations  regarding  the 
process  of  cellular  immortalisation. 
At  the  current  state  of  knowledge,  none  of  the  features  of  oral  premalignant  lesions  that  can 
be  assessed  by  clinical  or  histologic  examination  have  shown  any  sort  of  correlation  with 
the  development  of  a  mortal  or  immortal  phenotype  in  culture.  We  have  found  that 
dysplasias  classified  as  mild  or  moderate  at  biopsy  had  no  greater  probability  of  giving  rise 
to  a  mortal  culture  than  those  classified  as  severe.  Similarly,  the  clinical  subdivision  of 
premalignant  lesions  into  leukoplakias  and  erythroplakias  was  not  predictive  of  their 
proliferative  life  span:  combining  our  data  with  Ken  Parkinson's  group's  data,  2/6 
erythroplakias  and  5113  leukoplakias  are  immortal  in  culture. 
Therefore,  if  a  correspondence  between  in  vitro  and  in  vivo  molecular  phenotypes  were  to 
be  established,  it  would  enable  us  to  predict  which  biopsies  are  likely  to  give  rise  to  an 
immortal/mortal  culture  based  solely  on  molecular  markers.  The  advantages  of  this 
approach  are  obvious.  Establishing  primary  cultures  from  oral  biopsies  is  a  time  and 
resource  consuming  process,  accompanied  by  a  significant  culture  failure  rate  mainly  due 
to  bacterial/fungal  contamination  of  the  original  biopsy  (50%  in  our  group's  experience). 
In  addition,  the  dimensions  of  the  biopsy  samples  are  often  not  sufficient  to  establish  a 
culture  along  with  DNA/RNA/protein  extraction  and  in  situ  studies;  thus  being  able  to 
assign  all  of  the  available  material  to  one  or  few  purposes  would  certainly  be  of  value. 
Another  approach  that  we  propose  to  further  refine  the  molecular  differences  between 
mortal  and  immortal  dysplasias  is  the  gene  expression  profiling  by  microarray  analysis.  As 
previously  stated,  our  group  is  already  undertaking  a  research  project  aimed  at  identifying 
molecular  markers  regulating  mortality  using  this  novel  approach.  The  availability  of 
biopsy  material  and  corresponding  cultures  from  three  mortal  and  three  immortal 
dysplasias  will  enables  us  to  identify  those  molecular  changes  (some  of  which  may  be 
novel)  consistently  associated  with  keratinocyte  immortalisation  in  culture  and  verify  their 
occurrence  in  the  original  biopsies. Chapter  12 
12.5  Prognostic  value  of  our  observations 
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The  identification  of  a  panel  of  markers  consistently  associated  with  the  mortal  to  immortal 
transition  in  oral  cancer  is  useful  not  only  because  it  elucidates  the  molecular  biology  of 
cellular  immortalisation,  but  also  for  its  potential  clinical  and  prognostic  applications. 
It  is  generally  accepted  that  the  acquisition  of  an  immortal  phenotype  is  an  important  step 
in  carcinogenesis,  and  our  earlier  findings  have  clearly  demonstrated  that  in  oral  cancer 
progression  it  most  commonly  occurs  in  premalignant  lesions.  The  percentage  of  biopsies 
presenting  an  immortal  phenotype  in  culture  is  significantly  higher  in  late  stage  oral  cancer 
(86%)  than  in  dysplasias  (37%).  Nevertheless,  there  is  no  clear  indication  that  the 
dysplasias  that  progress  to  fully  developed  SCC  are  actually  a  subset  of  the  immortal 
dysplasias,  or  even  occur  with  a  higher  frequency  in  this  group. 
Mortal  Immortal  Total 
Leukoplakias  1/8  0/5  1/13 
Erythro(leuko)plakias  4/4  2/2  6/6 
Both  5/12  2/7 
This  table  represent  the  ratio  of  mortal  and  immortal  dysplasias  having  evolved  to  SCC, 
stratified  in  leukoplakias  versus  erythroleukoplakias.  Combining  our  data  with  Ken 
Parkinson's  group's  observations,  only  1/13  leukoplakias  evolved  into  SCC,  and  it  was 
mortal  in  culture.  In  contrast,  all  of  our  6  erythroleukoplakias  evolved  to  SCC,  regardless 
of  their  proliferative  fate  in  culture.  This  is  in  keeping  with  the  literature  reports  describing 
a  clear  difference  in  progression  rate  between  these  two  types  of  oral  dysplasias  (5%  for 
leukoplakias  and  25-50%  for  erythroplakias  within  5-10  years).  It  would  be  interesting  to 
investigate  how  these  two  types  of  premalignant  lesions  differ  in  molecular  terms,  by 
comparing  the  genetic  profiling  of  a  reasonable  number  of  such  two  types  of  premalignant 
lesions  through  microarray  analysis.  Considering  that  erythroplakias  and  leukoplakias 
present  a  substantially  different  progression  rate,  if  molecular  markers  typically  expressed 
in  erythroplakias  were  found  in  a  subset  of  leukoplakias  they  could  be  indicative  of  a Chapter  12  131 
higher  chance  of  cancer  development  for  these  lesions  and  therefore  be  of  prognostic 
significance. 
In  contrast,  the  acquisition  of  unlimited  proliferative  potential  in  culture  does  not  appear  to 
be  a  good  prognostic  indicator  in  oral  premalignant  lesions.  In  fact,  2/7  (29%)  immortal 
dysplasias  and  5/12  (42%)  mortal  dysplasias  have  evolved  so  far,  with  patients  being 
followed  up  for  3-7  years.  However,  the  statistical  significance  of  such  small  numbers  is 
debatable  and  will  be  necessary  to  obtain  data  on  a  wider  number  of  samples/patients 
before  considering  this  data  conclusive.  It  could  be  argued  that  although  immortality 
generally  occurs  at  early  stages  of  oral  cancer  progression,  the  acquisition  of  such 
phenotype  becomes  of  crucial  and  possibly  of  selective  importance  only  at  later  stages  of 
carcinogenesis.  We  currently  have  no  data  to  support  or  discard  the  hypothesis  that  a 
neoplastic  lesion  that  generates  a  mortal  culture  when  sampled  at  the  dysplasia  stage  could 
generate  an  immortal  culture  if  biopsied  after  malignant  transformation.  On  these  grounds, 
it  would  be  extremely  useful  and  informative  to  obtain  serial  biopsies  from  a  neoplastic  site 
before  and  after  progression,  and  assess  the  proliferative  potential  of  the  corresponding 
cultures. 
As  reported  in  literature,  the  histological  grading  of  dysplasias  is  not  thought  to  be  a 
reliable  prognostic  indicator  but,  in  fact,  all  three  of  our  dysplasias  that  evolved  had  been 
graded  as  moderate/severe  or  severe/CIS.  Again,  this  correlation  is  weak  in  view  of  the 
small  numbers  currently  analysed,  but  it  could  prove  significant  after  completion  of  the 
prospective  study  on  a  larger  number  of  patients  that  has  been  set  up  by  our  group. 
12.5.1  Ultimate  objective 
Clearly,  the  most  valuable  end  point  of  most  research  projects  is  their  potential  clinical  and 
prognostic  applications.  As  extensively  discussed  in  previous  chapters,  oral  cancer  still  has 
a  low  5  year  survival  rate,  and  the  medical  or  surgical  treatment  of  premalignant  lesions 
often  proves  ineffective  because  of  the  high  percentage  of  patients  dropping  out  of  medical 
treatment,  or  lesions  recurring  after  laser  ablation. 
It  would  therefore  be  of  great  advantage  both  for  the  patients  and  for  the  National  Health 
System  to  selectively  treat  those  lesions  that  are  more  likely  to  undergo  malignant 
transformation.  At  the  moment,  no  combination  of  clinical  or  histological  criteria  allows 
this  distinction.  We  feel  that  a  considerable  amount  of  effort  should  be  spent  in  identifying 
a  panel  of  molecular  markers  that  have  prognostic  significance  in  oral  cancer,  and  probably Chapter  12  132 
the  most'appropriate  approach  would  be  microarray  analysis.  Even  if  a  rigid  distinction 
between  potentially  benign  and  malignant  lesions  proves  impossible,  being  able  to  classify 
the  biopsies  into  high  risk  or  low  risk  classes  would  be  useful.  A  similar  rationale  has  been 
widely  used  over  the  years  for  other  clinical  conditions,  like  prenatal  diagnosis  of  trisomy 
21  and  neural  tube  defects.  Having  proved  cost  effective  and  clinically  significant  in  those 
scenarios,  an  analogous  method  could  be  applied  with  success  for  prevention  of  oral 
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1 Abstract 
Our  previous  work  showed  that  acquisition  of  immortality  at  the  dysplasia  stage  of  oral 
cancer  progression  was  consistently  associated  with  four  changes:  loss  of  retinoic  acid 
receptor  (RAR)-P  and  pl6lNK4A  expression,  p53  mutations  and  activation  of  telomerase. 
One  atypical  dysplasia  (D17)  that  senesced  after  an  extended  lifespan  showed  loss  of 
RAR-P  and  p1eK4A/p14  ARF  expression  but  retained  wild-type  p53  and  telomerase  was 
not  activated.  We  now  demonstrate  that  retroviral  delivery  of  hTERT  results  in  telomere 
lengthening  and  immortalization  of  D17  with  no  change  in  wild-type  p53.  In  contrast, 
e  xpression  of  hTERT  in  two  other  typical  mortal  dyplasia  cultures  (that  retain  RAR-P 
and  pl61NK4A  expression)  does  not  extend  their  lifespan,  even  though  telomeres  are 
lengthened. 
Introduction 
Normal  cells  undergo  replicative  senescence  in  culture  due  to  erosion  of  telomeres  and 
fail  to  divide  further  but  remain  viable.  Although  the  role  of  senescence  in  vivo  remains 
to  be  established,  escape  from  senescence  and  acquisition  of  immortality  are  considered 
to  be  important  characteristics  of  cancer  cells  (1)  since  most  primary  cancers,  and 
virtually  all  recurrences,  are  immortal  (2).  Studies  with  various  cell  types  have  indicated 
that  senescence  can  be  bypassed  by  abrogation  of  the  p53  and  retinoblastorna  gene  (Rb)3 
pathways  but  the  cells  then  enter  a  second  proliferative  block  (crisis)  involving  genomic 
instability  and  cell  death,  from  which  rare  immortal  variants  emerge  due  to  activation  of 
telomerase  and  telomere  maintenance  (3).  Several  studies  have  reported  that  some  normal 
cell  types  can  be  immortalised  by  ectopic  expression  of  the  catalytic  component  of 
telomerase  (hTERT)  alone,  whereas  others,  such  as  mammary  epithelial  cells  and 
2 keratinocytes,  cannot  without  concomitant  loss  of  p16  INK4A  expression  (4).  However,  it 
remains  controversial  whether  this  loss  of  p16  INK4A  is  due  to  sub-optimal  culture 
conditions  or  simply  passage  in  culture  (4).  Senescence  can  also  be  induced  by  oncogene 
expression  in  cultured  cells  (5).  However,  it  is  not  clear  whether  the  mechanisms  of 
escape  from  senescence  by  normal  cells  are  the  same  as  those  in  mortal  preneoplastic 
cells  since,  for  example,  p161NK4A  is  known  to  be  regulated  positively  and  negatively  by 
oncogenes  (6).  This  report  addresses  these  issues  in  a  head  and  neck/oral  keratinocyte 
pre-neoplasia  model  of  squarnous  carcinoma  (SCC)  development.  In  our  previous  work, 
we  showed  that  acquisition  of  immortality  at  the  dysplasia  stage  of  oral  SCC  was 
consistently  associated  with  loss  of  retinoic  acid  receptor  (RAR)-P  and  p16  INMA 
expression,  p53  mutations  and  activation  of  telomerase,  suggesting  that  all  are  required 
for  immortality  (7,8).  None  of  the  mortal  dysplasias  showed  any  of  these  changes,  except 
one  (D17)  which  had  an  extended  lifespan  and  an  intermediate  molecular  phenotype  i.  e. 
loss  of  retinoic  acid  receptor  (RAR)-P  and  pl6lNK4A  expression,  but  not  p53  mutations 
and  activation  of  telomerase.  In  this  report  we  have  tested  whether  ectopic  activation  of 
telomerase  by  transduction  of  a  retroviral  hTERT  expression  vector  is  sufficient  to 
immortalise  naturally  occurring  oral  dysplasias,  or  whether  other  changes,  such  as  p53 
mutations  and  loss  of  RAR-P  and  p161NK4A  expression  are  also  required. 
3 Materials  and  Methods 
Cell  Culture.  The  methods  for  isolation,  establishment  and  culture  of  the  primary  human 
oral  cultures  used  in  this  study  have  been  described  previously  (7,8).  The  irradiated  3T3 
feeder  cells  were  removed  by  EDTA  treatment  before  analysis  of  keratinocytes. 
Retrovirus  production  and  ectopic  expression  of  hTERT.  The  retroviruses  were 
produced  by  infecting  the  amphotropic  packaging  line  Phoenix  A  with  pBabeNeo  or 
pBabest2  (hTERT)  retroviral  constructs  (9)  and  selecting  with  the  minimum 
concentration  of  G418  found  to  kill  the  uninfected  cultures.  Dysplasia  cultures  were 
infected  at  about  80%  confluency  with  1.35x104  infectious  units/ml  in  the  presence  of  4 
[tg/ml  of  polybrene.  The  dysplasia  cells  were  plated  on  G418-resistant  3T3  feeder  cells, 
selected  48h  later  with  200  [tg/ml  of  G418  and  cultured  under  constant  selection.  Pooled 
G418-resistant  colonies  were  used  in  all  experiments  to  avoid  variability  due  to  clonal 
heterogeneity  of  the  population. 
Senescence  assays.  Cells  were  stained  for  senescence-associated  P-galactosidase  activity 
(SABG)  (8),  DNA  fragmentation  measured  by  the  TUNEL  assay  (10)  and  the 
proliferative  index  of  colonies  determined  by  BrdU  labelling  (11). 
Telornerase  Assay.  Telomerase  activity  was  measured  as  described  previously  (8). 
TRF  measurement.  This  was  carried  out  as  described  by  (11)  except  that  the  blot  was 
hybridised  with  a  radiolabeled  oligonucleotide  probe  (TTAGGG)3  at  42*C  and 
subsequently  washed  in  6xSSC/1%SDS  at  42*C. 
p53  sequencing.  DNA  was  isolated  form  hTERT  transduced  D17  cultures  once  they  had 
reached  86  population  doublings.  Sequencing  of  exons  2-11  was  performed  as  described 
previously  (8). 
4 Western  blots.  The  levels  of  total  p53,  p53  phosphorylated  at  serine  15  ,  p14  ARF  and 
ERKs  1&2  were  determined  using  the  following  antibodies  as  indicated  by  the 
maunufacturers:  total  p53  (D01;  Santa  Cruz  Biotechnology);  ser  15  phospho-specific  p53 
(16G8,  New  England  BioLabs);  p14ARF  (C-18,  sc-8613;  Santa  Cruz  Biotechnology); 
ERKs  1&2  (ERK1(C-16)-G;  Santa  Cruz  Biotechnology). 
Results  and  Discussion 
Ecotopic  expression  of  telomerase  in  mortal  dysplasia  cultures.  In  previous  work  (7, 
8),  we  established  a  panel  of  primary  cultures  of  oral  dysplasias  using  the  3T3  feeder 
layer  culture  system  of  Rheinwald  and  coworkers  which  has  been  shown  to  facilitate 
growth  of  keratinocytes  at  all  stages  of  cancer  progression  and  to  maintain  the 
characteristics  of  the  original  tumors  (12):  it  has  also  been  reported  to  avoid  the 
premature  growth  arrest  associated  with  culture  of  epithelial  cells  in  chemically-defined 
keratinocyte  growth  medium  directly  on  plastic  culture  dishes  (13).  In  our  previous 
analysis,  we  demonstrated  that  about  half  of  oral  dysplasias  were  immortal  in  culture  and 
that  they  showed  four  characteristic  molecular  differences  from  mortal  dysplasias:  loss  of 
expression  of  RAR-P  and  p16  INMA 
.  reactivation  of  telomerase  through  hTERT 
upregulation  and  mutations  in  p53  (7,8).  One  dysplasia  culture  (D17)  with  an  atypically 
extended  life  span  (45  population  doublings  (PDs))  (compared  to  4-30  PDs  for  other 
mortal  dysplasias)  showed  an  intermediate  molecular  phenotype:  loss  of  expression  of 
RAR-P  and  p161NK4A,  like  immortal  dysplasias,  but  no  detectable  telomerase  activity  and 
wild  type  p53  like  mortal  dysplasias.  The  loss  of  RAR-P  and  p16  INK"expression  in  D17 
is  not  a  culture  artefact  since  we  have  also  shown  loss  of  both  markers  in  the  biopsy  from 
which  D17  was  derived  (data  not  shown).  All  our  mortal  dysplasia  cultures  undergo 
5 terminal  growth  arrest  due  to  senescence  rather  than  'crisis'  since  the  arrested  colonies 
show  no  apoptosis  by  TUNEL  staining  and  the  percentage  of  proliferating  cells  by  BrdU 
labelling  is  low  (less  than  20%)  (Fig.  1). 
In  order  to  assess  the  importance  of  telomerase  activation  in  cellular  immortalization  of 
our  mortal  dysplasias,  we  used  the  amphotropic  retroviral  vector  pBabeEST  to 
ectopically  express  hTERT  into  two  typical  mortal  cultures  (D25,  D30)  and  also  D17. 
Parallel  cultures  were  also  infected  with  the  'empty'  retroviral  vector  expressing  the 
neomycin  resistance  gene  alone.  After  infection,  neomycin-resistant  colonies  were 
pooled,  checked  for  telomerase  activity  and  telomere  lengths  as  soon  as  sufficient  cells 
were  available  and  monitored  for  their  life  span. 
The  mortal  dysplasia  culture  D30  had  an  expected  life  span  of  30  PDs  and  was  infected  at 
8.5,9,17  and  18  PDs  in  four  separate  experiments.  D25  had  an  expected  life  span  of  25 
PDs  and  was  infected  at  7,9  and  18  PDs  in  three  separate  experiments.  In  parallel 
experiments,  the  D17  dysplasia  culture  was  infected  after  having  reached  34.5  and  39 
PDs,  with  an  expected  lifespan  of  45  PDs.  With  D25  and  D30  dyplasias,  no  difference  in 
growth  rate  or  lifespan  was  observed  between  the  uninfected  cultures,  the  cultures 
infected  with  the  empty  vector  and  those  infected  with  the  hTERT  vector.  However,  with 
D17,  the  cells  infected  with  the  hTERT  vector  grew  for  at  least  130  PI)s  and  thus  appear 
to  be  immortal,  but  this  did  not  occur  with  uninfected  cells  or  cells  infected  with  the 
gempty'  vector,  which  senesced  like  the  uninfected  cells  (Fig.  1). 
To  check  whether  the  dysplasias  infected  with  the  hTERT  vector  had  functional 
telomerase,  telomerase  activity  was  assayed  as  well  as  telomere  length  maintenance.  In 
both  D30  and  D17,  telomerase  activity  was  undetectable  in  uninfected  cultures  and 
6 cultures  infected  with  the  empty  vector,  but  activity  was  readily  detectable  in  cultures 
infected  with  the  hTERT  vector  (Fig.  2).  In  both  cases,  the  activation  of  telomerase  after 
infection  with  the  hTERT  vector  was  functional  in  maintaining/elongating  telomeres: 
during  culture  of  D30  and  D17  to  senescence,  telomeres  progressively  became  shorter, 
but  were  increased  significantly  after  infection  with  the  hTERT  vector  but  not  the 
empty'  vector  (Fig.  3).  Finally,  infection  with  the  hTERT  vector,  but  not  the  'empty' 
vector,  abrogated  the  increased  phosphorylation  of  p53  at  serine  15  that  otherwise  occurs 
during  dysplasia  senescence  (Fig.  4A):  this  site  is  known  to  be  involved  in  p53-mediated 
DNA  damage  responses  (14)  and  seems  to  be  a  sensor  of  DNA  damage  signals  relayed 
by  the  ATM  pathway  in  response  to  critically  short  telomeres  (14,15).  Overall,  these 
experiments  expressing  hTERT  ectopically  in  D30/D25  and  D17  strongly  suggest  that 
telomerase  activation/telomere  maintenance  is  not  sufficient  per  se  to  immortalise 
naturally-occurring  mortal  dysplasias  unless  they  have  lost  expression  of  RAR-P  and/or 
p161NK4A.  Loss  of  p16  INMA  and  RAR-P  in  dysplasias  is  not  an  in  vitro  artefact  since  both 
changes  have  been  found  in  large  fraction  of  dysplasias  in  vivo  (16,17). 
However,  a  recent  report  showed  that  in  normal  human  keratinocytes,  p16  dysfunction 
and  telomerase  over-expression  were  insufficient  for  immortalisation  and  that  p53 
dysfunction  was  also  required  (18).  In  these  experiments  p16  and  p53  dysfunction  in 
concert  lead  to  an  accumulation  of  the  other  protein  encoded  by  the  INK4A  locus, 
p14  ARF 
. 
Since  p14  ARF  can  stabilise  p53  by  inhibiting  the  MDM2  ubiquitin  ligase  (see 
(18)  and  references  therein),  the  accumulation  of  p14  ARF  in  P16INK4A  -deficient  normal 
keratinocytes  (18)  would  provide  a  plausible  explanation  for  the  necessity  .  to  additionally 
disrupt  the  p53  pathway  in  their  experiments.  On  the  basis  of  these  results,  Rheinwald  et 
7 al  (18)  suggested  that  the  telomere-mediated  activation  of  p53  by  short  telomeres, 
previously  shown  to  occur  in  human  fibroblasts  (14),  might  be  unnecessary  for  the 
senescence  of  normal  human  keratinocytes.  To  address  the  role  of  p14  ARF  in  the 
immortalisation  of  D17,  we  attempted  to  detect  p14  ARF  by  western  blotting  and  showed 
that  it  was  undetectable  (Fig.  4B),  consistent  with  the  frequent  co-deletion  of  the  proteins 
in  oral  dysplasia  (19).  Thus  in  the  neoplastic  D17  culture  the  co-dysfunction  of  p16  and 
p14  ARF  (together  with  RARP)  allows  these  cells  to  undergo  further  telomeric  attrition  and 
procede  to  a  further  senescence  checkpoint  that  involves  the  phosphorylation  of  p53  at 
serine  15.  The  current  observations,  and  those  recently  reported  (18),  suggest  that  p53 
can  mediate  two  distinct  mechanisms  of  senescence  in  neoplastic  oral  keratinocytes. 
Furthermore,  this  hypothesis  is  also  consistent  with  the  observed  co-existence  of  p14  ARF 
dysfunction  and  p53  mutation  in  the  same  immortal  neoplastic  keratinocyte  lines  (19). 
Since  our  previous  work  demonstrated  a  frequent  association  between  p53  mutations, 
telomerase  activation  and  acquisition  of  immortality  in  our  series  of  oral  dysplasia 
cultures  (7,8)  we  determined  whether  immortalization  of  our  D17  culture  by 
hTERT/telomerase  activation  also  required  p53  mutation.  However,  sequencing  of  the 
entire  p53  coding  region  using  DNA  from  the  hTERT  infected  D  17  culture  at  86  PDs 
revealed  no  mutations.  Thus,  p53  mutation  is  not  an  obligatory  requirement  for 
immortalization  of  oral  dysplasias  provided  that  telomerase  is  activated  exogenously. 
Wild  type  p53  is  known  to  down-regulate  hTERT  in  other  contexts  (20)  and  thus  p53 
mutation  may  be  one  route  for  hTERT/telomerase  activation  for  acquisition  of 
immortality  during  oral  dysplasia  progression.  Alternatively,  since  p53  appears  to  sense 
telomere  dysfunction  to  mediate  a  G1  cell  cycle  checkpoint  (14,15),  correcting  telomere 
8 dysfunction  by  ectopically  activating  telomerase  may  remove  any  requirement  for  p53 
mutation  in  this  situation.  Clearly,  these  alternatives  are  not  mutually  exclusive.  Finally, 
although  p53  dysfunction  is  highly  correlated  with  the  immortal  phenotype  of  the  cancer 
cell  (8),  abrogation  of  other  functions  of  wild  type  p53  may  be  required  for  the 
development  of  other  aspects  of  the  cancer  cell  phenotype. 
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12 LEGENDS  TO  FIGURES 
Fig.  l.  Oral  dysplasias  senescence.  (A)  SABG  staining  of  uninfected  D17  and  D30 
cultures  and  after  infection  with  the  hTERT  retroviral  vector.  Colonies  were  stained  at 
terminal  growth  arrest  or  at  85  PDs  in  the  case  of  D17  cultures  infected  with  the  hTERT 
vector.  (B)  D17  cultures  were  labelled  for  48  h  with  BrdU  to  measure  their  proliferative 
index  or  assayed  for  DNA  breaks/apoptosis  by  TUNEL  staining.  Colonies  were  analysed 
during  terminal  growth  arrest  or  at  85  PDs  in  the  case  of  hTERT  infected  cultures. 
Fig.  2.  Telomerase  activity  in  (A)  D30  and  (B)  D17  cultures  before  and  after  infection 
with  hTERT  expression  vector.  TRAPeze  assay  was  performed  on  400ng  (left  panel)  or 
200  ng  (right  panel)  of  protein  extract.  The  gels  show  the  PCR  products  generated  after 
staining  with  ethidium  bromide.  The  uninfected  cultures  were  analysed  at  the  indicated 
PDs,  and  as  soon  as  sufficient  numbers  of  cells  were  available  after  infection  with  the 
empty  vector  or  with  the  hTERT  vector.  W138  and  HeLa  cells  were  included  as 
telomerase  negative  and  positive  controls  respectively. 
Fig.  3.  Telomere  lengths  were  measured  by  Southern  blotting  in  (A)  D30  and  (B)  D17 
cultures  at  different  stages  of  their  life  span,  comprising  senescence  (the  number  of 
population  doubling  is  indicated  for  each  sample),  after  infection  with  the  empty  vector 
(NEO)  and  with  the  hTERT  transducing  vector  (hTERT).  With  both  D30  and  D17,  the 
intensity  of  signals  with  the  'empty'vector  infected  cultures  is  weaker  than  for  the  other 
13 samples  due  to  the  small  amounts  of  DNA  available  but  show  that  the  telomeres  are 
significantly  shorter  than  in  cells  infected  with  the  hTERT  vector. 
Fig.  4.  (A)  Total  p53  levels  and  p53  phosphorylation  status  at  serine  15.  D17  cultures  at 
various  stages  of  progression  towards  senescence,  or  after  infection  with  the  hTERT 
vector  were  analysed  for  the  levels  of  p53  and  phospho  serine15  p53  status  by  Western 
blotting.  (B)  Measurement  of  p14  ARF  in  D17  cultures  at  various  stages  of  progression 
towards  senescence.  A  SCC  previously  shown  to  express  ARF  (BICR  3)  and  a  SCC 
lacking  p14  ARF  (19)  were  also  included  as  positive  and  negative  controls.  In  both  (A) 
and  (B),  're-'probin'g  of  tSe'blots  *to  measure  the  levels  of  ERKs  1  &2  were  included  as 
loading  controls. 
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